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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
Since the 1980s, computerized multichannel systems for endocardial and epicardial 
mapping became available and gave insight into the mechanisms of arrhythmias and 
the opportunity to eliminate the source of arrhythmias with radiofrequency (RF) 
current. In the last decade the number of ablation procedures of complex atrial 
arrhythmias such as atrial fibrillation (AF), atypical atrial flutter and focal atrial 
tachycardia (AT) are increasing exponentially whereas the number of relatively simple 
ablation procedures such as atrioventricular (nodal) reentry tachycardia hardly 
increase over the last 10 years.1 In addition with the rising number of AF/AT ablation 
procedures, the technique is rapidly changing and knowledge of pathological 
mechanisms of these conditions is increasing. Despite this progress, efficacy and 
efficiency of invasive treatment of complex atrial arrhythmias is still limited and AF is 
far from a curable disease.
Epidemiology and electrophysiological mechanism of AF
AF is the most common arrhythmia, affecting 1-2% of the population and this number 
is expected to increase in the next decades due to enhanced detection, increases in 
attributable risk factors and improved survival in patients with cardiovascular 
conditions predisposing to AF.2 The most feared complications of AF are thrombo-
embolic stroke and heart failure due to rapid ventricular rate. Data from the Stockholm 
Cohort Study of Atrial Fibrillation showed that the increased mortality seen in patients 
with paroxysmal AF compared with the general population (HR 1.6; 95% CI, 1.4–1.8; 
P < 0.05) was accounted for by deaths due to cardiovascular causes rather than stroke 
alone.3 In addition long-term follow-up of the Framingham population demonstrated 
still a 1.5- to 1.9-fold increase in mortality in patients with AF after adjustment for 
preexisting cardiovascular (CV) conditions associated with AF.4 Taking all this into 
account an increase in survival trend is seen over the last decades, presumably due 
to improvements in patient care such as oral anticoagulation to reduce risk of 
thrombo- embolic complications, together with better and more aggressive diagnosis 
and treatment of hypertension, ischemic heart disease, heart failure and hypercho-
lesterolemia.1,5
It is well known that onset of AF requires triggers to induce the arrhythmia. Triggers 
increasing vulnerability to AF include alterations in sympathetic or parasympathetic 
tone resulting in a disturbance of sympathovagal balance. Increased sympathetic 
tone predisposes to AF by increasing automaticity and triggered activity including 
early and delayed afterdepolarizations. Enhanced vagal tone increases inducibility of 
AF by shortening of atrial effective refractory period, increasing dispersion of 
refractoriness, thereby increasing potential for re-entry. Electrical and structural 
remodeling may facilitate perpetuation of AF. Clinical, lifestyle and environmental 
factors play an important role in the genesis of AF. Complex interaction of these 
12 13
CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
Many mechanisms have been proposed to explain how AF is commonly encountered 
in the setting of acute coronary syndrome (ACS). Although many theories exist, the 
pathophysiological mechanism of the onset of AF in the setting of ACS is still not fully 
delineated yet.  Experimental models and clinical investigations have shown different 
factors accounting for new-onset AF in ACS. Myocardial infarction causing atrial 
ischemia or atrial stretch, enhanced inflammation and changes in autonomic nervous 
system activity. In addition to neurohormonal factors, changes in RAAS and other 
hormone activations are involved in the pathogenesis of AF development in this 
patient subset.8 AF in the setting of ACS is associated with increased morbidity and 
mortality. Thus, proper understanding of the role of new onset AF complicating ACS 
will enable clinicians in tailoring treatment in these patients.  
New trends in the treatment of AF 
Recent data overwhelmingly support an association between numerous modifiable 
cardiovascular risk factors and AF; hypertension, obesity, smoking, diabetes mellitus, 
obstructive sleep apnea and metabolic syndrome. The most recent European Society 
of Cardiology (ESC) guidelines emphasize the need for a multidisciplinary approach 
and targeting these risk factors in addition to conventional AF treatment including 
arrhythmia control and prevention of thromboembolic events.9 A team of health  care 
professionals, active patient involvement and education on lifestyle and risk factor 
management is required for the so called integrated AF management. A randomized 
study in 712 AF patients demonstrated that the nurse-led AF management (nurse-led 
care consisted of guidelines based, software supported integrated chronic care 
supervised by a cardiologist) compared to standard AF care resulted in increased 
use of evidence-based care and reduced by one third the composite outcome of 
cardiovascular hospitalization and cardiovascular death over a mean follow up of 22 
months (14.3% vs. 20.8%, HR 0.65;95% CI 0.45-0.93;p=0.017). 10
When confronted with the AF patient, a decision should be made as to which approach 
will be used for long-term management, rhythm control versus rate control. Rhythm 
control is established with antiarrhythmic drug therapy, cardioversion, radiofrequency 
(RF) catheter ablation, and/or a surgical procedure to maintain sinus rhythm. Rate 
control includes rate-slowing drugs or AV nodal ablation plus ventricular pacing. As a 
consequence many patients need to be reconsidered for the alternate strategy as the 
natural history of their disease progresses. 
Based on the associated medical consequences seen in patients with AF, one would 
assume that maintenance of normal sinus rhythm would significantly reduce mortality, 
stroke, heart failure and decline in quality of life. However, the benefit of rhythm control 
compared with rate control only remains unclear and is an area of considerable debate.
factors result in changes creating an arrhythmogenic mileu favoring re-entry and 
perpetuation of this arrhythmia. 6 AF itself promotes a process of structural atrial 
remodeling by alterations in calcium handling, fibroblast activation, connective tissue 
deposition and fibrosis resulting in electrical dissociation of muscle bundles, which 
leads in turn to local conduction heterogeneity promoting re-entry and maintenance of 
the arrhythmia.6,7 Figure 1 demonstrates a scheme representing the key mechanisms 
of AF. Most important etiological factors causing enhanced atrial remodeling are 
diabetes, heart failure, obesity, coronary artery disease, hypertension, aging and 
genetic predisposition. 
Figure 1  Principle mechanisms that produce and maintain AF, including focal 
ectopic firing and vulnerable substrates that can maintain re-entry. 
APD = action potential duration; DAD = delayed afterdepolarization; EAD = early afterdepolarization; ERP = 
effective refractory period.
* figure adapted from Andrade J, Khairy P, Dobrev D, Nattel S. Circ res.2014;114:1453-1468.
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recurrences of AF on antiarrhythmic drug therapy, which is classified as a I A indication 
for paroxysmal AF and IIa, level of evidence C for persistent AF. Ablation therapy is 
even a valid first-line alternative to antiarrhythmic drugs in selected patients with 
symptomatic paroxysmal AF (IIa B).9
Catheterablation techniques of paroxysmal AF and “single shot” 
device techniques
Haïssaguerre and colleagues are the pioneers of techniques  ablating ectopic 
triggers that arise from the pulmonary veins (PV) in paroxysmal AF.17  Whereas initial 
reports describe segmental PVI, several randomized trials highlight the importance 
of complete isolation of the PVs in patients undergoing AF ablation (IIa B).9,18
To reach such objectives it is essential to increase catheter stability, achieve predictable 
lesion formation, reduce procedure and X-ray exposure time, and make simple and 
automatic either different steps or the whole procedure by using an anatomically- 
based ablation approach.
The conventional technique for many years was ostial, lasso-guided, circumferential, 
point-by-point RF ablation of the PVs.  These point-by point ablation procedures are 
relatively complex, lengthy procedures, requiring extensive left atrial (LA) mapping 
and the use of multiple catheters and often multiple transseptal punctures.  This 
results in a slow learning curve, with success and safety dependent on operator 
experience. Spragg et al analyzed the complication rate in 641 AF ablations at the 
Johns Hopkins Hospital. Major complications occurred in 5% of the patients. Operator 
experience played a significant role; 9% occurred during the first 100 and 4.3% during 
the subsequent 541 pro cedures. The most recent consensus statement on AF 
ablation suggest that safety and efficacy results are better in centers performing 
more than 100 procedures annually.19,20
With the growing demand for AF ablation and relatively limited experienced operators, 
the use of a simpler, faster and less expensive technique for PVI was desirable. New 
technical developments aiming to simplify PVI and increase safety were developed in 
the last decade. The  so called single-shot devices require a single trans-septal 
punc ture and the simultaneous application of energy in order to perform easier, faster 
and safer procedures using circular catheters or balloon-like ablation devices. Four 
types of energy sources exist for single shot devices, i.e.  RF, cryo-energy, ultrasound 
and laser energy. 
Several prospective randomized trials and meta-analysis were conducted to compare 
the strategy of rate control with that of rhythm control.11 The first major trials the Atrial 
Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) and the Rate 
Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) trial, 
including 4060 and 522 patients respectively, did not demonstrate a benefit of rhythm 
control on prognosis in terms of survival or combined end point of cardiovascular 
mortality, hospitalization for heart failure, thromboembolic complications, bleeding, 
pacemaker implantation, and severe adverse events. 12,13 Also trials conducted in the 
following years comparing rate- with rhythm control did not show a clear benefit of 
one approach over the other. In general, limitations of the trials are: a relatively short 
follow up period, the large cross over between the groups-mainly due to drug 
intolerance and toxicity-, discontinuation of anticoagulant therapy and a small number 
of patients actually achieving sinus rhythm (ranging from 26% to 63%).11
Moreover at the time the studies were performed, pulmonary vein isolation (PVI) was 
not yet a widespread method to treat patients with (especially paroxysmal) AF. It is 
therefore not clear what the effect of rhythm control, including PVI, would be on the 
prognosis. Ongoing studies such as the Early treatment of Atrial fibrillation for Stroke 
prevention Trial (EAST) will test whether an early, modern rhythm control therapy can 
reduce cardiovascular complications in AF.14
 “Real world” data from European registries show that rate- and rhythm control is not 
a very strict division. The Euro Heart Survey demonstrates that among all rhythm 
control patients, 54% was also on typical rate control drugs (digitalis, beta-blocker, 
verapamil, or diltiazem) and 52% were on amiodarone or sotalol, which are known to 
also have rate control properties. Taken together, 84% of patients had some type of 
rate control besides the rhythm control treatment.15 More recently, the PREFER in AF 
registry shows that rate control was given to nearly 80% of the entire AF population in 
Europe, but an isolated rate control strategy was used in only 40%. Rhythm control 
was the selected strategy in almost 60% of patients. Ablation was undertaken in 12% 
of those who received rhythm control management, and nearly one-quarter of those 
with recurrent forms of AF that were not associated with significant underlying heart 
disease. Thus in practice phycicians mostly combine rhythm and rate control and 
offer ablation mainly in patients without structural heart disease.16
Rhythm control therapy is primarily designed to improve AF-related symptoms. 
Antiarrhythmic drugs, supplemented with cardioversion are recommended treatment 
options (I A/I B). The choice of antiarrhythmic drugs is based on safety considerations. 
Catheter ablation has evolved as a first therapeutic choice in AF management. 
Catheter ablation is the rhythm control therapy of choice in patients with symptomatic 
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Cryoballoon ablation (Artic Front®, Medtronic) is an ablation technique which relies 
on a nitrogen filled bal loon capable of reaching temperatures of -50º -60º C leading 
to necrosis by freezing. The balloon is insert ed into the ostium of the PV allowing a 
real one-shot energy delivery to the PV antrum, an additional multipolar wire distal to 
the balloon shows electrogram recordings  and allows evaluation of PVI during the 
Cryo energy application. Recently the results of the FIRE AND ICE trial were published. 
This was a multicenter, randomized, noninferiority trial, with blinded end-point 
assessment, in which cryoballoon ablation was compared with RF ablation in 762 
paroxysmal AF patients. The primary efficacy end point of time to first recurrence of 
The ‘single shot‘ multi-electrode circular ablation catheter, i.e. pulmonary vein ablation 
catheter (PVAC) consists of a 9 French (Fr), over-the-wire, decapolar circular mapping 
and ablation catheter (Medtronic Ablation Frontiers LLC, Carlsbad, CA, US). The 
system is designed to apply duty-cycled phased unipolar and bipolar RF energy over 
initially 10 and in the latest design 9 PVAC electrodes positioned at the antral part of 
the PV. The application of energy can shift from unipolar (deeper lesion) to bipolar 
(more contiguous lesion). Clinical success rates of PVI were similar to conventional 
point-by-point ablation using a three-dimensional (3D) navigation system. However, 
total procedural and fluoroscopic times were significantly shorter by using the 
PVAC.21,22  Studies by Gaita et al. and Siklódy et al. raised a safety concern for the 
first generation PVAC catheter with platinum electrodes. This first generation PVAC 
was associated with a significantly higher rate of (asymptomatic) cerebral micro- 
embolisms occurring after PVAC ablation compared to irrigated RF ablation and 
cryoballoon.23,24 The cause for embolism was electrode overheating, which was 
particularly found when electrodes 1 and 10 were in close proximity during ablation. 
In order to overcome this problem, a trial with specific procedural changes was 
carried out, the evaluation and Reduction of Asymptomatic Cerebral Embolism 
(ERACE) study. In this trial the ablation procedure was undertaken under ther apeutic 
vitamin K antagonist and heparin for an activated clotting time > 350 seconds, the 
catheter was loaded into the introducer while sub merged in saline solution to prevent 
air entrance, and the distal or proximal electrode of the circular catheter was shut off 
to prevent bipolar RF interaction. Using this strategy, the rate of subclinical cerebral 
embolism was re duced to a much lower 1.7%.2 
Recently  a new design of the PVAC catheter, PVAC-Gold was introduced which 
contains 9 gold electrodes instead of 10 electrode to overcome the overlapping, 
interaction issue (figure 2). Gold has more than 4 times better thermal conductivity 
than that of platinum, thereby providing faster cooling and more precise temperature 
control. Additionally, the array of the PVAC GOLD catheter is tilted forward by 20° 
relative to the catheter shaft in order to improve electrode to tissue contact 26
The first studies with the PVAC gold catheter demonstrate that the efficiency is 
comparable to the first generation device. Furthermore an improved biophysical 
efficiency and low incidence of asymptomatic cerebral embolism with the PVAC-Gold 
catheter is found.26,27
Another RF single shot device is the nMARQ (Biosense Webster) which is an  irrigated 
circular multi polar catheter which allows for simultaneous mapping and ablation. The 
catheter is integrated into the CARTO electro-ana tomic mapping system. Small series 
report efficacy and safety outcomes comparable to other techniques.2
Figure 2   PVAC catheter design.
a)  The newly designed PVAC Gold catheter 
b)  The 1st generation PVAC catheter. Several key improvements have been implemented: the ablation 
electrodes are made of Gold instead of Platinum; the new catheter consists of 9 electrodes; the inter-elec-
trode spacing is increased to 3.75 mm to retain the effective arc length; the electrodes are at a 20º 
forward tilt.
* figure adapted from . Gal P, Buist T, Smit JJJ et al. Neth Heart J. 2017 Jan; 25(1): 16–23.
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has the ability to selectively titrate energy to each part of the circumferential lesion set 
like point-by-point RF ablation. In addition, the laser balloon diameter can be changed 
dynamically to suit each PV antrum. Furthermore it is the first ablation technology to 
allow the operator to directly visualize tissue changes during ablation.32
There is one randomized controlled study comparing the efficacy and safety of VGLB 
ablation with standard point-by-point RF ablation. A total of 353 patients (178 VGLB, 
175 control) were randomized to either technique. A 12 months 61.1% in the VGLB 
group versus 61.7% in controls (absolute difference 0.6%; lower limit of 95% 
confidence interval [CI]: 9.3%; p < 0.003 for noninferiority) were free of AF.  Adverse 
events occurred in 11.8% of the VGLB group versus 14.5% in controls (absolute 
difference 2.8%; upper limit of 95% CI: 3.5; p < 0.002 for noninferiority), and was 
mainly driven by cardioversions. The mean procedure time for VGLB was 236.0 ± 
52.8 minutes which is remarkably long for a single shot device. This may be in part be 
due to the relative inexperience of the operators.33
Single shot devices are nowadays routine ablation tools for paroxysmal AF in many 
electrophysiology laboratories worldwide. One has to acknowledge that more 
advanced substrate requires more than PVI alone. Therefore alternative ablation 
instruments are indispensable.
Macro reentry- and focal atrial tachycardia
AT is defined as an organized atrial arrhythmia with a stable morphology and a stable 
activation sequence in both atria.  The cycle length of an AT is usually stable, although 
there may be some variation depending on the underlying mechanism. The 2 
following types of AT can be clearly differentiated based on their electrophysiologic 
mechanisms: macro re-entrant AT and focal AT (due to an automatic, triggered, or 
micro re-entrant mechanism)  
Macro re-entrant AT comprises a heterogeneous group of right- or left atrial macro re/
entrant circuits related to different anatomical and electrophysiological substrates. 
These arrhythmias are frequently associated with structural heart disease, congenital 
cardiac defects, previous cardiac surgical procedures, or surgical or catheter ablation 
procedures for AF. Often, these arrhythmias coexist with AF. Particularly extensive 
substrate modification generates focal areas of slow conduction and low voltage 
capable of sustaining localized reentry. The post-AF ablation macro reentry AT is a 
novel “iatrogenic” arrhythmia which is rapidly rising in number in a time where AF 
ablation procedures are expanding and the amount of tissue is not restricted to the 
PV antrum. The prevalence of left atrial AT after antral PVI is 4-11% and these 
arrhythmias typically occur within the first months of the initial ablation procedure.34,35 
AF (lasting >30 seconds), atrial flutter, or AT, use of antiarrhythmic drugs, or reablation 
occurred in 34.6% of the cryoablation group and 35.9% of radiofrequency ablated 
patients. The results met the noninferiority threshold (hazard ratio [HR] 0.96; 
P<0.001).29 Moreover, regarding the secondary endpoints, cryoballoon ablation, as 
opposed to radiofrequency ablation, showed significantly fewer repeat ablations, 
direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehos-
pitalizations during follow-up. Both patient groups improved in quality-of-life scores 
after AF ablation.30
High-intensity focused ultrasound (HIFU), applied via a balloon catheter, integrates a 
9 megahertz ultrasound crystal which generates a ring of ultrasound energy at the 
base of the balloon. The third generation of HIFU-BC is steerable through a pull wire 
mechanism integrated in the handle of the catheter and is available in different 
balloon sizes from 20 mm to a maximum of 32 mm diameter (ProRhythm Inc, 
Ronkonkoma, New York, US). The catheter also has a lumen for insertion of a 
hexapolar spiral mapping catheter to record PV potentials. Initial reports using first 
and second generation HIFU balloon catheters describe long procedure times and 
limited efficacy (isolation of all PVs in 50 % of patients). Serious complications such 
as phrenic nerve palsy and deleterious atrial–oesophageal fistula were also reported. 
Later series with a technically improved third generation HIFU balloon demonstrated 
better outcome (acute PVI in 80% of all PV and 60% of veins after a single shot). No 
atrial–oesophageal fistula was reported and phrenic nerve palsy incidence was 
comparable to other balloon technologies. Despite of technical improvements, 
navigation and positioning were still challenging and this technique therefore has 
been abandoned for clinical use.31
The visually-guided ablation using a laser balloon (VGLB) technology (HeartLight, 
CardioFocus, Marlborough, Massachusetts)  is a catheter with a variable-diameter, 
compliant balloon with a flexible tip that is delivered through a 12-Fr deflectable 
sheath. Within the central shaft of the balloon catheter is a 2-Fr endoscope that 
permits real-time visualization of the target tissue. The central shaft contains lumens 
for circulating deuterium oxide (D2O) to cool the balloon, a maneuverable optical 
fiber that generates a ~30° arc/spot of both nonablative visible light and near-infrared 
ablative light energy. This arc of light can be maneuvered to any location along the 
surface of the balloon to allow aiming and then ablation using diode laser energy 
(980 nm). The shaft of the catheter contains a radiopaque marker that can be 
visualized on fluoroscopy and allows correlation orientation between endoscopic 
and fluoroscopic images.  In theory, this technology has distinct advantages over 
both point-by-point ablation and the cryoballoon catheter. It offers stable catheter 
position and contiguous lesions like other balloon-based technologies. Moreover it 
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mapping of the noncoronary cusp is not a standard procedure for perinodal ATs.43,44 
Pharmacological treatment generally has limited efficacy and many patients experience 
side effects of antiarrhythmic drugs. Therefore, RF ablation is the preferred strategy 
for patients with significant symptoms. The major limitations to success is insufficient 
ectopy or tachycardia to allow the detailed activation mapping required to identify the 
site of origin (and provide an accurate end point to the procedure) and safe and 
stable catheter position. Multi-electrode three-dimensional electroanatomic mapping 
systems and image integration has enormously facilitated these procedures.
Stand alone surgical AF therapy and hybrid ablation
Surgical therapy for AF is generally reserved for patients refractory to antiarrhythmic 
dugs and catheterablation. The classic cut-and-sew maze procedure has been 
applied by relatively few surgeons. Although a 80-90% maintenance of sinus rhythm 
is described without antiarrhythmic medication on long term follow up, this procedure 
hasn’t gained widespread acceptance due to its complexity and associated 
morbidity. 45,46 The Cox-maze IV procedure has replaced the “cut-and-sew” technique 
of the original Cox-maze operation with lines of ablation created by using bipolar RF 
and cryothermal energy devices.47
In 2005 a minimally invasive video-assisted thoracoscopic surgical (VATS) approach 
has been introduced. In contrast to the traditional Cox-maze procedures, the VATS 
technique is an epicardial stand-alone ablation on the beating heart using bipolar 
radiofrequency energy.48
Since its introduction there is a wide variety of approaches regarding access site 
(right, bilateral, subxyphoidal), lesion sets and energy sources to cre ate lines of 
conduction block including RF, microwave, ultrasound, cryothermy, and laser. RF, 
laser, ultrasound and microwave are heat-based energy sources that create lines of 
conduction block through thermal injury. Nowadays bipolar RF ablation is mostly 
used, it is performed by clamping atrial tissue and heating it between two electrodes 
until irreversible protein denaturation occurs. Its jaw-clamp structured device has the 
advantage of allowing real-time assessment of transmural lesions by measurement 
of impedance as atrial tissue is clamped and ablated.48
Three broad lesion sets in the surgical treatment of AF include (wide) PV isolation, LA 
lesion set and biatrial lesion set resembling a cox maze IV pattern (figure 3). Commonly 
performed lesions apart from the PV circles include a roofline connecting both 
superior PVs, a line from the roof line to the left trigone, a line from the superior PV to 
the LA appendix (LAA), a line from the RIPV to the coronary sinus, a superior vena 
cava and inferior vena cava circumferential lesion, and an intercaval line (line between 
However after stepwise approach of persistent AF, including PVI and extended 
lesions in left and right atrium up to 40% of patients may develop post procedural 
ATs.36
The ECG has limited value in localizing the AT mechanism and circuit especially in the 
ablated atrium. The first step in the electrophysiology laboratory is the diagnosis of 
the mechanism underlying the AT.  A simple distinction can be made by mean cycle 
length variation. If the variation of the mean cycle length during one minute is >15% 
a focal mechanism is the most likely diagnosis. On the other hand if the variation is 
<15% it does not rule out focal mechanism. Entrainment mapping is the next step; 
if the AT is entrained from three distinct atrial segments (e.g. septal, posterior or lateral 
LA for perimitral flutter) with post pacing intervals (PPI) < 30 msec at each of the 
sites, macro re-entry is confirmed. If this is not the case, macro re-entry is ruled out. 
Three dimensional electro-anatomic activation mapping displays the activation 
sequence of the AT within the atrial anatomy. Areas of constrained activation (usually 
scar or anatomic barrier) can be identified as a potential critical isthmus and is the 
target for ablation.37,38
Shah et al., demonstrated that 73% of ATs developing after AF ablation in paroxysmal 
and persistent AF were related to narrow, critical isthmuses usually involving the ridge 
between the left PVs and the LA appendage. When this isthmus was found, the AT 
usually could be terminated with 1 RF energy application; otherwise, long linear 
lesions (mitral isthmus or LA roof) lines had to be performed. RF ablation of these 
arrhythmias can be challenging and time consuming often due to tissue thickness, 
inability to create a transmural lesion or modification of the circuit resulting in new 
flutter circuits.39
True focal AT can have a variety of causes and mechanisms; (micro-)reentry, 
abnormal automaticity, and triggered activity.40 Often focal AT occurs in patients 
without structural heart disease.  The AT has a focal origin of activation that spreads 
centrifugally to both atria. Typically, activation is not continuous throughout the 
cardiac cycle length, which is the hallmark of re-entry. The origins are seen in both 
atria and are not randomly distributed. Kistler et al reported on 186 consecutive 
patients presenting for AT ablation and found that 63% of them were located in the 
right atrium (RA) and 37% in the LA.41 In the LA, preferential AT sites include the PVs 
(upper veins are more common than the lower veins), mitral annulus, and coronary 
sinus musculature or atrial appendage. In the RA, preferential AT sites include the 
crista terminalis, tricuspid annulus, and perinodal area.42 The perinodal origin may in 
fact arise from either side of the inter atrial septum or from the noncoronary aortic 
cusp. Tachycardias from this particular region are probably underestimated because 
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The hybrid thoracoscopic and transvenous approach combines an epicardial 
ablation with a percutaneous endocardial ablation in a single-step or sequential 
procedures. The combination of endocardial/epicardial lesions potentially improves 
transmurality. The exact approaches, techniques, lesion sets, periprocedural care, 
and endpoints differ substantially per center. However the fundamental principle is 
that the procedure starts with thoracoscopic epicardial ablation including antral PV 
isolation and  a roofline. The right atrial lesions are less frequently used than the left 
atrial lesions. The endocardial procedure, either immediate or staged, is performed 
to ensure adequacy of PVI and bidirectional block across lines of ablation as well. 
The mitral isthmus and the tricuspid isthmus lines are particularly difficult to ablate 
from the epicardial surface of the heart and often require additional endocardial 
touch up. 52,53
Data comparing immediate versus delayed endocardial procedure is limited. Each 
approach has advantages and disadvantages. The one step is time-consuming for 
both the surgeon and electrophysiologist and it requires careful periprocedural anti-
coagulation management with simultaneous transseptal and endoscope access. 
Furthermore a delayed endocardial procedure allows for healing from surgical 
wounds as well as epicardial lesion maturation. Advantages of a one step approach 
are that epicardial ablation can be guided by endocardial mapping and additional 
epicardial applications can be performed. Furthermore the surgeon is able to protect 
the phrenic nerve and esophagus from injury during endocardial ablation.52, 53
Mahapatra et al compared hybrid ablation in 15 patients with persistent and long- 
standing persistent AF to a matched control group of patients undergoing a repeat 
catheter ablation procedure. The surgical lesion set consisted of epicardial PVI, roof 
line, trigone line, superior vena cava isolation, LAA amputation, and ablation of the 
ganglionated plexi. After 3 to 5 days, all patients were brought to the electrophysio-
logical lab for cavotricuspid isthmus and coronary sinus ablation. The authors 
reported a hybrid ablation success rate of 86.7% (13/15), off antiarrhythmic drugs, 
during a mean follow-up of 20.7±4.5 months whereas only 53% (16/30) of patients 
with extensive catheter ablation alone were free of AF without drugs.54
Monitoring for AF recurrences
Assesment of clinical mid- and long term outcome after catheter- or surgical AF 
ablation remains a subject of discussion. 
Success rates after AF ablation are currently based on symptoms, intermittent standard 
ECG recordings, and ambulatory long-term monitoring. However, asymptomatic AF 
is very common. Hindricks et al showed that >50% of patients with AF had a mixture 
SVC and IVC). Additional lesions and different combinations of these lines varies 
between operators and generally depends on the amount of substrate and registered 
arrhythmias. Paroxysmal AF, which is mainly PV trigger related, can be treated by 
wide PVI. There is growing consensus that in patients with persistent or long-standing 
persistent AF a lesion set that incorporates more than PVI is more effective. In such 
pa tients, the lesion from the right PVs to the mitral annulus may be particularly 
impor tant in prevention of post-procedure LA flut ter.49
A randomized controlled trial comparing minimally invasive surgical ablation vs 
catheter ablation (FAST trial). The surgical ablation consisted of the “Dallas” lesion 
set, which includes the use of bilateral PV antral isolation using a bipolar RF clamp 
with ganglionic plexi ablation. Subsequent linear ablation included a LA roof line, a 
line between the roof and the left fibrous trigone (anterior trigone line), and a line to 
the base of the resected LAA. This study demonstrates superior freedom from AF at 
12 months with surgical ablation though at the cost of a higher rate of adverse events 
(23% vs. 3% in the catheter ablation group; P<0.001). Adverse events related to 
surgery include need for pacemakers (5%), hemothorax (3%), phrenic nerve injury 
(3%), transient ischemic attack (1%) and pulmonary embolism (1%). 50 
Outcomes from the Society of Thoracic Surgeons (STS) database from 2005 to 2010, 
comparing minimally invasive surgical ablation vs. sternotomy for lone AF, 
demonstrated a complication rate of 0.7% for mortality or stroke, 1% for need of 
pacemaker and a median length of hospital stay of 4 days.51
Figure 3   Posterior view of the heart with common epicardial  ablation lines (red) as 
applied In minimal invasive thoracoscopic AF ablation. See text for details.
24 25
CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
References
1.  Koopman C, van Dis I, Vaartjes I, Visseren FLJ, Bots ML. Hart- en vaatziekten in Nederland 2014, cijfers 
over kwaliteit van leven, ziekte en sterfte. Den Haag: Hartstichting, 2014.
2.  Frost L, Vestergaard P, Mosekilde L, Mortensen LS. Trends in incidence and mortality in the hospital 
diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol. 2005 Aug 3;103(1):78-84.
3.   Friberg L1, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: 
report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007 Oct;28(19):2346-53.
4.  Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on 
the risk of death: the Framingham Heart Study. Circulation. 1998 Sep 8;98(10):946-52.
5.  Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani 
JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in atrial fibrillation 
prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. . 
Lancet. 2015:11;386(9989):154-62. doi: 10.1016/S0140-6736(14)61774-8. 
6.  Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner 
PM, Van Wagoner DR, Waldo AL. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001: 
6;103(5):769-77.
7.  Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in 
awake chronically instrumented goats. Circulation. 1995 Oct 1;92(7):1954-68.
8.  Patel NJ, Patel A, Agnihotri K, Pau D, Patel S, Thakkar B, Nalluri N, Asti D, Kanotra R, Kadavath S, Arora 
S, Patel N, Patel A, Sheikh A, Patel N, Badheka AO, Deshmukh A, Paydak H1, Viles-Gonzalez J. 
Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure 
and chronic kidney disease. World J Cardiol. 2015 Jul 26;7(7):397-403. 
9.  Kirchhof P, Benussi S, Kotech D et al. 2016 ESC Guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS.  European Heart Journal (2016) 37, 2893–2962
10.  Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, Tieleman RG. Nurse-led 
care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. 
routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012 Nov;33(21):2692-9
11.  Chinitz JS, Halperin JL, Reddy VY, Fuster V. Rate or rhythm control for atrial fibrillation: update and 
controversies. Am J Med. 2012;125(11):1049–1056.
12.  Wyse DG, Waldo AL, DiMarco JP, et al., The Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with 
atrial fibrillation. N Engl J Med 2002, 347:1825-1833. 
13.  Van Gelder IC, Hagens VE, Bosker HA, et al.: Rate Control versus Electrical Cardioversion for Persistent 
Atrial Fibrillation (RACE) Study Group. N Engl J Med 2002, 347:1834-1840. 
14.  Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving outcomes 
in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke 
prevention Trial. Am Heart J. 2013 Sep;166(3):442-8.
15.  Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le 
Heuzey JY, Prins MH, Lévy S, Crijns HJ; European Heart Survey Investigators. Atrial fibrillation 
management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. 
Eur Heart J. 2005;26(22):2422-34
16.  Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J-Y, Schilling RJ et al. Management of 
atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial 
fibrillation. Primary results of the PREFER in AF Registry. Europace 2014;16:6–14.
17.  Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats 
originating in the pulmonary veins. N Engl J Med 1998;339:659–66.
18.  Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, Breithardt 
G, Willems S, Gap-AF–AFNET 1 Investigators. Impact of Complete Versus Incomplete Circumferential 
Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation: Results 
From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial. Circ Arrhythm 
Electrophysiol. 2016 Jan;9(1):e003337.
of symptomatic and asymptomatic AF prior to ablation, whereas only 38% of patients 
recognized all AF episodes accurately. After catheter ablation, the incidence of 
asymptomatic AF significantly increased: At 3, 6, and 12 months’ follow-up, 38%, 
37%, and 36% of patients with arrhythmia recurrence were completely asymptomatic.55
Several reasons may explain this phenomenon. First of all the placebo effect of an 
invasive procedure on the perception of AF. Another reason is a change in arrhythmia 
pattern after ablation therapy. Furthermore PVI creates partial autonomic denervation 
which may have an impact on the perception of AF. 
Although symptomatic AF is the main indication for ablation, symptoms alone are an 
unreliable instrument for determination of success given the poor correlation between 
reported symptoms and AF. Also, from a scientific point of view and for comparing 
different ablation therapies an accurate number of recurrence of atrial arrhythmias is 
essential.
Implantable loop recorders have a sensitivity of > 95% and a negative predictive value 
which is even higher for identifying patients with any AF compared to Holter recordings, 
which makes it an attractive tool for detecting patients with AF recurrences.56
Outline of this thesis
This dissertation comprises ten chapters grouped in three parts. The first part 
(Chapter 2 and 3) elaborates on clinical aspects and pathology of AF. Chapter 2 
addresses the prognostic predictive value of AF in the setting of an ST elevation 
acute coronary syndrome. Chapter 3 describes the electrophysiological effects of 
acute left atrial dilatation and dedilatation in humans with long-standing persistent 
AF. The second part of the thesis (chapters 4, 5 and 6) focusses on percutaneous 
ablation of AF and AT. Chapter 4 and 5 present the efficacy and efficiency of 
paroxysmal AF ablation with the multi-electrode duty-cycled RF ablation catheter. 
Chapter 6 reviews the characteristics of focal AT originating from the aortic cusp. 
The third part (Chapter 7-9) discusses surgical management of AF and follow up 
methods. Chapter 7 describes the results of a randomized, clinical trial comparing 
surgical ablation to catheter ablation for lone AF. Chapter 8 demonstrates aspects 
and catheter ablation results of recurrent atrial arrhythmias after surgical AF ablation. 
Chapter 9 evaluates AF burden monitoring techniques after AF surgery. Chapter 10 
contains the general discussion and summary of this thesis.
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Introduction
Atrial fibrillation (AF) is a commonly encountered arrhythmia in patients with acute 
myocardial infarction (AMI) with an overall incidence of 5–22%.1, 2, 3, 4, 5, 6, 7, 8, 9 
The predictive value of AF in diverse forms of ACS has been extensively studied. 
These observations stressed the importance of the time of the onset, the duration 
and the recurrence rate of AF to identify patients in increased risk of adverse 
events. 4, 6, 10, 11 The incremental predictive value of AF, however, has remained a 
matter of discussion given the large overlap between factors increasing the risk of 
developing AF and other cardiovascular adverse events. Furthermore, most of these 
results are provided by studies conducted in the thrombolysis or pre-thrombolysis 
era, and little is known about the impact of AF on cardiovascular risk in patients 
undergoing primary PCI for ST-segment elevation MI (STEMI). 4 Besides, the majority 
of studies on this subject are substudies of clinical trials and due to specific exclusion 
criteria, characteristics of the patient samples studied are different from the average 
patient hospitalised with a myocardial infarction. Our aim was to investigate the 
predictive value of AF with regard to its time of onset (i.e. before or after reperfusion 
therapy) in patients undergoing primary PCI for STEMI and to identify predictors for 
development of AF in STEMI patients.
Methods
Patients
Between April 1997 and December 2002, 2134 patients with symptoms consistent 
with acute MI of >30 min duration, presenting within 24 h after the onset of symptom 
and with a ST-segment elevation of more than 1 mm (0.1 mV) in two or more 
contiguous leads on the electrocardiogram, were admitted. All patients were treated 
with an invasive approach, with primary PCI performed with standard techniques if 
the coronary anatomy was suitable for PCI. Angiographically successful reperfusion 
was defined as TIMI flow grade 3, in combination with a myocardial blush grade 2 
or 3. Additional treatment consisted of intravenous heparin, nitroglycerin and aspirin. 
After sheath removal, low-molecular-weight heparin was given for 1 to 3 days. 
Follow-up data were collected up to 18 months after randomisation via the registry 
office, the general practitioner, or via direct contact with the patient or his relatives by 
telephone. The research protocol was reviewed and approved by the medical ethics 
committee of our hospital, and patients were included after informed consent.
Abstract
Aim
In patients with ST-segment elevation myocardial infarction (STEMI), it is uncertain 
whether atrial fibrillation has prognostic implications. There may be a difference between 
atrial fibrillation before and after reperfusion therapy.
Methods and results
In patients with STEMI treated with primary percutaneous coronary intervention (PCI), 
ECGs were analysed before and after primary PCI. Of the 1623 patients with electro-
cardiographic data before primary PCI, 53 patients (3.3%) had atrial fibrillation. 
Patients with atrial fibrillation were older, were more often female, and less often had 
anterior MI location. Of the 1728 patients with electrocardiographic data after primary 
PCI, 52 patients (3.0%) had atrial fibrillation. Atrial fibrillation was more common in 
older patients and in those with Killip class >1. Also patients with occlusion of the 
right coronary artery or TIMI flow 0 before primary PCI more commonly had AF after 
the procedure. Not successful reperfusion was also associated with a higher 
incidence of AF after primary PCI. Although both atrial fibrillation before and after 
primary PCI were associated with increased mortality, multivariable analyses, 
adjusting for differences in age, gender and Killip class on admission, revealed that 
atrial fibrillation after PCI (OR 3.69, 95% CI 1.87–7.29) but not before PCI (OR 1.86, 
95% CI 0.89–3.90) was independent and statistically significantly associated with 
long-term mortality.
Conclusion
In patients with STEMI, atrial fibrillation after but not before primary PCI has independent 
prognostic implications. Possibly, atrial fibrillation after the PCI is a symptom of failed 
reperfusion and a sign of heart failure. 
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in older patients and in those with Killip class >1. Also patients with occlusion of the 
RCA or TIMI flow 0 before primary PCI more commonly had AF after the procedure. 
Unsuccessful reperfusion was associated with a higher incidence of AF.
Multivariable analyses revealed that statistically significant independent predictors of 
AF after PCI were age (OR 1.06/years, 95% CI 1.03–1.09), Killip class >1 (OR 2.6, 95% 
CI 1.2–5.7), and occluded RCA (OR 2.2, 95% CI 1.3–3.9). Failed reperfusion by 
primary PCI was not independently associated with post-procedure AF (OR 1.88, 
95% CI 0.93–3.79).
Measurements
Electrocardiography (ECG) was performed at admission (first ECG), and at 3 h after 
PCI (second ECG), according to the protocol. All ECGs were analysed as pairs by an 
independent core laboratory (DIAGRAM BV, Zwolle, the Netherlands) and graded for 
ST-segment elevation resolution by two investigators who were unaware of the clinical 
data, angiographic findings, and outcome.
Statistical analysis
Differences between group means at baseline were assessed with the two-tailed 
Student’s t-test. Chi-square analysis or Fisher’s exact test was used to test differences 
between proportions. Survival was calculated by the Kaplan-Meier product-limit 
method. The log-rank test was used to evaluate differences in survival curves. 
The Cox proportional- hazards regression model was used to calculate relative risks 
adjusted for differences in baseline characteristics. To predict the independent 
association between atrial fibrillation and clinical characteristics, multivariable logistic 
regression analysis was performed. Statistical significance was considered a two- 
tailed p value <0.05. The Statistical Package for the Social Sciences (SPSS Inc., 
Chicago, IL, USA) version 10.1 was used for all statistical analysis.
Results
Of the included 2134 patients, electrocardiographic data were available in 1623 
patients (76%) before the primary PCI, and in 1728 patients (81%) after the primary 
PCI. Paired ECGs were available for 1472 patients. The mean age of the 2134 patients 
was 60.7 years (range 24–89) and there were 475 females (22%).
Atrial fibrillation before primary PCI
Of the 1623 patients with electrocardiographic data before primary PCI, 53 patients 
(3.3%) had atrial fibrillation. Differences between patients with and without atrial 
fibrillation before primary PCI are summarised in Table 1. Patients with atrial fibrillation 
were older, were more often female and less often had anterior MI location. 
Independent predictors of AF before PCI were age (OR 1.04/years, 95% CI 1.03–1.07), 
Killip class >1 (OR 4.7, 95% CI 2.38–9.36), and inferior infarct location (OR 2.39, 95% 
CI 1.3–4.38).
Atrial fibrillation after primary PCI
Of the 1728 patients with electrocardiographic data after primary PCI, 52 patients 
(3.0%) had atrial fibrillation. Differences between patients with and without atrial 
fibrillation after primary PCI are shown in Table 2. Atrial fibrillation was more common 
Table 1   Baseline characteristics of 1623 patients with data on atrial fibrillation  
before primary PCI.
Characteristic Atrial Fibr. Sinus rhythm p-value
(N=53) (N=1570)
Age, yrs (mean ± SD) 66 ± 11.2 60.5 ± 11.3 0.001
Men 66 78 0.03
Previous MI 9.4 9.7 0.95
Previous PCI 2  4.5 0.36
Previous CABG 0 2 0.30
History of stroke 2 3 0.67
Diabetes mellitus 8 11 0.45
Hypertension 25 28 0.60
Currently smoker 43 53 0.19
Hypercholesterolaemia 17 21 0.46
Killip class > 1 25 6 0.001
Family history 40 40 0.92
Anterior MI 30 49 0.009
Multi-vessel disease 60 53 0.28
Occlusion of LAD 30 45 0.04
Occlusion of RCA 47 34 0.06
TIMI 0 flow before PCI 57 60 0.59
Collaterals 6 9 0.38
Successful reperfusion* 79 88 0.06
Data are mean (standard deviation) or % unless otherwise indicated. MI = myocardial infarction. CABG = 
coronary artery bypass grafting. * Successful reperfusion denotes TIMI 3 flow and blush grade 2 or 3
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Both atrial fibrillation before and after primary PCI were associated with increased 
long-term mortality. Mortality in patients with pre-PCI AF was 21% while in those 
without AF only 5% (p < 0.01). In patients with AF after primary PCI, mortality was 23% 
in contrast to 4.7% in those without AF after primary PCI (p = 0.001).
After adjusting for differences in age, gender and Killip class on admission by means 
of multivariable analyses, however, atrial fibrillation after PCI (OR 3.69, 95% CI 
1.87–7.29) but not before PCI (OR 1.86, 95% CI 0.89–3.90) remained statistically 
significantly associated with long-term mortality.
Mortality
Data on long-term survival were available in 1683 patients (79%) in the total study 
group, with a mean follow-up duration of 481 days (SD: 281). In this group, a total of 
129 patients (7.7%) died during follow-up. In the 1623 patients with data on atrial 
fibrillation before PCI, follow-up data were available in 1198 patients; 72 patients 
(6.0%) died during long-term follow-up (Fig. 1). Among the 1728 patients with data on 
atrial fibrillation after PCI, follow-up was available of 1270 patients (71%). Of these 
patients, 71 (5.3%) died during the follow-up period (Fig. 2). Particularly in patients 
who died before the PCI, or shortly thereafter, no data on rhythm were available.
Table 2   Baseline characteristics of 1728 patients with data on atrial fibillation  
after primary PCI.
Characteristic Atrial Fibr. Sinus rhythm p-value
(N=52) (N=1676)
Age, yrs (mean ± SD) 67 ± 9.8 60.2 ± 11.3 0.001
Men 75 78 0.59
Previous MI 17 9.5 0.06
Previous PCI 5.8 4.1 0.56
Previous CABG 2 2 0.99
History of stroke 2 3 0.66
Diabetes mellitus 6 11 0.25
Hypertension 33 27 0.37
Currently smoker 40 54 0.05
Hypercholesterolaemia 25 21 0.53
Killip class > 1 17 6 0.001
Family history 33 42 0.20
Anterior MI 40 49 0.23
Multi-vessel disease 69 52 0.02
Occlusion of LAD 39 46 0.28
Occlusion of RCA 54 34 0.003
TIMI 0 flow before PCI 75 61 0.04
Collaterals 6 9 0.40
Successful reperfusion* 79 89 0.03
Data are mean (standard deviation) or % unless otherwise indicated. MI = myocardial infarction. CABG = 
coronary artery bypass grafting. * Successful reperfusion denotes TIMI 3 flow and blush grade 2 or 3
Figure 1   Kaplan-Meier curves of patients with or without atrial fibrillation before 
primary PCI.
Figure 2   Kaplan-Meier curves of patients with or without atrial fibrillation after 
primary PCI.
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Predictive value of AF
The prognostic value of AF in long-term and in-hospital mortality has been extensively 
studied previously in the thrombolytic and pre-thrombolytic era, and a recent 
meta-analysis revealed that AF in myocardial infarction was associated with at least 
a 40% increase in mortality compared with patients with sinus rhythm. 15 However, 
there is great variation among the different studies. 9
In the pre-thrombolytic era, the prognostic importance of AF in patients suffering an 
AMI is not completely clear, but probably AF was an independent risk factor for 
long-term mortality. 3, 5, 7, 9
In patients receiving thrombolysis the impact of AF on mortality seems to be reduced, 
also with controversial results.1 In GUSTO-I late onset AF (onset during hospitalisation) 
was independently associated with increased 30-day mortality and in-hospital stroke 
but neither pre-admission nor late-onset AF had significant influence on 1-year 
mortality.2 However, in GISSI-3 (319 pre-admission AF and 1069 late onset AF 
patients) AF was an independent predictor of both in-hospital and 4-year mortality.6 
In GUSTO-III both early (within 48 h after onset of AMI symptoms) and late (after 48 h) 
onset AF were independently associated with increased 30-day and 1-year mortality.8 
Asanin et al. found that late AF was an independent predictor for long-term (seven- 
year) mortality but not for in-hospital mortality.16 Unfortunately, the definition of early 
and late onset AF varied between the different studies. In the GUSTO trials, late AF 
was defined as development of AF 48 h after onset of symptoms whereas Asanin et 
al. classified late AF as AF more than 24 h after symptom onset. Also the term ‘new 
AF’ may cause confusion. Some studies used ‘new AF’ to describe patients with AF 
on admission 8, 17 whereas other studies used this term exclusively to describe 
new-onset AF developed during admission.4, 6, 15
The prognostic value of AF in patients receiving primary PCI treatment for STEMI has 
been studied less extensively so far. Kinjo et al. proved the incremental value of late 
onset AF (AF during hospitalisation), but not baseline AF, in predicting long-term 
mortality in patients undergoing primary PCI for STEMI.4 In-hospital mortality, 
however, was not independently predicted by either baseline or late-onset AF. In the 
APEX-AMI trial, new onset AF was independently associated with 90-day mortality.18
Our data confirmed the findings of Kinjo et al. The strength of the present study is, 
however, that all patients were included who were hospitalised with acute STEMI 
minimising selection bias. In our study, ECGs were obtained 3 h after PCI, and so AF 
with later onset or earlier termination was not taken into consideration. Therefore, our 
results suggest that early post-PCI AF may reflect less complete reperfusion or a 
Discussion
The current study underlines the importance of AF in identifying STEMI patients in 
increased risk, probably requiring more aggressive therapy and closer follow-up.
Prevalence of AF
The overall prevalence of AF among AMI patients has been reported in a range of 
5–22%. More recent studies show a slight decrease in incidence of AF in acute 
myocardial infarction compared with studies of the 1990s. This observed trend might 
be due to changing definitions of AF, size and characteristics of patient samples 
studied and differences in therapies that may decrease the risk of AF.1-8, 12 This trend may 
be countered by the fact that patients involved in more recent studies (i.e. treated with 
thrombolysis or primary PCI) were older and in a worse cardiovascular condition than 
those involved in studies of the pre-thrombolytic era.1 Advanced age and worse 
haemodynamic state (worse Killip class) have been uniformly associated with the 
development of AF in studies involving patients treated conservatively or with 
thrombolysis or, most recently, with primary, PCI.2, 3, 4 Divergent results are available 
about the relation between the development of AF and the infarct-related artery (IRA), 
male or female gender, the presence of hypertension or diabetes.1-8 In the present 
study, AF was diagnosed in 3.3% of patients on admission and was associated with 
advanced age, worse Killip class and inferior infarct location.
Post-PCI AF was diagnosed in 3% of our patients and was associated with advanced 
age, worse Killip class and the occlusion of RCA. Post-PCI AF, however, was assessed 
on ECGs obtained 3 h after the procedure, thus representing early AF occurrence. No 
additional data are available about AF occurrence during the preceding and the 
following period of hospitalisation. This offers an explanation for the lower post-PCI 
AF rate as compared with the findings of Kinjo et al. 4 In that study the rate of post-PCI 
AF was 7.7% representing AF occurrence rate during the entire hospitalisation. Similar 
in-hospital occurrence rates were reported by Pizzetti et al. (6%), Wong et al. (6.5%) 
and Crenshaw et al. (7.9%) among patients treated with thrombolysis. 2, 6, 8 Associated 
risk factors have been divergent among these studies regarding infarct-related artery, 
hypertension and diabetes, but worse Killip class and advanced age have been 
uniformly associated with the development of AF. The AF mechanism in acute 
coronary artery disease is multifactorial. Experimental studies in dogs revealed that 
atrial ischaemia promotes AF triggers and creates a substrate for AF maintenance by 
sustained reentry. 13, 14
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more compromised cardiac status, even though these potential confounders were 
included in our multivariate analyses. The possible causative role of AF also has to be 
taken into consideration, given its well-known detrimental effect on myocardial 
metabolism, blood supply and remodelling in such a highly vulnerable period.
The divergent way ‘early’ and ‘late’ onset AF and ‘long-term follow-up’ are defined in 
the above-mentioned studies makes the interpretation of the data harder and partially 
explains the controversial results. The establishment of a uniform classification may 
aid further evaluations and lead to a consensus regarding the incremental predictive 
value of AF in patients with acute STEMI .
Study limitations
Evaluation of pre-PCI AF’s prognostic value is always hindered by the absence of 
data on AF history, making it impossible to really distinguish between acute onset 
and persistent AF (i.e. not related to the acute ischaemic event). It is possible that 
pre-PCI AF could also have represented significant prognostic value if only patients 
with new onset AF had been taken into consideration.
Post-PCI AF was assessed routinely on ECGs obtained 3 h post-procedure. Therefore 
are conclusions about the prognostic value of post-PCI AF only applicable for 
patients with early AF occurrence, and not for the entire hospitalisation period? The 
results, however, are in agreement with the findings of Kinjo et al.4 where any AF 
period during hospitalisation was taken into consideration. We had no data on 
medication during the follow-up period, such as aspirin, clopidogrel or coumarins.
Conclusion
In patients treated with primary PCI for STEMI, atrial fibrillation after but not before the 
PCI has independent prognostic implications. It is unclear what the mechanism is of 
the worse prognosis, decreased LV function, less complete reperfusion or other 
medication during the follow-up period.
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Introduction
Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia in clinical 
practice and is likely to become even more common with the expected aging of the 
population. Atrial dilatation is a well-established risk factor for the development of 
AF.1 On the other hand, AF is also a cause of atrial dilatation2 and is accompanied by 
a decrease in atrial contractility and decrease in the compliance of fibrillating atria.3 
Acute atrial dilatation has been shown to cause an increase in local conduction 
delays.4 In experimental studies, AF with concomitant congestive heart failure was 
associated with structural remodeling, including atrial fibrosis, causing an increase in 
anisotropy, and local conduction delays.5,6 The increase in spatial heterogeneity of 
excitable properties by atrial dilatation raises the question whether acute dedilatation 
of chronically fibrillating atria would result in (partial) recovery of these atrial excitable 
properties. The hypothesis that electrical cardioversion of persistent AF was facilitated 
by lowering atrial pressure was supported by the impression of our thoracic surgeons 
performing surgical AF ablation. The objective of the present study was to evaluate 
whether acute dedilatation and dilatation of the atria in patients with long-standing 
persistent AF and structural heart disease could change the electrophysiological 
characteristics of AF. In particular, we hypothesized that acute dedilatation of 
fibrillating atria would diminish the amount of conduction block (CB) and reduce the 
degree of spatiotemporal dissociation during AF.
Methods
Patient selection
Nine patients with long-standing persistent AF (>1 year) scheduled for elective 
cardiac surgery and concomitant radiofrequency-modified Maze surgery were 
included. All patients gave written informed consent. The intraoperative measurements 
were all performed in the Isala Klinieken, Zwolle, The Netherlands. The research 
protocol was approved by the hospital board and the medical ethics committee. 
Patients receiving class I or class III antiarrhythmic drugs were excluded from the 
study unless the drugs were stopped for more than 5 half-lives prior to surgery. 
Patients with prior cardiac surgery were also excluded. A 12-lead electrocardiogram, 
24-hour cardiac rhythm monitoring, and transthoracic echocardiography were 
performed the day before surgery.
Acute atrial dedilatation and dilatation
During general anesthesia, sternotomy was performed and the pericardium was opened 
to expose the heart. Cardiopulmonary bypass was accomplished by cannulation of 
Abstract
Background
The electrophysiologic effects of acute atrial dilatation and dedilatation in humans 
with chronic atrial fibrillation remains to be elucidated.
Objective
To study the electrophysiological effects of acute atrial dedilatation and subsequent 
dilatation in patients with long-standing persistent atrial fibrillation (AF) with structural 
heart disease undergoing elective cardiac surgery.
Methods
Nine patients were studied. Mean age was 71±10 years, and left ventricular ejection 
was 46%±6%. Patients had at least moderate mitral valve regurgitation and dilated 
atria. After sternotomy and during extracorporal circulation, mapping was performed 
on the beating heart with 2 multielectrode arrays (60 electrodes each, interelectrode 
distance 1.5 mm) positioned on the lateral wall of the right atrium (RA) and left atrium 
(LA). Atrial pressure and size were altered by modifying extracorporal circulation. AF 
electrograms were recorded at baseline after dedilation and after dilatation of the 
atria afterward.
Results
At baseline, the median AF cycle length (mAFCL) was 184±27 ms in the RA and 
180±17 ms in the LA. After dedilatation, the mAFCL shortened significantly to 168±13 
ms in the RA and to 168±20 ms in the LA. Dilatation lengthened mAFCL significantly 
to 189±17 ms in the RA and to 185±23 ms in the LA. Conduction block (CB) at 
baseline was 14.3%±3.6% in the RA and 17.3%±5.5% in the LA. CB decreased 
significantly with dedilatation to 7.4%±2.9% in the RA and to 7.9%±6.3% in the LA. 
CB increased significantly with dilatation afterward to 15.0%±8.3% in the RA and to 
18.5%±16.0% in the LA.
Conclusions
Acute dedilatation of the atria in patients with long-standing persistent AF causes a 
decrease in the mAFCL in both atria. Subsequent dilatation increased the mAFCL. 
The amount of CB decreased with dedilatation and increased with dilatation afterward 
in both atria.
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The protocol for dilatation and dedilatation was as follows: First, left atrial pressure 
was adjusted to the baseline value measured prior to sternotomy. Then, after the atrial 
pressure had been stable for 2 minutes, it was lowered to 5 mm Hg. This caused a 
decrease in the circumference of the LA from 15.2±3.4 to 12.2±3.8 cm. This 
dedilatation was maintained for 2 minutes, and then atrial pressure was increased to 
twice the baseline pressure (with a maximum of 25 mm Hg). This resulted in dilatation 
of the LA to 18.1±3.5 cm. After 2 minutes the baseline pressure was restored.
High-density epicardial atrial mapping
Intraoperative mapping during AF was performed at normothermia while on 
extracorporal circulation. Right and left AF electrograms were recorded continuously 
with 2 mapping arrays of 64 electrodes (interelectrode distance 1.5 mm; surface area 
1 cm2). In the online supplement (Figure S1), an example of the mapping catheter is 
provided. During dilatation and dedilatation of the atria, the position of the mapping 
electrodes was kept constant. The right atrial electrode was positioned directly ventral 
to the crista terminalis in the middle of the inferior and superior vena cava. The left 
atrial mapping electrode was positioned at the posterior base of the left atrial 
appendage. A silver plate was placed subcutaneously in the thoracic wall to serve as 
an indifferent electrode. The epicardial electrograms were recorded together with a 
surface electrocardiogram (lead II) and transferred to a computer by means of a 
custom-made 256-channel amplifier (0.75-Hz high-pass filter, 470-Hz low-pass filter; 
sampling rate 1000 Hz). Ten consecutive seconds of AF were analyzed during 
baseline and during dilatation and dedilatation of the atria. Local activation times at 
each electrode were determined from the steepest negative deflection in fibrillation 
potentials. In the case of double potentials or fractionated electrograms, the largest 
potential was taken. The median AF cycle length (mAFCL) was calculated from all 
fibrillation intervals recorded by the mapping arrays. The temporal variation in AFCL 
was measured as the beat-to-beat changes in AFCL at all electrodes. It was expressed 
as the standard deviation of the distribution of all beat-to-beat variations (p5-p50). 
The irregularity index was defined as the temporal variation of the time intervals 
between successive AF cycle lengths divided by the mAFCL for the total number of 
cycle lengths analyzed. The interelectrode conduction times were used to measure 
the amount of local conduction delays and intra-atrial block. The lower level of atrial 
conduction velocity is 25–30 cm/s,7 and slower velocities are regarded as slow 
conducting areas. When conduction slows further to 10–15 cm/s, propagation of 
conduction fails. CB was therefore defined as a local conduction delay of≥15 ms 
between 2 neighboring electrodes, corresponding to a conduction velocity of≤10 
cm/s. Since during atrial dilatation the same distance between the electrodes is 
covered by less myocardial cells, the conduction times were normalized for the 
degree of atrial stretch. The increase in the amount of atrial tissue between electrodes 
the superior and inferior caval veins and the aorta. A pressure catheter was inserted 
in the left atrial appendage to record left atrial pressure. Arterial blood pressure was 
recorded continuously in the femoral artery. Central venous pressure, pulmonary 
capillary wedge pressure, and cardiac output were measured with a Swan-Ganz 
catheter. The pulmonary capillary wedge pressure prior to sternotomy was taken as 
the baseline pressure in the left atrium (LA). Right and left atrial pressures were 
changed acutely by varying the amount of blood flow through the extracorporal 
circulation. This was associated with a change in mean arterial pressure of 5±3 mm Hg. 
The amount of atrial dilatation and dedilatation was measured by transesophageal 
echocardiography. The size of the LA was measured by determining mediolateral and 
caudocranial size and also by tracing its circumference and calculating the surface 
area of the left atrial cavity as viewed in the 4-chamber mid-esophageal view (Figure 1).
Figure 1   Overview of right and left atrial and arterial pressures at baseline,  
after dedilatation, and after dilatation in a patient. Corresponding 
 transesophageal images with left atrial circumference are depicted. 
Acute atrial dedilation and dilatation were successful, with similar  
arterial pressures.
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dedilatation, and 23.1±3.5 mm Hg during dilatation (Figure 3). The corresponding 
central venous pressures were 8.2±1.6, 3.7±0.9, and 13.0±2.8 mm Hg, respectively. 
The left atrial size measured with transesophageal echo was 26.2±6.2 mm2 at 
baseline, 19.3±7.8 mm2 during dedilatation (P = .0005), and 29.9±6.2 mm2 during 
dilatation (P = .001).
Effects on AFCL
Table 2 gives the average effects for all patients. In the RA, dedilatation shortened the 
mAFCL from 184±27 to 168±13 ms (P = .10). Dilatation of the RA thereafter 
significantly prolonged the mAFCL to 189±17 ms (P = .01). The temporal irregularity 
interval (70% DI 60%) in the RA showed a nonsignificant reduction by dedilatation 
from 50.4±26.5 to 43.5±17.1 ms (P = .18). Dilatation thereafter did not show changes. 
In the LA, dedilatation caused a statistically significant shortening of the mAFCL from 
180±17 to 168±20 ms (P = .007), whereas dilatation thereafter significantly increased 
the mAFCL to 185±23 ms (P = .03). The temporal irregularity interval (70% dominant 
intervals [DI] 60%) in the LA showed a nonsignificant reduction by dedilatation from 
38.3±24.0 to 32.3±18.3 ms (P = .34). Dilatation thereafter did not show changes (see 
Table 2). The AFCL between the RA and the LA did not differ during baseline, after 
dedilatation, and after dilatation (P≥.66). Figure 4 shows an example of the effects of 
atrial dedilatation and dilatation in a patient.
was calculated from the change in left atrial size measured in the 4-chamber view. 
The factor by which the individual electrophysiological parameters were corrected 
was c after dilatation or dedilatation divided by c at baseline (where a is the 
mediolateral atrial size and b is the caudocranial atrial size, and c is calculated by 
using Pythagoras’ principle a2 + b2 = c2).
Statistical analysis
Data were expressed as mean±SD, with the range of the data where appropriate. 
Fibrillation intervals were expressed as mAFCL. The statistical effects of acute atrial 
dedilatation and dilatation on mAFCL, temporal variability of AF, and amount of atrial 
CB were checked by a paired Student t test after testing whether variables were 
normally distributed. A P value of<.05 was considered statistically significant.
Results
Baseline characteristics
Table 1 summarizes the clinical characteristics of the patients. Mean age was 
70.6±10.2 years. All patients were men and had an average AF duration of 5.3±5.0 
years. All patients had structural heart disease. Mean left ventricular ejection fraction 
was 46.1%±6.0% (range 35%–55%). Mean left atrial size was 49.6±4.5 mm in the 
parasternal long-axis view and 69.2±4.7 mm in the 4-chamber view. Mean right atrial 
size was 62.6±4.2 mm. 
Simultaneous mapping of right and left atria
Figure 2 shows some simultaneously recorded fibrillation electrograms from the right 
atrium (RA) and the LA in a patient with mitral regurgitation. The electrograms and 
maps on the right side were recorded from the lateral wall of the RA and on the left 
side from the lateral wall of the LA. The 3 fibrillation maps of the LA show a more 
complex pattern of activation with multiple wavelets and areas of CB, whereas the 3 
consecutive activation maps of the RA demonstrate a more uniform activation pattern 
with broad wave fronts and a limited number of wavelets. In this patient, there was a 
higher amount of CB in the LA (21.0% in the LA vs 14.7% in the RA). In all 9 patients 
with mitral valve disease, the mean percentage of left atrial CB tended to be higher 
than that of right atrial CB at baseline; however, this difference was not statistically 
significant.
Changes in atrial pressures and size
Acute atrial dedilatation and dilatation were successfully performed in all patients. 
Mean left atrial pressure was 14.4±3.2 mm Hg at baseline, 5.0±1.2 mm Hg during 
Table 1   Baseline characteristics.
Number of patients 9
Age (years) 70.6±10.2 (56-80)
Male (n) 9
AF duration (years) 5.3±5.0 (1-15)
Atrial dimensions
    RA 4 chamber view (mm) 62.6±4.2  
    LA parasternal long axis (mm) 49.6±4.5 
    LA 4 chamber view (mm) 69.2±4.7
Cardiac disease
    MR (n) 6
    MR + CAD (n) 3
LVEF (%) 46.1±6.0 (35-55)
Data are mentioned as frequencies, means ±SD, and the range between parentheses where appropriate. 
AF: atrial fibrillation; CAD: coronary artery disease; LVEF: Left ventricular ejection fraction; LA: left atrium; 
MR: mitral valve regurgitation; RA right atrium
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Figure 2   Simultaneously recorded fibrillation electrograms from the lateral wall of 
the left and right atria. The 3 fibrillation maps of the left atrium show a 
more complex activation pattern with multiple wavelets and areas of 
conduction block compared to a more uniform activation pattern with 
broad wave fronts and a limited number of wavelets in the right atrium.  
In this patient, there was a higher amount of conduction block in the left 
atrium (21.0%) than in the right atrium (14.7%).
Figure 3   A: Mean atrial pressures + SD at baseline, after acute dedilatation, and 
after dilatation. B: Mean left atrial area±SD at baseline, after acute 
dedilatation, and after dilatation.
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Figure 4   Example of the effects of atrial dedilatation and dilatation afterward on 
the atrial fibrillation cycle length (AFCL) and the irregularity index (ΔAFCL) in 
the left atrium. In this patient, the median AFCL during baseline was  
150 ms, with an irregularity index of 41 ms. Atrial dedilatation shortened 
the AFCL to 139 ms and reduced the irregularity index to 32 ms. Dilatation 
afterward lengthened the AFCL to 155 ms and increased the irregularity 
index to 36 ms.
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the LA and RA significantly during persistent AF. This was associated with a shortening 
of the AFCL by 7% and 9% in the LA and RA, respectively. Spontaneous conversion 
to sinus rhythm as a result of atrial dedilatation was not observed. Increasing the atrial 
pressure above the baseline values significantly prolonged the AFCL compared to 
dedilated atria. Moreover, a significant increase in the amount of CB of fibrillation 
waves was observed in both the LA and the RA.
Intra-atrial CB during AF
Direct measurements of the amount of CB during AF did not show a significant 
alteration after atrial dilatation or dedilatation. Only after correction for the amount of 
atrial tissue between the electrodes, the degree of CB was significantly altered. Atrial 
dedilatation caused a decrease in the amount of CB, whereas an increase in atrial 
pressure above the baseline led to an increase in the degree of atrial CB. The 
differences in CB were not significantly different between atria. In 1963, Penefsky and 
Hoffman8 showed that mild atrial stretch did not affect the conduction velocity and 
transmembrane potentials in the atria. During excessive stretch, however, multiple 
deflections were observed as a sign of discontinuous conduction. More recently, 
experimental studies in rabbit and canine hearts4,9 showed that acute atrial stretch 
clearly increased the amount of atrial CB. However, in these studies, structurally 
normal hearts were used without preexistent AF, whereas in our study population, the 
atria were chronically dilated owing to mitral regurgitation and long-standing 
persistent AF. We think that our study design more closely represents the clinical 
practice.
Kuijpers et al10 showed that pacing-induced atrial stretch in new-onset AF caused 
increased dispersion of the atrial effective refractory period (AERP). Furthermore, 
conduction slowing and local CB were observed owing to the heterogeneous 
activation of a nonselective stretch-activated cation current. Ravelli et al11 proved that 
pacing-induced atrial stretch (23% increase in atrial volume) resulted in a decrease in 
atrial conduction velocity. They objectified an increased incidence of slow conduction 
sites or local CBs and increased AF vulnerability, with as much as 6 of 10 patients 
developing AF episodes under stretch conditions. Kalifa et al12 investigated the 
metabolic effects of acute atrial stretch-induced AF in rabbit hearts. Specific 
modifications of atrial myocytes energetics, such as lower the total adenine 
nucleotides’ pool, could play a pivotal role in the perpetuation of the arrhythmia. 
Coronel et al13 demonstrated in patients with mitral stenosis undergoing percutaneous 
transvenous mitral balloon valvotomy that this resulted in shortening of left atrial and 
right atrial activation times. The dispersion in activation times in the LA decreased 
significantly after than before the procedure. Fan et al14 showed that the reduction of 
chronic atrial stretch in patients with mitral stenosis resulted in a homogeneous 
Effects on intra-atrial CB
Figure 5 illustrates the effects of atrial dilatation and dedilatation on the amount of CB 
in the left lateral wall. The activation maps do not show a change in the number of 
fibrillation waves at different atrial pressure levels. The mean amount of right atrial CB 
(≥15 ms) in the study population at baseline (10.3%±3.5%) was similar to that after 
dedilatation (11.8%±4.9%) and dilatation (11.2%±6.1%; P value of differences≥.25). 
In the left atrial wall, these values were 14.7%±9.9% at baseline compared to 
13.9%±9.5% after dedilatation and 13.9%±10.6% after dilatation (P values of 
differences ≥.57). After correction for the amount of atrial tissue under the mapping 
electrode, dedilation caused a decrease in right atrial CB during AF to 7.4%±2.9% 
(P = .047 vs baseline). Dilatation afterward raised the percentage of CB to 15.0%±8.3% 
(P = .028 vs dedilatation). After correction for the amount of atrial tissue under 
the mapping electrode, dedilation caused a decrease in left atrial CB during AF to 
7.9%±6.3% (P = .026 vs baseline). Dilatation afterward raised the percentage of CB 
to 18.5%±16.0% (P = .058 vs dedilatation). Figure 6 exhibits an example of a patient 
with a significant reduction of CB after dedilatation and an increase after dilatation.
Discussion
Main findings
We tested the hypothesis that acute atrial dedilatation would decrease the amount of 
intra-atrial CB and diminish the number of fibrillation waves, thereby potentially 
increasing the likelihood of successful cardioversion. To our knowledge, this is the 
first study that reports the electrophysiological effects of acute dedilatation and 
dilation in patients with long-standing persistent AF with dilated atria and structural 
heart disease. We found that acute atrial dedilatation decreases the amount of CB in 
Figure 6   Example of a patient with 21.0% conduction block (≥15 ms) at baseline, 
with a significant reduction to 12.1% after dedilatation and an increase to 
22.0% after dilatation.
0 10 20 30 40 >=50 
conduction times (ms) 
# 
1075 
1935 
1505 
645 
215 
N 
# CB 21.0% 
0 10 20 30 40 >=50 
conduction times (ms) 
# 
1025 
1845 
1435 
615 
205 
N 
# CB 12.1% 
0 10 20 30 40 >=50 
conduction times (ms) 
# 
# CB 22.0% 
1025 
1845 
1435 
615 
205 
N 
56 57
CHAPTER 3 EFFECTS OF ACUTE ATRIAL STRETCH
3
different atrial pressures with slow fixed-rate atrial pacing.22 Such measurements 
would take quite some time in the operating room, which was the reason for us to 
omit these measurements.
Limitations
The present study has limitations and strengths. Unfortunately, the number of 
mapped patients is too small to calculate correlations between changes in pressure 
and atrial size and changes in electrophysiological parameters. The directions of 
electrophysiological changes were similar and significant, however. The protocol of 
first dedilation and dilatation afterward was consequent and not varied. Variation of 
the protocol could have increased the reliability of the observations; however, at least 
double the patients would have been necessary to prove significance of changes. 
The amount of CB was, as in previous studies,7 normalized for the degree of atrial 
stretch, and thus the amount of atrial tissue between electrodes. However, since the 
degree of stretch can vary at different sites, especially at sites with fibrosis, this 
normalization carries a certain inaccuracy. Further errors could be induced by an 
incomplete adaption of the mapping catheter to changes in atrial size. However, the 
mapping catheter was small and was consequently placed in the same regions, 
probably with the similar tissue thicknesses and with similar degrees of fibrosis. 
Furthermore, proper signals were observed at all stages, pointing toward good 
contact of the electrodes to atrial tissue. Although the electroanatomic properties of 
the atria changed beneficially, the hypothesis that electrical cardioversion of AF was 
more successful at lower atrial pressures was not directly tested and is subject to 
further studies. We reduced atrial pressure, size, and stretch by reducing the flow of 
the cardiopulmonary bypass. It remains unknown how to achieve the reduction of 
atrial stretch in patients with nonoperated AF. One way to try this is (aggressive) 
diuretic therapy during antiarrhythmic therapy or before and after cardioversion. 
Other methods are “upstream therapeutic medicines,” such as angiotensin receptor 
blockers (“sartans”), because of their beneficial effect on the angiotensin II type 2 
receptor, with positive remodeling of the myocardium and regression of hypertrophy 
and fibrosis.23
Implications for clinical practice
Chronic atrial stretch induces activation of numerous pathways, leading to cellular 
hypertrophy, fibroblast proliferation, and tissue fibrosis.3 The resulting substrate in 
dilated atria is characterized by increased electric alternans in atrial myocytes and 
slowing of conduction, promoting reentrant circuits in the atria and raising the 
vulnerability for persistent AF.24 In our study, we acutely reduced atrial size and 
pressures, providing acute changes in some electrophysiological parameters. 
However, one should keep in mind that patients had chronic AF with chronically 
increase in regional AERP in the group of patients without preexistent AF and a 
decrease in the dispersion of refractoriness in patients with long-standing persistent 
AF. Satoh and Zipes15 studied the influence on electrophysiological properties 
caused by atrial stretch in open chest dogs. They observed significantly higher 
increases in AERP owing to stretch in thin parts of the atria. This pointed toward an 
increased dispersion of refractoriness caused by stretch to atrial tissue with different 
thickness and/or elasticity. An increase in AERP dispersion resulted in vulnerability to 
AF in all the 5 dogs studied, whereas at baseline, AF was not inducible. Thus, our 
results are in line with previous reports regarding the effects of atrial stretch on atrial 
conduction velocity and blocks.
AF cycle length
In our study, acute dedilatation of the atria resulted in the shortening of the mAFCL by 
7%–9%. Acute dilatation showed large increases in the mAFCL compared to 
dedilated atria (12.7% in the RA vs 10.1% in the LA). This is in contrast with the results 
of 2 animal studies that found an increase in dominant frequency (DF) by atrial 
dilatation.16,17 In contrast to our study, the atria were not enlarged at baseline. Since 
AF was induced acutely, no electrical or structural remodeling was present in these 
atria.18 Since DFs are measured by spectral analysis, they do not always correspond 
to the actual dominant AFCL.19 DFs are especially affected by signal fractionation, 
which is an expression of underlying conduction disturbances.20 Considering the 
increase in the amount of CB with acute atrial dilatation in the rabbit heart,4 it is 
possible that the observed increase in DF by acute atrial dilatation reflects an increase 
in fractionation rather than an increase in the AFCL. Different electrophysiological 
mechanisms can explain the change in the AFCL with atrial stretch: a change in the 
amount of CB, an increase in the AERP, a change in conduction velocity, or a 
combination of the 3.
Our present report shows that lowering atrial pressures shortens the mAFCL slightly 
and lowers the amount of CB. Dilating the atria through raising the pressure from low 
to high lengthens AFCL, as well as increases the amount of CB. Our results are 
further supported by a report by Neuberger et al,21 who observed that in dilated atria 
the excitable gap during AF is wider, probably caused by intra-atrial conduction 
defects and a higher contribution of anatomically defined reentrant circuits. A third 
explanation of the change in the AFCL with atrial dilatation is that atrial dilatation 
influences conduction velocity. Slowing of the conduction velocity lengthens the 
wavelets, and thus the number of wavelets decreases and AFCL lengthens. Slowing 
of conduction velocity by atrial dilatation is also directly or circumstantially supported 
by other studies.4 To unravel the underlying mechanism of the change in the AFCL 
with atrial stretch, measurements of ERP should be performed during AF and at 
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dilated and remodeled atria. This could be the reason for the relatively modest, 
however significant, changes we have observed. Whether longer term reduction in 
atrial size and pressure could result in larger changes in electrophysiological 
properties, and possibly spontaneous cardioversion to sinus rhythm or higher 
success rates of active cardioversion, remains an issue for further research. These 
changes could facilitate beneficial atrial remodeling, easier conversion to sinus 
rhythm, and higher rates of long-term sinus rhythm.
Conclusions
Acute dedilatation of the atria in patients with long-standing persistent AF causes a 
decrease in the mAFCL in both atria. Subsequent dilatation increased the mAFCL. 
The amount of CB decreased with dedilatation and increased with dilatation afterward 
in both atria. We did not observe changes in the temporal variation of the AFCL. 
These findings indicate beneficial electrophysiologic changes induced by dedilatation 
of the atria, which could possibly result into a higher chance of conversion to sinus 
rhythm.
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Introduction
Catheter ablation of atrial fibrillation (AF) is an acceptable option in patients whose 
quality of life is severely disturbed by AF and the arrhythmia has not responded to drug 
therapy or cardioversion. 1 Catheter ablation of AF requires expertise and remains a 
time-consuming procedure.2–7 Newer catheter designs have been developed to 
reduce procedure time.8–13 Radiofrequency (RF) ablation has become a successful 
therapeutic option for patients with symptomatic AF. Isolation of triggers within the 
pulmonary veins (PVs) is the main treatment strategy in these patients.2 Conventional 
techniques use a ring-shaped mapping catheter and a second ablation catheter that 
applies RF energy in a unipolar fashion. Complete isolation of all electrical potentials at 
the PV ostium is a technically challenging procedure requiring a long learning curve 
and extensive fluoroscopy. In addition, serious complications have been reported 
including the creation of atrio-oesophageal fistulas by inadvertent high-power 
delivery.1–7 New developments in catheter ablation of AF have attempted to address 
these challenges in a variety of methods. The pulmonary vein ablation catheter (PVAC) 
(Medtronic, Ablation Frontiers, Carlsbad, CA, USA) is a novel circular multi-electrode 
catheter that has been used to isolate PVs with duty-cycled radiofrequency energy. This 
multi-electrode over the wire device capable of circular mapping and RF energy 
delivery is intended to simplify the PV isolation procedure while reducing the risk of 
complications. Limited data are available on the safety and efficacy of this approach.8 
The objective of this study was to evaluate the efficacy of multi-electrode duty-cycled 
RF ablation with the use of PVAC. 
Methods
Patients
A total of 102 patients with paroxysmal or persistent AF, who were scheduled to undergo 
elective PV disconnection and left atrial ablation, were included in a prospective registry. 
None of the patients had an ablation procedure before. All patients consented to their 
data being registered and used for publication as did the Board of Hospital 
Administrators. Patients were admitted 24 h prior to the ablation procedure. During 
hospitalization, cardiac rhythm in all patients was continuously monitored. Transthoracic 
echocardiography was performed routinely prior to ablation to determine right and left 
ventricular function, valvular abnormalities, and left and right atrial dimensions. Tran-
soesophageal echocardiography was performed to assess inter-atrial septum and to 
rule out intra-cardiac thrombus. Multi-slice CT angiography was performed in all 
patients to asses the anatomy of the PVs, left atrium, and adjacent structures. Routine 
blood tests were performed, including electrolytes and cardiac enzymes.
Abstract
Aim
A novel multi-electrode pulmonary vein ablation catheter (PVAC) combining circular 
mapping and duty-cycled multi-electrode radiofrequency (RF) energy delivery has 
been developed to map and isolate the pulmonary veins (PVs). The aim of this study 
was to assess the efficacy of multi-electrode RF ablation using the PVAC device.
Methods and results
A total of 102 consecutive patients, age 57.9 ± 9.6 years, with paroxysmal or persistent 
drug refractory atrial fibrillation (AF) were referred for ablation. All patients had 
documented AF episodes with an AF duration of 9.3 ± 7.5 years (range 1.5–25). The 
mean total procedure time was 139.30 ± 37.72 (median 135, range 115–172). The 
mean fluoroscopy time required for PVAC ablation was 17 ± 12 min (median 16, 
range 12–33) and the total fluoroscopy time was 32.1 ± 11.3 min (median 29, range 
25–39). The mean multi-electrode RF ablation time required to achieve complete PV 
isolation was 31 ± 6.7 min (range 16–51). In eight patients with persistent AF, 
additional ablations were performed to defragment septal and posterior part of the 
left atrium. In five patients additional RF ablations using conventional catheters were 
necessary. After multi-electrode duty-cycled RF ablation, 62 of 102 (60.8%) patients 
were in sustained sinus rhythm without anti-arrhythmic drugs. The mean follow-up 
duration was 12.2 ± 3.9 months (range 6–15).
Conclusion
This novel multi-electrode ablation technique can be used for PV isolation and left 
atrium ablation with a relatively low medium-term success rate after the first ablation 
of ~61%. Larger studies with longer follow-up are required to evaluate the efficacy 
and whether multi-electrode RF ablation is associated with a different complication 
rate compared with standard PV isolation.
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Radiofrequency generator settings
The GENius™ generator (Medtronic, Ablation Frontiers) is a multi-channel RF 
generator capable of simultaneously delivering duty-cycled energy to up to 12 oper-
ator-selected electrodes. The generator has five preset energy settings: bipolar, 
unipolar, and three ratios of bipolar-to-unipolar energy: 4:1, 2:1, and 1:1. The energy 
was delivered in a temperature-controlled, power-limited manner with a maximum of 
10 W per electrode. The generator displays in real-time the temperature and power 
for each electrode, as well as the number of seconds each electrode was within 5°C 
of target temperature during the application.
Post-ablation management and follow-up
Post-ablation, patients were hospitalized for at least 24 h and monitored telemetrically. 
AF recurrence was defined as an atrial arrhythmia of >30 s. Low-molecular-weight 
heparin was given for 2–7 days and acenocoumarol for at least 3 months. Anti- 
arrhythmic drugs (Class I or III) were continued during the first 3 months and gradually 
tapered. About 24–48 h Holter monitoring was performed at 3, 6, and 12 months 
Ablation procedure
The ablation procedures were performed under conscious sedation or general 
anaesthesia. Two return electrode patches were placed between the scapulae. Two 
fixed-curve 8.5F SL-1 sheaths (St Jude Medical), and in selected cases a steerable 
sheath (Channel, Bard, Lowell, MA, USA), were introduced into the right femoral vein. 
A 6F deflectable quadripolar electrode catheter (Bard) was positioned into the 
coronary sinus. Transseptal puncture was performed with a modified Brockenbrough 
needle. An initial bolus of 10 000 units of heparin was given and 2 500–5 000 unit IV 
additional boluses to maintain an activated clotting time (ACT) between 300 and 350 
s were given. ACT was determined every 30 min. Pulmonary vein angiography was 
performed for all PVs in anteroposterior, 30° left anterior oblique and 30° right anterior 
oblique positions to provide a geometric reference for catheter navigation. The PVAC 
(Medtronic, Ablation Frontiers) is a mapping and ablation catheter with a 25 mm 
diameter circular electrode array. This catheter has a bidirectional steering mechanism 
and an over-the-wire design. The details of this device have been described 
previously. 8 Experience with the PVAC in our centre was gained prior to this study in 
a pilot study of 15 patients. 
The PVAC was introduced into the left atrium via the SL-1 sheath. Using a 0.032 in. 
guidewire placed in the vein, the catheter was positioned at the antrum of each PV to 
record local electrical activity at the veno-atrial junction prior to RF energy application. 
The PV ostia were visualized by selective contrast injection. Figure  1 is a representative 
example showing the fluoroscopic image of the position of the PVAC at the ostium of 
the left superior PV and the recorded electrograms at this position are shown in 
Figure  2 . The positions of the PVAC catheter were documented using fluoroscopy. 
RF energy was applied using the RF generator with a target temperature of 60°C, 4:1 
or 2:1 ratio between bipolar and unipolar energy, and 60 s duration. Multiple 
applications of RF were delivered using the available energy settings until isolation of 
the antrum of each vein was achieved. After extensive ablations were performed at all 
veno-atrial junctions, the PVAC was used to map all PV ostia. With the aid of the 
steerable channel sheath, the PVAC could be deployed in all right inferior pulmonary 
veins (RIPVs). If the PVs appeared to be incompletely isolated, additional RF 
applications were delivered using the PVAC until the PVs were completely 
disconnected based on PVAC signals. Thirty minutes post-ablation all PVs were 
mapped again with the PVAC and if necessary additional ablations were performed. 
In the case of failure to isolate the PVs with the PVAC, a conventional irrigated tip 
ablation catheter was used to isolate the PVs. 
Figure 1   Angiography (AP view) of the left atrium and the left sided pulmonary 
veins. In this representative example, the PVAC catheter is positioned in 
the LSPV. AP, anteroposterior; LA, left atrium; CS, coronary sinus; LIPV, 
left inferior pulmonary vein; LSPV, left superior pulmonary vein; PVAC, 
pulmonary vein ablation catheter. See text for details.
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Statistical analysis
Categorical variables are expressed as frequencies and percentages. Continuous 
data are presented as mean ± SD. Comparison of continuous variables was 
performed with the Student’s t -test. Comparison of proportions was performed with 
the χ 2 analysis or Fisher’s exact test. All P -values are two-sided and P -value <0.05 
was considered statistically significant. A two-tailed P value of <0.05 indicated 
statistical significance. Statistical analysis was performed using SPSS (SPSS Inc, 
Chicago, IL, USA). 
Results
Clinical characteristics of the patients
A total of 102 consecutive patients, age 57.9 ± 9.6 years, with paroxysmal (n = 90) or 
persistent (n = 12) drug refractory AF were referred for ablation. All patients had 
documented AF episodes with an AF duration of 9.3 ± 7.5 years (range 1.5–25). 
Clinical characteristics of the patients are summarized in Table 1. Echocardiographic 
recordings demonstrated an average left atrial size of 41.2 ± 6.5 mm in the parasternal 
long-axis view. Left ventricular ejection fraction was 59 ± 4.3 (range 45–61). 
intervals. Furthermore, 1-week AF alarm monitoring was performed 6 ± 1.5 (range 
5–8) months after ablation. The AF alarm is a battery-powered electronic arrhythmia 
detection device with ECG recording capabilities. The device automatically detects 
arrhythmias and stores a digitalized ECG of arrhythmias. Furthermore, ECG storage 
can also be manually triggered to investigate if symptomatic episodes are actually 
related to an arrhythmia.14 Oesophagoscopy was not performed routinely post-
procedure. Transthoracic echocardiography was performed 1 day after the procedure 
in all patients. All patients visited our outpatient clinic at 1, 3, 6, and 12 months 
intervals. A standard 12-lead ECG was recorded at each outpatient visit. Transthoracic 
echocardiography and spiral CT or magnetic resonance imaging of the PVs were 
performed 3 months after RF ablation to document atrial size and PV ostial 
dimensions, respectively. 
Figure 2   Tracings are surface ECG leads I, III, and V1 and intra-cardiac signals 
recorded from the proximal pair of a quadripolar catheter positioned in 
the coronary sinus and the pulmonary vein ablation catheter positioned 
in the left superior pulmonary vein. (A) The pre-ablation signals during 
sinus rhythm; (B) the pre-ablation signals during coronary sinus pacing; 
and (C and D) the signals post-ablation during sinus rhythm and 
coronary sinus pacing, respectively. See text for details
Preablation SR Preablation CS pacing Postablation SR Postablation CS pacing 
Table 1   Baseline patient characteristics.
Number (±SD) Range
No of Patients 102
Gender (m/f) 87/15
Age (years) 53.4±8.9 38-72
No. of cardioversions 43 (42%)
No of ineffective AADs 2.9±1.7 1-4
Hypertension 21 (20.6%)
Diabetes 4 (3.9%)
History of TIA/stroke 6 (5.9%)
Ischemic heart disease 5 (4.9%)
Family history of AF 2 (2%)
Left atrial size PSLAX (mm) 41.2 mm±6.5 31-44
LVEF (%) 59±4.3 45-61
Duration of AF (years) 9.4±7.1 1.5-25
Type of AF
Paroxysmal
Persistent
90
12
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Procedural success
The mean total procedure time was 139.30 ± 37.72 (median 135, range 115–172), 
including transseptal puncture and pre- and post-ablation mapping of the PVs. PV 
angiography was performed prior to ablation. Thirty patients had a left common trunk 
(Table  2). Deployment of the PVAC was successful in all the left-sided PVs and all 
right superior PVs. Deployment of the PVAC was not successful in 17 right inferior 
PVs. In these patients, a steerable channel sheath (Bard) was used. In 12 (11.8%) 
patients with persistent AF, the superior vena cava (SVC) was isolated using the 
PVAC. In 3 of these 12 patients, AF was converted to sinus rhythm during RF 
application around the SVC. The mean duty-cycled RF ablation time required to 
achieve complete PV isolation was 31 ± 7 min (range 16–51). The RF duration for 
complete PV isolation tended to be greater for the common trunks in comparison with 
the other veins (P -value left common trunk vs. others, P < 0.01). Table  2 summarizes 
the procedural data including PVAC ablation time per PV. There was no statistically 
significant difference in the PVAC ablation time between the right-sided and the 
left-sided PVs except for the left common trunks. The mean fluoroscopy time required 
for PVAC ablation was 17 ± 12 min (median 16, range 12–33) and the total fluoroscopy 
time was 32.1±11.3 min (median 29, range 25–39).
Cardiac rhythm during follow-up
The mean follow-up duration was 12.2 ± 3.9 months (range 6–15). In the total study 
population (n = 102), 62 (60.8%) patients were in sustained SR without anti-arrhyth-
mic drugs. In the paroxysmal AF group (n = 90), after the PVAC ablation procedure, 
Table 2   Procedural data.
Number  
of PVs
Diameter,  
mm
PVAC RF 
time, min
Additional 
ablations  
with irrigated  
tip catheter  
(n, pts)
Final  
confirmation of  
PV isolation  
(%)
LSPV 72 20.9±6.3 6.7±1.6 0 100
LIPV 72 18.2±4.1 5.7±1.9 0 100
RSPV 102 20.6±4.3 5.6±1.6 1 100
RIPV 102 16.9±3.9 5.5±1.4 2 100
LCPV 30 28.7±4.0* 10.5±2.1# 2 100
Overall 378 20.9±4.8 31±6.7 5 100
*P<0.01 LCPV vs other PVs; #P<0.01 LCPV vs other PVs.
Figure 3   This diagram shows the radiofrequency ablation results. (A) Circle diagram 
showing pulmonary vein ablation catheter and re-ablation results for 
patients with paroxismal and persistent AF. (B) Results for separate 
categories (persistent-, paroxismal AF, with- and without anti-arrhythmic 
drugs). RFCA, radiofrequency ablation; AF, atrial fibrillation; SR, sinus 
rhythm; AAD, anti-arrhythmic drugs.
79 SR 
58 no AAD 
21 ≥1 AAD 11 redo RFCA 
3 recurrent AF 
A
B
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Multi-electrode duty-cycled radiofrequency ablation
Boersma et al.8 reported that duty-cycled bipolar/unipolar RF ablation is effective in 
isolating PVs using relatively low power (<10 W). The success rate, defined as 
freedom from AF without anti-arrhythmic drugs, was 83% with a follow-up duration of 
6 months.8 Unfortunately, there is no information regarding the distribution among 
both types of AF (persistent vs. paroxysmal) in this latter study. Our data indicate a 
lower success rate. The possible explanations in the different success rates may be 
the longer follow-up duration in our study and/or the intensity of rhythm monitoring 
post-ablation. Scharf et al.15 investigated the efficacy and safety of duty-cycled RF 
ablation with multi-electrode ablation in 50 patients with long-standing persistent AF. 
The 6-month success rate was 80% and the 20-month success rate 66%. However, 
success was defined as a ≥80% reduction in AF burden on the 7-day ECG recording 
at 6 months, with or without anti-arrhythmic drug treatment. In fact, only 54% of 
patients were free of AF without anti-arrhythmic drugs after 6 months. 
Symptomatic vs. asymptomatic atrial fibrillation
Vasamreddy et al.16 demonstrated that PV isolation resulted in 70% of patients 
remaining free of symptomatic AF recurrences over a 6-month time period, while only 
50% remained free of episodes when asymptomatic AF recurrences were included in 
the outcome. Purerfellner et al.17 demonstrated that many patients had many more 
asymptomatic AF episodes than formerly known or documented post-ablation. 
Long-term follow-up of the patients seems to be essential as success rates of the 
initial ablation procedure might vary over time. Freedom from AF after conventional 
ablation varies between 80 and 90%.3–5
PVAC compared with other pulmonary vein isolation techniques
Multi-electrode duty-cycled RF ablation is a relatively novel ablation technique and 
was designed to make PV isolation procedures less complex and less time-
consuming, since a single catheter can be used to produce contiguous lesions with 
each RF application. Our data indicate that freedom from AF after PVAC ablation is 
relatively low compared with published results of conventional ablation techniques.3–5 
Conventional techniques use a circular mapping catheter and a second ablation 
catheter to deliver RF energy in a unipolar fashion. Complete isolation of all electrical 
potentials at the PV ostium is a technically more challenging procedure requiring a 
longer learning curve and extensive fluoroscopy. New developments in catheter 
ablation of AF have attempted to address these challenges in a variety of methods. 
Arentz et al.18 found that large circumferential periostial large area ablation around 
ipsilateral PVs with verification of conduction block is a more effective treatment of AF 
than isolation of each individual PV. Although the procedure and ablation times were 
significantly longer for isolation of large areas, the fluoroscopy time with a three-di-
58 patients (64.4%) had sustained SR without anti-arrhythmic drugs. In the paroxysmal 
AF group, 11 (12.2%) patients with recurrent AF/AFl during follow-up underwent Lasso 
and Carto guided re-ablation using conventional irrigated tip catheters. In all the 11 
patients, gaps in the ablation lines were identified and additional ablations were 
applied to create complete circumferential PV isolation. Three patients had a gap at 
the ridge between the left superior PV and the left atrial appendage. Three patients 
had a gap at the antero-inferior part of the right inferior PV antrum. Five patients had 
gaps at both right- and left-sided LA–PV junctions. Three patients had a drug 
refractory and highly symptomatic left atrial flutter after the PVAC procedure. 
Electro- anatomic propagation mapping and entrainment mapping were performed. 
These atrial flutters were due to incomplete ablation lines at the junction of the left 
superior PV and the left atrial appendage in two patients and an incomplete ablation at 
the anterior part of the RIPV antrum in one patient. All patients underwent successful 
flutter ablation. In the persistent AF group (n = 12), six patients (50%) had AF 
recurrences. Four of these six patients underwent re-ablation with isolation of PVs, 
defragmentation of the left atrium, and isolation of the SVC. For defragmentation, 
multi-array septal catheter and multi-array ablation catheter were used. Figure 3 shows 
the cardiac rhythm during the follow-up of the total study population. Oral anti- 
coagulation was taken by all patients. 
Complications
There were no procedural complications in this study. Specifically, there was no 
thrombus formation or charring detected on the electrodes of the PVAC catheter. 
Additionally, there were no phrenic nerve injuries and no oesophageal damage 
revealed by oesophagoscopy. CT angiography of the PVs performed 3 months 
post-ablation did not reveal PV stenosis.
Discussion
Main findings
The main findings are that duty-cycled multi-electrode ablation with the PVAC can be 
used for PV isolation with an acute success rate for PV isolation of 95% using the 
PVAC alone. In a minority of the patients (5%), PV isolation could not be achieved with 
the PVAC and additional ablations using conventional catheters were necessary. 
Furthermore, after a mean follow-up of 12 months, freedom from AF/AFl after 
multi-electrode duty-cycled RF ablation was ~61% (i.e. percentage of patients in SR 
without anti-arrhythmic drug therapy).
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mensional mapping system was significantly shorter. Recent technical advances in 
robotic and magnetic steering have facilitated catheter manipulation and 
demonstrated reduced radiation dosage for the physician, but are likely to increase 
procedural complexity, cost, and time. Variations on catheter design have also been 
proposed, with coiled electrodes implemented on helical and linear catheters 
demonstrating limited effectiveness and unsatisfactory complication rates. Alternative 
catheter shapes combined with novel energy sources have been proposed and are 
being evaluated in the clinical setting, including balloon catheters that deliver laser, 
cryoablation, and ultrasound energy.9–13 However, these approaches are yet to 
demonstrate the ability to consistently isolate all veins without supplemental ablation 
catheters. Procedure or fluoroscopy times are not reduced, and reports have shown 
collateral damage complications such as phrenic nerve damage. 
Limitations and clinical implications
This study suggests that PVAC can be used for PV isolation. However, percentage of 
patients free from AF after ablation is relatively low (~58%). The follow-up duration is 
relatively short and longer follow-up is necessary to assess the long-term efficacy of 
this ablation technique. Although the PVAC has the potential advantage of being both 
a therapeutic and diagnostic tool, the current version of the PVAC is not ideal for 
larger veins. Therefore, CT or MR imaging of the PVs prior to ablation is needed to 
select patients. In the majority of the patients, this single catheter can be used to 
isolate the PVs and document isolation without switching to another mapping 
catheter. The ablations with the PVAC can be performed using a single transseptal 
puncture. The complication rate seems to be low, there were no adverse events in this 
study. However, only limited reports of experience with PVAC ablation have been 
published. Larger studies are required to evaluate whether the PVAC is associated 
with a different complication rate compared with standard PV isolation. 
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Introduction
Haissaguerre et al. have demonstrated that arrhythmogenic activity that originates in 
the muscle sleeves of the pulmonary veins (PVs) may trigger or perpetuate atrial 
fibrillation (AF).1 Circumferential peri-ostial ablation to electrically isolate the PVs from 
the left atrium has been performed to eliminate paroxysmal AF (PAF).2, 3, 4, 5 Studies 
have shown that circumferential PV isolation guided by a circular mapping catheter 
and 3D electro-anatomic mapping technique is effective in eliminating PAF in 
patients. This “conventional” pulmonary vein isolation (CPVI) is an accepted 
technique for the treatment of patients with PAF.2, 3, 4, 5 Another technique that has 
been used recently to treat PAF has been a single curvilinear catheter multi-electrode 
ablation with duty-cycled radiofrequency (RF) energy (MEA).6, 7, 8 Studies investigating 
MEA approach are limited, generally small-sized, and have less than 1 year 
follow-up.9, 10, 11, 12, 13 Therefore, the purpose of this prospective study was to 
compare the long-term efficacy and risk of conventional PV isolation with RF energy 
and a single catheter multi-electrode PV isolation ablation with duty-cycled RF energy 
in patients with PAF.
Methods
Patient characteristics
This prospective non-randomized study included 185 consecutive patients with 
symptomatic PAF referred for catheter ablation. The institutional review board 
approved this prospective registry. Exclusion criteria consisted of heart failure, a left 
ventricular ejection fraction <45%, a left atrial diameter >45 mm in the parasternal 
long axis view, and a previous ablation procedure for AF. In this study, multislice 
computed tomographic (CT) angiography was performed in all patients to asses the 
anatomy of the pulmonary veins, left atrium, and adjacent structures. Of 185 patients, 
89 patients were treated with MEA and 96 patients were treated with CPVI. The clinical 
characteristics of the patients are described in Table 1.
Electrophysiological study
All catheters were introduced through a femoral vein. A quadripolar electrode catheter 
(EPX, Bard, USA) was positioned in the coronary sinus. In the CPVI group, two 8.5F 
SL1 sheaths (St. Jude Medical, Inc) were advanced to the left atrium by a modified 
Brockenbrough technique. After transseptal catheterization, intravenous heparin was 
administered to maintain an activated clotting time of 300 to 350 s. Additionally, 
continuous infusions with heparinized saline were connected to the transseptal 
sheaths (flow rate of 1 mL/min) to avoid thrombus formation or air embolism. 
Abstract
Purpose
For patients with symptomatic atrial fibrillation (AF), a curvilinear multi-electrode 
ablation (MEA) catheter has been reported to be successful to achieve pulmonary 
vein (PV) isolation. However, this approach has not been compared prospectively 
with conventional PV isolation (CPVI) using a standard circular mapping catheter and 
3D electro-anatomic mapping. In this prospective non-randomized study, we compared 
the efficacy of these two techniques.
Methods
Of 185 consecutive patients, age 54.6 ± 10.1 years, with symptomatic paroxysmal AF 
(PAF), 96 patients underwent PV isolation by CPVI and 89 patients underwent MEA 
to isolate the PVs. CPVI was performed by encircling the left- and right-sided PVs. 
During MEA, the PV ablation catheter (Medtronic, USA) was used to isolate PVs with 
duty-cycled radiofrequency energy.
Results
The mean procedure time was 171.73 ± 52.87 min for CPVI and 133.25 ± 37.99 min 
for MEA, respectively (P < 0.001). The mean fluoroscopy time was 31.07 ± 14.97 for 
CPVI and 30.07 ± 11.45 min for MEA (P = 0.651). At 12 months, 80% of patients who 
underwent CPVI and 82% of patients who underwent MEA were free of symptomatic 
PAF off antiarrhythmic drug therapy (P = 0.989). Among the variables of age, gender, 
duration and frequency of PAF, left ventricular ejection fraction, left atrial size, 
structural heart disease, and the ablation technique, only an increased left atrial size 
was an independent predictor of recurrent PAF. Left atrial flutter occurred after CPVI 
in two patients and after MEA ablation in three patients.
Conclusion
In patients undergoing catheter ablation for PAF, MEA and CPVI proved equally 
efficacious.
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the earliest bipolar PV potentials and/or the unipolar electrograms with the most rapid 
intrinsic deflection were recorded. A 3D shell representing the left atrium was 
constructed by use of an electroanatomic mapping system (CARTO, Biosense-Web-
ster, USA). Irrigated RF energy was delivered with a target temperature of 43°C, a 
maximal power limit of 40 W, and an infusion rate of 15–20 mL/min during RF energy 
delivery. RF ablation sites were tagged on the reconstructed 3D map of the left atrium. 
RF energy was applied for 20–60 s until the maximal local electrogram amplitude 
decreased by ≥70% or double potentials were documented. Irrigated RF ablation 
was performed away from the angiographically defined PV ostia—more than 1 cm 
away on the posterior wall, and more than 5 mm on the anterior wall. At the narrow 
border between the anterior aspect of the left PVs and the left atrial appendage 
(LAA), ablation was performed within approximately 5 mm of the ostium of the PVs, 
i.e., ablation was performed on the PV-side of the LAA ridge. The endpoint of the 
ablation procedure was defined as the absence or dissociation of PV potentials 
documented with a standard circular mapping catheter within the PVs ≥30 min 
Angiograms of the PVs were performed in all patients. Bipolar and unipolar 
electrograms were filtered at band-pass settings of 30 to 500 and 0.05 to 200 Hz, 
respectively, and were recorded digitally (LabPro, Bard, USA). Pacing was performed 
from the coronary sinus or left atrial appendage with a stimulator (Bard, USA).
3D Electroanatomic mapping and irrigated tip radiofrequency 
ablation
Conventional PV isolation was performed in 96 patients. Mapping was performed 
with a steerable catheter with a 3.5-mm-tip electrode (ThermoCool Navistar, Bio-
sense-Webster, USA) during coronary sinus pacing or sinus rhythm. In case of AF, 
sinus rhythm was restored by external cardioversion. In selected patients with 
recurrent AF after electrical cardioversion, flecainide 2 mg/kg IV with a maximal dose 
of 150 mg was administered. Flecainide administration was necessary in three 
patients in the MEA group and two patients in the CPVI group. After 3D reconstruction 
of the left atrial anatomy (Fig. 1), each PV ostium was identified by selective 
angiography and tagged on the electroanatomic map. A decapolar circular mapping 
catheter (Lasso, Biosense-Webster, USA) was positioned within the PVs during RF 
delivery as described previously by Ouyang et al.4  Electrograms were recorded at 
the ostia of the PVs with a circular decapolar catheter (Lasso, Biosense-Webster). PV 
isolation was performed by applying radiofrequency energy at ostial sites at which 
Table 1   Patient Characteristics.
Total CPVI MEA P value
No. of patients 185 96 89
Age (mean±SD) 55.9±9.95 55.9±9.9 56.0±10.4 0.823
Male gender 142/185 (76.8%) 71/96 (74.0%) 74/89 (78.7%) 0.514
Diabetes 12/185 (6.5%) 9/98 (9.4%) 3/89 (4.5%) 0.086
Hypertension 32/185 (17.3%) 13/96 (13.5%) 19/89 (21.3%) 0.141
Pacemaker 8/185 (4.3%) 4/96 (4.2%) 4/89 (4.5%) 0.964
Reveal AF 20/185 (10.8%) 10/96 (10.4%) 10/89 (11.2%) 0.901
Familial AF 6/185 (3.2%) 4/96 (4.2%) 2/89 (2.2%) 0.683
COPD 3/185 (1.6%) 0/96 3/89 (3.4%) 0.115
Ischemic heart disease 9/185 (4.8%) 3/96 (3.1%) 6/89 (6.7%) 0.326
Non ischemic heart disease 6/185 (3.2%) 5/96 (5.2%) 1/89 (1.1%) 0.212
Left atrial diameter (mm) 40.59±5.37 40.02±5.74 42.50±3.40 0.047
LVEF 56±4.3 55±3.5 57±6.1 0.882
Data are shown as mean±SD. COPD indicates chronic obstructive pulmonary disease and LVEF indicates 
left ventricular ejection fraction
Figure 1   Electro-anatomic 3D map of the left atrium and the pulmonary veins with 
the circumferential ablation lines around the ipsilateral pairs of pulmonary 
veins on the right and left side of the left atrium. This lesion pattern was 
applied in the CPVI (circumferential pulmonary vein isolation) group.  
LAO is left anterior oblique view. RAO is right anterior oblique view.  
LAA is left atrial appendage. LSPV is left superior pulmonary vein.  
LIPV is the left inferior pulmonary vein. RSPV is the right superior pulmonary 
vein. RIPV is the right inferior pulmonary vein. See text for details.
LAO RAO 
LAA 
LSPV 
LIPV 
LAA 
RSPV 
RIPV 
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rhythmic drugs (class I or III) were continued during the first 3 months and gradually 
tapered. A 24–168 h Holter monitoring was performed at 3-, 6-, and 12-month 
intervals. Furthermore, 1 week AF alarm monitoring was performed 6 ± 1.5 (range, 
5–8) months after ablation. The AF alarm is a battery-powered electronic arrhythmia 
detection device with ECG recording capabilities. The device automatically detects 
arrhythmias and stores a digitalized ECG of arrhythmias. Furthermore, ECG storage 
can also be manually triggered to investigate if symptomatic episodes are actually 
related to an arrhythmia.14 Patients were instructed to report symptoms suggestive 
of PAF and were provided with an event recorder to document the cause of their 
symptoms. During a mean follow-up period of 363.98 ± 138.65 days (median, 380; 
interquartile range, 310–596 days), no patient was lost to follow-up. Transthoracic 
echocardiography and spiral CT or magnetic resonance imaging (MRA) of the PVs 
were performed 3 months after RF ablation to document atrial size and PV ostial 
dimensions, respectively. Esophagoscopy was not performed routinely post-
procedure, but only if a complication was suspected. In the present study, no patients 
post-ablation.
Multi-electrode ablation procedure
Multi-electrode ablation procedures were performed in 89 patients. Prior to the 
initiation of this study, we gained experience with the pulmonary vein ablation catheter 
(PVAC) catheter.6 Two operators (AE and JJS) performed the ablation procedures in 
this study. Two return electrode patches were placed between the scapulae. One 
fixed-curve 10F SL-1 sheath (St Jude Medical, USA) and, in selected cases (n = 16, 
18%), a steerable sheath (Channel, Bard, USA) were introduced into the right femoral 
vein. A 6F deflectable quadripolar electrode catheter (EPX, Bard, USA) was positioned 
into the coronary sinus. The PVAC (Medtronic, USA) is a mapping and ablation 
catheter with a 25 mm circular electrode array. This catheter has a bidirectional 
steering mechanism and an over-the-wire design. The details of this device have 
been described previously.6, 7, 8 The PVAC was introduced into the left atrium via the 
SL-1 sheath. Using a 0.032 guidewire placed in the vein, the catheter was positioned 
at the antrum of each PV to record local electrical activity at the veno-atrial junction 
prior to RF energy application (Fig. 2). The pulmonary vein ostia were visualized by 
selective contrast injection. A pre-ablation template of electrical signals of all 
veno-atrial junctions was recorded using the PVAC. This enabled us to compare the 
pre-ablation PVAC signals with the signals recorded after every RF application. The 
GENius™ generator (Medtronic, USA) was used for RF energy delivery. This is a 
multi-channel RF generator capable of simultaneously delivering duty-cycled energy 
to up to 12 operator-selected electrodes. The generator has five preset energy 
settings: bipolar, unipolar, and three ratios of bipolar-to-unipolar energy—4:1, 2:1, 
and 1:1. The 4:1 modus was generally used. Only when the PV signals were not 
eliminated in a minority of cases was a 2:1 mode used, and sporadically, the 1:1 
modus. Energy was delivered in a temperature-controlled, power-limited manner with 
a maximum of 10 W per electrode. The generator displays in real-time the temperature 
and power for each electrode, as well as the number of seconds each electrode was 
within 5°C of target temperature during the application. After ablations were performed 
at all veno-atrial junctions, the PVAC was used to map all PV ostia. If the PVs appeared 
to be incompletely isolated, additional RF applications were delivered using the PVAC 
until the PVs were completely disconnected based on PVAC signals (Fig. 3(a)–(c)). All 
PVs were mapped again 30 min post-ablation with the PVAC, and if necessary, 
additional ablations were performed. None of the patients who underwent MEA were 
converted to CPVI.
Patient follow-up
Post-ablation, patients were hospitalized for at least 24 h and monitored telemetrically. 
AF recurrence was defined as an atrial arrhythmia of >30 s. Low-molecular-weight 
heparin was given for 2 to 7 days and acenocoumarol for at least 3 months. Anti-ar-
Figure 2   Panel (A) shows angiography (AP view) of the left atrium and the 
left-sided pulmonary veins. The PVAC catheter is positioned in the LSPV. 
Panel (B) shows the surface ECG leads I, III, and V1. The intracardiac 
signals from proximal electrode pair of the quadripolar catheter 
positioned in the CS. Five bipolar PVAC signals from the ostium of the 
LSPV. LA = left atrium; CS = coronary sinus; LIPV = left inferior pulmonary 
vein; LSPV = left superior pulmonary vein; PVAC = pulmonary vein 
ablation catheter. See text for details.
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Study end point
The primary end point of the study was freedom from recurrent PAF after a single 
ablation procedure. Freedom from recurrent PAF was defined as the absence of 
symptomatic PAF off antiarrhythmic drug therapy. Previous studies have suggested 
that early recurrence of AF may be a transient phenomenon. Therefore, early 
recurrences of PAF within the first 3 months after PV isolation were excluded from the 
analysis.
Statistical analysis
Continuous variables are expressed as mean ± SD and were compared with Mann–
Whitney U test. Categorical variables were compared by χ2 analysis or with Fisher’s 
exact test. A Kaplan–Meier analysis with the log-rank test was used to determine the 
probability of freedom from recurrent PAF. A multivariate Cox regression analysis was 
performed to determine the independent predictors of recurrence of PAF. A value of 
P < 0.05 was considered statistically significant.
Figure 3   Tracings are ECG leads I, III, and V1 and bipolar intracardiac 
electrograms recorded from the proximal electrode pair of a catheter 
located in the coronary sinus and bipolar recordings from the pulmonary 
vein ablation catheter (PVAC). Panel (A) shows the right inferior 
pulmonary vein (RIPV) antrum signals during sinus rhythm pre-ablation. 
Panel (B) shows the signals from the RIPV post-ablation; note the 
dissociated PV spike in the PVAC recordings 1–2 and 3–4. In panel (C), 
note the irregular PV tachycardia with sinus rhythm recorded at  
the surface ECG leads and the recordings from the coronary sinus.
Figure 3   Continued.
A C
B
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the MEA group (P < 0.001). The mean total fluoroscopy times were 32 ± 11 (median, 
29; range, 25–40) min for the CPVI group, compared with 31 ± 13 (median, 30; range, 
23–38) min for MEA group (P = 0.278).
Freedom from recurrent AF
After the first ablation procedure, PAF recurred in 18 of the 96 patients (18.8%) who 
underwent CPVI and 15 of the 89 patients (16.9%) who underwent MEA ablation. At 
12 months of follow-up, without any repeat ablation procedures, 83% of the patients 
who underwent conventional CPVI were free of symptomatic PAF, compared with 
84% of patients who underwent MEA ablation (P = 0.989, log-rank test). A Kaplan–
Meier curve of the arrhythmia-free survival after CPVI and MEA is shown in Fig. 5.
Redo ablation procedures
A redo ablation procedure within 1 year after the initial procedure was performed in 
28 patients (15.1%) in the total study group—15 (15.6%) of the patients who initially 
underwent CPVI and 13 (14.6%) of the patients who initially underwent MEA ablation. 
Three of the 89 (3.4%) patients in the MEA group and two of the 96 (2.1%) patients in 
the CPVI group had a drug refractory and highly symptomatic left atrial flutter. During 
Results
Conventional versus multi-electrode ablation for PV isolation
Conventional 3D electro-anatomic mapping and Lasso-guided isolation of all PVs 
(CPVI) was performed successfully in all patients (N = 96). PV isolation using the 
multi-electrode ablation approach with the PVAC was successful in all patients 
(N = 89). In none of the patients in the MEA group was additional ablation using a 
conventional irrigated tip catheter necessary to achieve complete PV isolation. After 
the initial ablation to isolate the PVs, additional ablation after the 30 min waiting period 
was required in 11 of 96 patients in the CPVI group and 36 of 89 patients in the MEA 
group. In none of the patients was extra-PV ablation performed, so potential non-PV 
triggers were not targeted.
Total procedure and fluoroscopy times
As shown in Fig. 4, the mean total duration of the procedure was 175 ± 56 (median, 
165; range, 140–210) min for the CPVI group, compared with 138 ± 35 (median, 133; 
range, 115–163) min for MEA group (P < 0.001). The mean duration of radiofrequency 
energy applications was 52.69 ± 34.91 min in CPVI group and 33.92 ± 13.26 min in 
Figure 4   Bar graph showing the total procedure time, total ablation time, and total 
fluoroscopy time for the MEA and CPVI groups. See text for details.
Figure 5   Freedom from recurrent PAF after multi-electrode ablation  
(MEA, green line) and circumferential pulmonary vein isolation  
(CPVI, dark blue line). See text for details.
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the greatest flexibility to accommodate multiple LA-PV anatomies such as common 
left PVs. We have to recognize that other groups are working with a single transseptal 
puncture that is used to introduce both the ablation catheter and the sheath supporting 
the Lasso catheter into the left atrium to perform CPVI. Furthermore, CPVI is also 
performed without the use of a 3D mapping system in several well-recognized 
centers. It is important to emphasize the fact that multi electrode ablation is associated 
with more ostial lesions as compared with more atrial lesions with conventional 
pulmonary vein isolation. Also, it is important to recognize that one difference in the 
acute procedural endpoint of the two arms relates to the fact that electrical PV 
isolation was defined using a standard circular mapping catheter in the CPVI arm, 
while only the MEA catheter was used to verify isolation in the MEA arm. Thus, one 
cannot rule out the possibility that the difference in procedure times was related in 
part to a potentially different endpoint. Indeed, the higher PV reconnection rate seen 
in those patients who initially underwent MEA ablation (as opposed to CPVI) may be 
related to this. But an important counterpoint is the similar overall 1-year clinical 
success rates in the two groups.
The fluoroscopy times were not different between the two ablation techniques. 
However, procedure and fluoroscopy times are operator-dependent. Our experience 
with CPVI has been more than ten times as large as with multi-electrode ablation. 
Previous studies reported a mean procedure time of 148 ± 26 min using the 
conventional electro-anatomic approach.2, 3 The impact of this ostial ablation 
approach for procedural efficacy and safety remains undetermined, and further 
studies are needed to compare the clinical outcome. The ostial ablation site is 
inherent to all multi-electrode ablation devices and all balloon technologies currently 
under investigation.
Mechanism of arrhythmia recurrence after PV isolation
Both in the CPVI and the MEA group, we found during repeat procedure that the 
electrophysiological mechanism of the atrial arrhythmias was recovered PV 
conduction. In the current study, all patients with recurrent atrial tachycardia/flutter 
and all patients with recurrent AF had PV reconnection. This high PV reconnection 
rate in patients with clinical recurrences is consistent with prior data of AF recurrences 
after PV isolation. We eliminated atrial tachycardia/flutter and AF successfully by 
segmental RF applications in these patients. Satomi et al.15 and Ouyang et al.16 
have elegantly demonstrated that when only the pulmonary veins are targeted for 
ablation during the initial ablation procedure, the incidence of non-PV atrial 
tachycardia/flutter is very low. In our study, none of the patients had a non-PV 
tachycardia.
the redo procedures, recovery of conduction was found in ≥1 PV in all patients. In the 
CPVI group, 27 PVs in 15 patients were reconnected (average of 1.80 ± 0.41 PVs per 
patient), and in the MEA group, 34 PVs in 13 patients were reconnected (average of 
2.61 ± 0.65 PVs per patient). The difference was statistically significant (P < 0.001). 
During the redo ablation procedures, CPVI was performed in all patients. In patients 
with atrial flutter, electro-anatomic propagation mapping and entrainment mapping 
were performed. These atrial flutters were due to incomplete ablation lines at the 
junction of the left superior PV and the left atrial appendage in two patients and an 
incomplete ablation at the anterior part of the RIPV antrum in three patients; thus, 
even these LA flutters were the result of PV reconnections. All five patients underwent 
successful left atrial flutter ablation.
All patients who underwent a redo ablation procedure subsequently remained free of 
symptomatic PAF. In the final analysis, after a mean of 1.15 procedures per patient 
(213 procedures in 185 patients), the freedom from symptomatic PAF at 12 months of 
follow-up (after the most recent ablation) was 92% in patients who initially underwent 
CPVI, compared with 93% in patients who initially underwent MEA ablation (P = 0.708). 
The mean duration of follow-up in the group of patients with repeat ablation was 
mean 318 ± 236 days and median (Q1–Q3) was 355 (196–427) days.
Discussion
Main findings
In this prospective non-randomized study, symptomatic PAF was eliminated with 
electro-anatomic Lasso-guided circumferential peri-ostial encircling of the PVs (CPVI) 
and by multi-electrode duty-cycled RF ablation of the PVs (MEA) with equal efficacy. 
On the other hand, the total procedure time was significantly shorter with the 
multi-electrode ablation approach. Complications were rare with both catheter 
ablation techniques. The only complication in this study was left atrial flutter after 
CPVI in two patients and after multi-electrode ablation in three patients. PV stenosis 
was not observed in this study.
Comparison of the two techniques
In our center, CPVI is performed with double transseptal puncture and the insertion 
of two catheters into the left atrium, whereas the multi-electrode ablation is performed 
with only a single catheter in the left atrium. We performed CPVI with the use of a 3D 
mapping system and a circular mapping catheter, which increases the cost of the 
procedure. The multi-electrode ablation obviates the need for 3D mapping and was 
associated with a shorter procedure time. On the other hand, the CPVI approach has 
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The most feared complication of left atrial ablation is atrio-esophageal fistula due to 
the thermal effect on the esophagus. Esophageal thermal alterations may be a 
precursor for potentially fatal atrio-esophageal fistula. As the PVAC-based ablation 
uses relatively low power (maximum 10 Watt), the risk of collateral damage is 
minimized compared with other techniques. Deneke et al. evaluated thermal effect of 
PVAC technique on the esophageal wall by using an esophageal temperature probe 
with metal thermocouple electrodes for continuous luminal esophageal temperature 
(LET) monitoring. Interestingly, endoscopy revealed only esophageal alteration in 
patients when LET monitoring was used and not in the control group of patients 
ablated with PVAC technique without LET monitoring.21 Another study demonstrated 
no thermal esophageal lesions by endoscopy in 12 patients within 24 h of PVAC 
ablation.22 We did not perform esophageal temperature monitoring neither routine 
endoscopy after the ablation procedure, but there were no symptoms suggesting 
collateral damage.
Previous studies
Two randomized studies compared MEA to conventional point-by-point ablation. 
Bulava et al. included 102 patients (51 MEA versus 51 CARTO) and found significantly 
lower procedure and fluoroscopy times in the MEA group (171 ± 40 min vs 224 ± 27 
min, P < 0.001; 26 ± 8 min vs 35 ± 9 min, P < 0.001; respectively). Seventy-two 
percent of patients in the MEA group and 68% of the control group were free of AF 
during a mean follow-up of 254 ± 99 days (P = not significant).10 Bittner et al. found 
similar results. They randomized 80 patients with paroxysmal and persistent AF to 
either MEA (n = 40) or CARTO (n = 40) based ablation. During a mean follow-up of 
254 ± 99 days, 72% in the MEA group and 68% in the CARTO group were free of AF 
recurrences (P = not significant). The procedure and fluoroscopy times were 
significantly lower in the MEA group compared with the control group.9 In contrast to 
these studies, the current study is non-randomized but shows a higher rate of 
freedom from AF after MEA during a longer follow-up (82% during mean follow-up of 
12 months). Possibly, the fact that we excluded persistent AF patients contributed to 
this difference.
A recent non-randomized (case control) study describes efficacy of MEA in 209 
patients with paroxysmal and persistent AF compared with a historical control group 
consisting of 211 patients treated with conventional PV isolation followed by 
anatomical lines at the roof and mitral isthmus. They reached success rates of 82% 
after 1.08 MEA procedures in the subgroup of patients with paroxysmal AF at a 
follow-up time of 7.1 ± 5 months which was comparable the conventional treatment. 
Multivariate analysis revealed that independent predictors of success were smaller 
left atrial size, younger age, and absence of previous pacemaker implantation.23
It is important to recognize that we did not assess the incidence of PV reconnection 
in asymptomatic patients. However, the relatively high rate of PV reconnection in the 
symptomatic patients—1.8 PVs/patient in the CPVI group and 2.6 PVs/patient in the 
MEA group—suggests that even the asymptomatic patients will likely have PV 
reconnections. And how any such reconnections would affect the long-term clinical 
outcome is not known in these patients. However, there is increasing data that 
long-term outcome after AF ablation in patients without symptoms at the end of 1 
year is not good; the long-term annualized AF recurrence rate has been reported to 
be linear at a rate as high as 10%/year (to 40% over the course of ~4 years).17 
The mechanism of these late recurrences is also thought to be a result of PV 
reconnection.18 Thus, the data from our study suggest that, while the 1-year success 
rates are quite favorable as compared with the literature, it is quite possible that the 
long-term success rate will be lower as a result of PV reconnection.
Safety
There were no complications in this study except for left atrial flutters, which are arguably 
more appropriately not considered as complications as much as proarrhythmic effect 
of left atrial ablation. None of the patients had PV stenosis after ablation.
A recent report on PVAC technique demonstrated a higher incidence of silent cerebral 
ischemic events compared with radiofrequency and cryoballoon ablation. In this 
study, 38.9% (14 of 36) of patients with paroxysmal AF, treated with MEA (PVAC) 
appeared to have new silent cerebral ischemic lesions at post procedural cerebral 
MRI. This number was significantly higher compared with irrigated RF ablation (8.3%) 
and cryoballoon (5.6%).19 Although there are no studies demonstrating any clinical 
consequences of silent cerebral events after PVI, this high number of cerebral lesions 
with MEA is a concerning phenomenon. However, one should be careful interpreting 
the result of this study. The study is non-randomized, and ACT values were <300 a 
considerable amount of time.20 The authors speculate that the fact that PVAC is a 
non-irrigated technique, using only cooling by local blood flow, and is insufficient in 
reducing thrombus formation. Another explanation is the fact that the non-simultane-
ous contact of the PVAC electrodes with the vein–atrium junction increases char 
formation on noncontact electrode tips. The rotations and pressing of the PVAC 
catheter to obtain better catheter–endothelium contact facilitates mobilization and 
embolization of char and thrombi. In our study, there were no symptomatic thrombo-
embolic complications. However, we did not perform post-procedure cerebral MRI to 
evaluate possible silent cerebral lesions.
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Limitations
This study is a non-randomized comparison of two approaches. In the future, a 
multicenter randomized comparison of the two techniques needs to be performed. 
The size of electrodes of the Lasso and the PVAC are different, and the mapping 
resolution is also different. We cannot exclude that the much higher pulmonary vein 
reconduction rate observed with multi electrode ablation could in fact be even higher. 
Another limitation is the relatively small left atrial size (mean LA size in MEA group 
42.50 ± 3.40). We realize that other studies included larger atrial sizes; this will 
influence the success rate. Another limitation of this study is that asymptomatic 
episodes of PAF may not have been recognized after the ablation procedures. The 
mean duration of follow-up in this study was 364 days. Long-term follow-up will be 
important to determine the long-term safety and efficacy of both ablation strategies. 
The complication rate seems to be low with both CPVI and MEA approaches, and 
there were no adverse events in this study. However, only limited reports of experience 
with PVAC ablation have been published. Larger studies are required to evaluate the 
whether the PVAC is associated with a different complication rate compared with 
standard PV isolation.
Conclusions
Although several centers have reported the clinical results of multi-electrode ablation, 
this is the first study that directly compared this technique to CPVI in a prospective 
fashion. The results of the present study indicate that both electro-anatomic/
Lasso-guided circumferential peri-ostial PV isolation and multi-electrode ablation 
eliminate PAF with equal efficacy. On the other hand, multi-electrode ablation was 
performed with a shorter procedure time. If the findings of this study are reproduced 
in a randomized study, it would be appropriate to use multi-electrode ablation as 
first-line therapy in patients with PAF who are appropriate candidates for catheter 
ablation. Lasso-guided 3D electroanatomic approach can be used as both first- and 
second-line therapy in patients referred for ablation of PAF.
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Introduction
Focal atrial tachycardias (ATs) have a predilection for specific areas within the atrium, 
such as the crista terminalis,1 pulmonary vein ostia,2 near the tricuspid and mitral 
annulus,3,4 the ostium of the coronary sinus (CS),5 and para-Hisian regions.6,7 In the 
last decade, a few reports were published on focal AT originating from the 
non-coronary cusp (NCC). The diagnosis of a NCC AT can be difficult and ablation 
therapy in the sinus of Valsalva can be challenging. In this report, we describe the 
electrophysiological (EP) characteristics of NCC AT and ablation techniques in seven 
patients with this arrhythmia. Secondly, we provide a comprehensive review of the 
available literature regarding NCC AT and its treatment.
Methods
Our study population consisted of 7 patients (4 males; age 40 ± 9 years, range 28–51 
years) from a consecutive series of 112 patients undergoing EP study and 
radiofrequency (RF) ablation for focal AT, between June 2009 and June 2011, at the 
Isala Hospital in Zwolle, The Netherlands.
All patients had complaints of palpitations with a sudden onset and offset. None of 
the patients had an incessant tachycardia. The mean duration of symptoms was 4.2 
± 1.9 years. Six patients had been ineffectively treated with beta-blockers and two 
patients with verapamil. One patient had a mitral valve prolapse with mild regurgitation. 
The remainder had structurally normal hearts. An EP study had previously been 
performed in three of seven patients. In one patient, an atrioventricular (AV) node 
reentrant tachycardia was confirmed and a successful ablation of the slow pathway 
had been performed 3 years prior to admission. Another patient had a prior history of 
lone atrial fibrillation for which a pulmonary vein isolation was performed 1 year prior 
to admission. Another patient had a past history of atrial fibrillation and supraventric-
ular tachycardias due to a concealed bypass for which a pulmonary vein isolation 
and ablation of a para-Hisian concealed bypass was performed.
Electrocardiogram analysis
The P-wave morphology and duration were assessed on the surface electrocardio-
gram (ECG) during the tachycardia. The morphology was described as positive, 
negative, biphasic, or isoelectric depending on deviation from baseline. Criteria as 
described by Kistler et al.8 were used to determine the likely site of origin.
Abstract
Aims
Focal atrial tachycardia successfully ablated from the non-coronary cusp (NCC) is 
rare. Our aim was to describe the characteristics of mapping and ablation therapy of 
NCC focal atrial tachycardias and to provide a comprehensive review of the literature.
Methods and results
Seven patients (age 40 ± 9 years) with symptomatic, drug-refractory atrial tachycardia 
were referred for electrophysiological study. Extensive right and left atrial mapping 
revealed atrial tachycardia near His in all patients but either failed to identify a 
successful ablation site or radiofrequency applications only resulted in temporary 
termination of the tachycardia. Mapping and ablation of the NCC were performed 
retrogradely via the right femoral artery. Mapping of the NCC demonstrated earliest 
atrial activation during atrial tachycardia 38 ± 14 ms (ranging 17–56 ms) before the 
onset of the P-wave. Earliest atrial activation in the NCC was earlier than earliest 
activation in the right atrium and left atrium in all patients. The P-wave morphology 
was predominantly negative in the inferior leads and biphasic in leads V1 and V2. The 
tachycardia was successfully terminated by radiofrequency application in 10 ± 6 s 
(2–16 s), without complications. All patients were free of symptoms during a follow-up of 
19 ± 9 months. Literature search revealed 18 reports (91 patients) describing NCC focal 
atrial tachycardia, with 99% long-term ablation success with a 1% complication rate.
Conclusion
Symptomatic focal atrial tachycardia near His may originate from the NCC and can 
be treated safely and effectively with radiofrequency ablation.
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Results
In all patients, the RA and LA were extensively mapped before proceeding to 
investigate the sinus of Valsalva. The EP characteristics are demonstrated in Table 1. 
The AT was inducible with programmed stimulation in all patients. In one patient, the 
arrhythmia occurred spontaneously, in another patient isoprenaline was needed in 
conjunction with programmed stimulation to induce the AT. The earliest atrial 
activation was registered at the HB area in all patients. In four patients, RA unsuccessful 
RF applications were performed at the site of earliest activation at the right-sided 
para-septal AV nodal region. In five patients, LA unsuccessful RF applications were 
performed at the left-sided para-septal area. The atrial RF applications only resulted 
in temporary termination of the tachycardia. 
Electrophysiological study
After giving informed consent and withdrawal of antiarrhythmic medication for at 
least five half-lives, all patients underwent an EP study. The procedure was performed 
in a fasting state under light sedation. Catheters were introduced via the femoral veins 
to the right atrium (RA), right ventricular apex (RVA), CS, and at the His bundle (HB) 
region. After placement of the catheters, an intravenous heparin bolus of 5000 IE was 
administered. The stimulation protocol consisted of programmed stimulation at two 
basic cycle lengths (CLs) with up to two extrastimuli and burst pacing at the RA and RVA. 
If necessary, intravenous isoprenaline was administered to provoke the tachycardia. 
Focal AT was confirmed by the following criteria: (i) the atrial activation sequence 
during the tachycardia was different from that recorded during sinus rhythm; (ii) the 
atrial activation sequence during the tachycardia was different from that obtained 
during ventricular stimulation with retrograde ventriculoatrial conduction; (iii) VAAV 
response after discontinuation of ventricular pacing; (iv) induction of tachycardia 
independent of a critical prolongation of the A–H interval; (v) transient AV block during 
tachycardia; and (vi) inability to obtain concealed entrainment of the tachycardia 
using ventricular extrastimuli.9
Mapping and ablation
Initially, mapping was performed in the RA in all patients using NaviStar ThermoCool, 
CARTO XP or CARTO 3 system (Biosense Webster, Johnson & Johnson). Activation 
time was measured from the onset of the local electrogram to a stable atrial 
electrogram recorded from the CS catheter. Whenever mapping in the RA and left 
atrium (LA) failed to identify a successful ablation site or the tachycardia was still 
inducible after focal ablation therapy, the aortic sinus (AS) was evaluated. The NCC 
was visualized retrogradely via the right femoral artery. Aortic root angiography and 
intracardiac echo (ICE) demonstrated the anatomical position of the NCC (Figure 1). 
After confirming the location of the coronary ostia, a 7Fr quadripolar catheter with 4 
mm tip electrode (NaviStar ThermoCool, Biosense Webster) was introduced for 
mapping and ablation in the NCC. 
Figure 2   (A) Aortic root angiogram in right anterior oblique view showing the 
anatomy on the NCC and the coronary arteries. (B) Catheter position 
and successful ablation site in the NCC. (C, D) Intracardiac echocardiog-
raphy confirming correct position of the ablation catheter in the NCC at 
the conjunction of the right coronary cusp in long axis (C).
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Mapping of the NCC revealed that the activation occurred 34 ± 21 ms earlier than 
atrial activation at the CS and preceded the onset of the P-wave by 38 ± 14 ms (range 
17–56 ms). The mean tachycardia CL was 368 ± 96 ms (range 228–536 ms). The 
P-wave duration was 122 ± 17 ms during sinus rhythm and shortened significantly 
to 56 ± 16 ms during tachycardia (P < 0.001). Atrial/ventricular (A/V) amplitude ratio 
at the site of successful ablation was >1 in all patients (3.7 ± 1.3).
P-wave morphology
P-wave morphology is provided in Figure 2. The P-wave morphology during tachycardia 
was clearly different from the P-wave morphology during sinus rhythm. The P-waves 
in the inferior leads were inverted in six of seven patients. P-wave morphology in 
leads I and AVL were mostly upright or isoelectric (six of seven patients). The leads V1 
and V2 showed a biphasic morphology in six of seven patients with an initial negative 
deflection in four patients. 
Catheter ablation
In four patients, ablation was performed with an irrigated tip catheter and in the 
remaining three patients conventional RF ablation was performed. The choice of 
catheter and energy source was based on personal preference and experience of the 
operator. The AT was terminated with a mean number of RF applications of 3.7 ± 2.4 
(range 1–7) within 16 s (mean duration until termination of arrhythmia 10 ± 5 s, range 
2–16 s). Representative intracardiac electrograms and electroanatomical mapping 
are demonstrated in Figures 3 and 4. 
Follow-up
There were no in-hospital or late complications. All patients were free of arrhythmias 
without antiarrhythmic drugs after a mean follow-up of 19 ± 9 months.
Discussion and literature review
Experience with RF ablation of AT in the NCC is limited. A review of existing reports is 
presented in Table 2.10–27 The first report was published in 2004 by Tada et al.,10 
who described a 35-year-old patient with a symptomatic AT, which was successfully 
ablated from within the NCC. The authors emphasize the close anatomical relation of 
the NCC to the AV node transitional area and suggest that RF energy delivery through 
the NCC might even be safer than a right-sided approach for selected ATs near the 
AV node. 
Ta
b
le
 1
   E
le
ct
ro
ph
ys
io
lo
gi
ca
l c
ha
ra
ct
er
is
tic
s 
of
 A
T.
1
2
3
4
5
6
7
st
im
ul
at
io
n
pr
ot
oc
ol
 (m
s)
40
0+
19
0,
 
40
0+
28
0
sp
on
ta
ne
ou
s,
 
50
0+
40
0,
 
60
0+
40
0 
50
0+
34
0
40
0+
34
0
+
 is
op
re
l
40
0+
29
0
60
0+
28
0
bu
rs
t C
S
, 
30
0+
28
0
si
te
 o
f e
ar
lie
st
 a
tri
al
  
ac
tiv
at
io
n
H
is
H
is
H
is
 
H
is
H
is
H
is
H
is
ta
ch
yc
ar
di
a 
cy
cl
e 
le
ng
th
(m
s)
23
0-
34
4
40
6-
43
8-
48
0
50
2
39
2-
53
6
27
0-
32
0
32
2-
33
4
22
8-
34
8
P
 w
av
e 
du
ra
tio
n 
(m
s)
S
in
us
 rh
yt
hm
 
ta
ch
yc
ar
di
a
13
2
80
10
8
42
13
0
60
12
0
48
10
0
44
11
4
44
15
0
66
ac
tiv
at
io
n 
tim
e 
N
C
C
 
pr
ec
ed
in
g 
p 
w
av
e 
(m
s)
53
56
39
26
17
33
39
E
ne
rg
y 
so
ur
ce
R
F
Irr
ig
at
ed
 ti
p,
 
th
er
m
oc
oo
l
Irr
ig
at
ed
 ti
p,
 
th
er
m
oc
oo
l
R
F
Irr
ig
at
ed
 ti
p,
 
th
er
m
o-
co
ol
R
F
Irr
ig
at
ed
 ti
p,
 
th
er
m
o-
co
ol
E
ne
rg
y 
se
tti
ng
s
30
W
, 3
3g
rC
40
W
, 3
7g
rC
30
W
, 3
6g
rC
30
W
, 4
3C
40
W
, 3
2g
rC
30
W
, 4
6g
rC
30
W
, 3
2g
rC
R
F 
ap
pl
ic
at
io
n 
at
te
m
pt
s 
 
le
ft/
rig
ht
 a
tri
um
LA
, R
A
 
LA
 
R
A
, L
A
 
R
A
, L
A
 
R
A
 
LA
-
N
r o
f R
F 
ap
pl
ic
at
io
ns
 N
C
C
4
7
3
1
7
2
2
To
ta
l R
F 
tim
e 
(s
ec
.)
22
7
39
7
16
6
64
43
4
..
95
R
F 
tim
e 
to
 te
rm
in
at
io
n 
 
of
 ta
ch
yc
ar
di
a
12
16
sp
on
ta
ne
ou
s
16
2
6
8
AV
 c
on
du
ct
io
n
2:
1
1:
1
1:
1 
an
d 
2:
1
1:
1
1:
1
1:
1 
an
d 
2:
1
1:
1
A
/V
 ra
tio
2.
6
4.
2
4.
7
3.
7
3.
4
1.
7
5.
6
N
ot
e:
 A
V:
 a
tri
o-
ve
nt
ric
ul
ar
; L
A
: l
ef
t a
tri
um
; N
C
C
: n
on
 c
or
on
ar
y 
cu
sp
; R
A
: r
ig
ht
 a
tri
um
; R
F:
 ra
di
o-
fre
qu
en
cy
.
106 107
CHAPTER 6 FOCAL AT FROM THE NON-CORONARY AORTIC CUSP
6
Figure 2   (A) Twelve-lead ECG of a patient with AT from the NCC showing typical 
P-wave morphology with negative P-wave in the inferior leads and 
biphasic, negative–positive deflection in lead V1. (B) Characteristics of 
P-wave morphology in studied patients during AT on surface ECG.
Figure 3   Intracardiac electrogram at the successful ablation site within the NCC. 
(A) The earliest activation within the NCC preceded the P-wave by 64 ms. 
(B) Radiofrequency application at this site terminates the tachycardia 
after prolonging the CL.
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Figure 4   Three-dimensional electroanatomical mapping (CARTO) in a patient with AT 
originating from NCC. (A) Activation map of the RA. The activation spreads 
from the interatrial septum towards the free wall. The corresponding 
intracardiac electrogram showing earliest atrial activation during AT  
at the RA septum (indicated by the blue point) preceding the reference  
CS by 54 ms. (B) Further mapping of the LA showing centrifugal spread 
from the interatrial septum. The green point indicates the earliest 
activation in the LA septum preceding the reference CS by 54 ms as well. 
(C). CARTO map displays the spatial relationship between the NCC,  
the interatrial septum, and HB. The light blue point indicates the earliest 
activation, deep within the NCC. (D) Intracardiac electrogram showing 
earliest atrial activation during AT in the NCC preceding the reference  
CS by 60 ms, no his potential was recorded at this site. (E) RF ablation  
at this site terminates the tachycardia in 6 s. AO, aorta; AT, atrial tachycardia; 
CS, coronary sinus; LA, left atrium; NCC, non-coronary cusp; RA, right 
atrium; RF, radiofrequency ablation.
Figure 4   Continued.
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Epidemiology
The prevalence of AT originating from NCC is unknown. Ouyang et al.11 found the 
prevalence of NCC AT in all patients with focal AT to be 4.1%. In the current study the 
prevalence was 6.3%. Park et al.25 found even a higher prevalence of 8.8%. These 
numbers might be overestimated in specialized centres, due to a referral bias. On the 
other hand, previously diagnosed para-Hisian ATs probably contain ATs originating 
from the NCC. Because mapping of the NCC is not a standard procedure for 
para-Hisian ATs, the published cases might underestimate the prevalence of 
NCC-related ATs.
Anatomy of non-coronary aortic sinus
The aortic root occupies a central position in the heart, all chambers of the heart are 
directly related to the aortic valve and its leaflets are incorporated directly into the 
cardiac skeleton. Whereas the right and left coronary cusps make direct contact with 
the ventricular myocardium, the NCC is located closer to the superior AV junction and 
is immediately adjacent to the atrial myocardium of the interatrial septum. Gami et al. 
examined 603 autopsy hearts and found myocardial sleeves in the aortic root, either 
above the semilunar cusps or intercuspally in 57% of examined hearts. However, 
myocardial extensions above the NCC were rare (0.66%) and extensions into the 
valve cusp even more exceptional.28 The NCC is exclusively composed of fibrous 
walls. Some suggest that this dispersed tissue might be a potential arrhythmogenic 
substrate as well.29,30 It remains unclear whether the arrhythmogenic substrate for 
NCC AT is actually a myocardial sleeve within the cusp, atrial tissue adjacent to the 
NCC, or fibrous tissue (microreentry).
Characteristics of atrial tachycardia from non-coronary cusp
As the NCC AT is sensitive to adenosine and the tachycardia is reproducibly inducible 
and terminated by atrial stimulation, the mechanism of NCC AT is due to either reentry 
or triggered activity.11 The atrial activation pattern of NCC AT is extensively described 
by Liu et al.: Initially, the tachycardia activates the RA para-Hisian area followed 
immediately by activation of the LA anteroseptal area. Rather than propagation of the 
impulse from the RA to the LA, the authors state that both atria become activated 
from the NCC. Furthermore, they found that the initial activation area in the first 20 ms 
is diffuse.20 This phenomenon is in line with our findings of a significantly shorter 
P-wave duration during tachycardia than during sinus rhythm, which clearly suggests 
a septal origin of the focal tachycardia. However, the P-wave duration on itself cannot 
distinguish between an AT with a left septal origin, which typically have a short P-wave 
duration, and a NCC AT.31
Figure 4   Continued.
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Table 2   Literature review of AT originating from the non-CS.
Investigator Number  
of patients
Type of
arrhythmia
Structural heart 
disease
Previous
unsuccessful
ablation
Tachycardia  
cycle length (msec)
Activation time  
NCC preceding  
p wave (msec)
Follow up
Time + method,
efficacy
complications
Tada, 200410 1 AT normal LV,
dilated aortic root
no 504 38 10 months
successful
None
Ouyang,200611 9 AT none 6 patients (67%) previously  
misdiagnosed as RA AT, AVNRT
358±63 32.4±4.6 9±3 months, 100% success
TTE+holter 3,6,9 month 
None
Yamada, 200612 1 AT not reported not reported 400 70 Not reported None
Raatikainen, 200713 1 AT no no 390 40 7 months
successful
None
Rillig, 200814 6 AT/VT/PVC
(6 AT and 15 VT)
not reported no 386 - 6 months, 100% success
6 mnth holter, TEE, cardiac MRI 
(cerebral MRI in 6 pts)
None
Das, 200815 10 AT 2 poor LV 1 previous EP study - - 41±12 months, 7/10 successful None
Joung, 200816 1 AT no no 480 55 10 months None
Kriatselis, 200817 7 AT near His,
(5 mitral annulus AT, 
7 NCC AT)
1 tachycardio-
myopathy
not reported 435±62 55±15 14±8, holter (10/12 patients) none
Gil-Ortega, 200918 1 AT poor LV, EF 25% no 460 12 5 months holter+TTE successful 
(LV function improved, EF 65%)
None
Weber, 200919 1 AT not reported no 544 51 not reported none
Liu, 201020 13 AT 3 pt’s (23%) previous  
unsuccessful ablation
391±79 37±3 13±3 months None
Zou, 201021 5 AT none not reported 363±44 - >3 months, 100% success None
Chen, 201022 1 AT no 1 week prior RA and LA  
ablation attempts
380 52 2 years None
Yamashita, 201023 1 AT no no 400 30 6 months none
Wang, 201124 16 AT
(16 NCC AT, 
6 LCAS AT)
1 valvular disease, 
1 tachycardio-
myopathy
no 341±60 21±9 30±13 months none
Park, 201225 10 AT
(10 NCC AT, 1 LCC 
AT, 1 RCC AT
7 aortic sinus AVRT)
Not reported Not reported 349±19 40±10 20±10 months, 1 recurrence Complete heart 
block in patient with 
AVRT from RCC
Mlčochovă, 201026 2 AT Not reported Not reported 387 36 14 months none
Ju, 201227 5 AT (5 NCC AT, 15 
RA para-Hisian AT)
None Not reported 366±39 35±7 19±12 months none
AT, atrial tachycardia; AVNRT, atrioventricular node reentrant tachycardia; EF, ejection fraction; EP, electro-
physiological; LA, left atrium; LCAS, left coronary aortic sinus; LV, left ventricle; MRI, magnetic resonance 
imaging; NCC, non-coronary cusp; PVC, premature ventricular complex; RA, right atrium; TEE, trans 
oesophageal echocardiography; TTE, trans thoracic echocardiography; VT, ventricular tachycardia.
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P-wave morphology
ATs might originate from different locations within the AS, mostly from the NCC but 
sporadically ATs arise from the left coronary cusp, only a single report described a 
case of AT originating from the right coronary cusp.32 The most useful tool to 
differentiate between the cusps, according to the authors, are the P-wave morphology 
in leads I and AVL on the surface ECG and the local A/V ratio at successful ablation 
sites. Non-coronary cusp AT typically shows a positive P-wave in leads I and AVL and 
a local A/V ratio of >1 (as opposed to a negative–positive P-wave deflection in left 
coronary cusp AT with a local A/V ratio ≤1).24 The P-wave morphology of the NCC AT 
in the different reports is not consistent. Some studies describe a typical P-wave 
morphology for this arrhythmia: predominantly negative P-waves in the inferior leads, 
positive or isoelectric in leads I and AVL, and biphasic in right precordial leads V1 and 
V2 (mostly negative–positive)—whereas other studies describe a wide variety of 
morphologies. Das et al.15 found a wide variation in P-wave morphologies in their 
patients and conclude that the NCC AT reflects a more heterogeneous origin. 
Although the present study shows a typical P-wave morphology pattern similar to 
Ouyang et al., one should be careful to use the P-wave morphology as a diagnostic 
instrument for NCC AT because para-Hisian AT, particularly anteroseptal AT, present 
with a similar P-wave morphology.11,33 Furthermore, variation in P-wave morphology 
can be explained by cardiac rotation, body habitus, and atrial tissue mass distribution.
Mapping and ablation
In the present study, the decision to evaluate the NCC was made after extensive LA 
and RA mapping revealed focal AT with earliest atrial activation near the HB. In most 
patients, attempts were made to ablate foci in the RA and LA before considering to 
proceed to NCC mapping. Because the focal atrial ablations only resulted in 
temporary termination of the arrhythmia, mapping of the NCC was performed. The 
majority of other reports describe a similar strategy.11,14,20 However, Das et al.15 
suggest to proceed to NCC mapping after RA mapping reveals earliest activation in 
the RA peri-AV nodal septum. The authors suggest to apply RF energy once in the 
NCC at the site of earliest activation. If the tachycardia terminates within 10 s, the 
procedure is successful. If the tachycardia persists after 10 s of RF application, one 
should consider to map the LA.15 We feel that the most reasonable strategy for 
selecting appropriate ablation site for focal ATs in the vicinity if the AV node should be 
to start with extensive activation mapping on both sides of the interatrial septum, 
followed by NCC mapping. To minimize the risk of inadvertent damage to the AV 
conduction system, these three compartments should be meticulously mapped to 
localize the exact origin of the tachycardia before considering ablation.
Safety of ablation in non-coronary cusp
Ablation in the NCC seems a safe procedure, as no complications were reported in 
the studies. However, the number of reports on this subject is very limited and 
possibly complications are underreported due to a publication bias. Rillig et al. 
describe safety issues of ablation in the NCC, particularly the potential risk for cerebral 
embolism. One of their patients showed transient thickening of the aortic valve. It was 
speculated that valve leaflet oedema was responsible for this phenomenon due to RF 
application on the valve surface. Another patient in their series showed silent cerebral 
ischaemia on the magnetic resonance imaging (MRI) scan 1 day after the ablation 
procedure, which was not identifiable on the MRI at 6-month follow-up. In this patient 
the transoesophageal echo showed plaque in the aortic wall in close proximity to the 
ablation site.14 Manipulation in the sinus of Valsalva is a potential risk for cerebral or 
peripheral thromboembolism. The NCC is even more prone to calcification compared 
with the other cusps due to the absence of diastolic coronary flow, which increases 
the shear stress.34 Therefore, a thorough assessment of the aortic root preferably by 
ICE is recommended as a standard peri-operative procedure or before ablation. 
Intracardiac echo can accurately guide the ablation catheter, identify endocardial 
details of the ASs, and the distance to the coronary ostia. Moreover, ICE is a tool to 
confirm stable contact and verify continuous stability during RF delivery.35
A variety of energy sources are currently available for ablation procedures. An in vitro 
study compared standard RF energy, cooled-tip RF energy, or cryothermal energy 
for coronary cusp ablation.36 Although none of the modalities caused acute damage 
to the coronary cusps, cryothermal ablation appeared to be the least thrombogenic 
and least traumatic technique. D’Avila et al. suggest cryoablation as the first choice 
technique for safety reasons. However, this technique was associated with lesser 
lesion depth and, particularly with NCC ablation, this might result in recurrence of the 
arrhythmia.36 Irrigated tip catheters are preferable as an alternative to cryoablation, 
as it causes larger lesions and is associated with less thrombo-embolic risk as 
compared with conventional RF. The risks and management of other potential 
complications such as AV block, aortic valve, or coronary arterial damage should be 
evaluated in further clinical research, as well as the optimal choice of energy sources 
and settings.
Conclusion
Symptomatic focal AT near the HB region may originate from the NCC. This arrhythmia 
can be treated effectively with RF ablation in the NCC. Further research is warranted 
to evaluate mapping strategy, ablation techniques, and safety issues.
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Introduction
Electrical isolation of the pulmonary veins (PV) by catheter ablation has emerged as 
a well established treatment for symptomatic, drug refractory AF. Multiple studies and 
meta-analyses have demonstrated the superiority of catheter ablation over AAD in 
patients with paroxysmal AF without structural abnormalities.1 
Single procedure success rates however are limited and patients who require a 
second procedure almost universally demonstrate recurrence of PV conduction. The 
surgical Cox-Maze-III procedure is recognized as a very effective treatment of AF but 
due to its invasiveness and complexity it is not widely used as a stand-alone 
procedure nowadays. As an alternative, MIPI was introduced in 1999 by Wolf et al, 
which allows an epicardial approach for pulmonary vein isolation on a beating heart 
through less invasive incisions.2 Although stand-alone surgical AF ablation is not 
common, ESC/AHA/ACC guidelines state that it can be considered (class IIb, level C) 
for either patients who failed catheter ablation in the past or when the patient prefers 
a surgical approach.3,4,5 Previous studies and recent meta-analysis even suggested 
that MIPI would have a better efficacy compared with endocardial CA.6
At present, no direct comparison has been made between surgical and CA as a first 
invasive procedure in patients with AF. The aim of the present study therefore was to 
perform a randomized controlled trial to compare the efficacy and safety of CA versus 
MIPI in the treatment of AF patients without structural heart disease. 
Methods
Purpose
The purpose of this prospective randomized clinical study was to compare the success 
rate of surgical versus percutaneous AF ablation, in order to prevent recurrences of 
AF, in patients without structural heart disease. Furthermore, we assessed the safety 
of both invasive treatment strategies. The study was approved by the Internal Review 
Board and registered (ClinicalTrials.gov Identifier: NCT00703157). 
Study population
Patients in the Isala Heart Center (Zwolle, the Netherlands) with symptomatic “lone” 
paroxysmal or early persistent AF (continuous AF duration < 3 months) with failure 
of at least one class 1 or 3 AAD were eligible. Patients should be aged ≥18 years. 
At least one symptomatic episode of AF was required within 6 months prior to 
inclusion. Structural heart disease, like coronary ischemia, cardiomyopathy and/or 
Abstract
Objectives
Current guidelines recommend both percutaneous catheter ablation and surgical 
ablation in the treatment of atrial fibrillation (AF), with different levels of evidence. No 
direct comparison has been made between surgical and percutaneous ablation as 
primary treatment of AF. We therefore conducted a randomized controlled trial 
comparing the safety and efficacy of these 2 treatment modalities. 
Methods 
Fifty patients, with symptomatic paroxysmal or persistent AF, and without structural 
heart disease, were randomized to either minimally invasive thoracoscopic pulmonary 
vein isolation and left atrial appendage ligation (MIPI) or percutaneous pulmonary 
vein isolation with point by point RF energy (CA). All patients received an implantable 
continuous looprecorder. The primary endpoint was defined as freedom of atrial 
tachyarrhythmias after 6 months of follow-up, without the use of anti-arrhythmic 
drugs (AAD). Secondary endpoints were AF burden <0.5% and reduction of AF 
burden after 6 months, whereas the safety endpoint was the absence of procedure 
related complications. 
Results 
Median age was 57 (37-75) and 78% was male. Paroxysmal AF was present in 74%. 
The primary endpoint was 59% versus 39% in favor of CA (P=0.156). The decrease in 
AF burden, six months after ablation, was 15.5% (95% CI 9.7%-43.1%) in MIPI 
compared to 26.1% (95% CI 11.2%-59.6%) in CA (P=0.375). A similar proportion of 
patients had AF burden <0.5% (63 versus 65%, P=0.87). More complications 
occurred after MIPI than CA (34.8% versus 11.1%; P=0.046).
Conclusions 
The short-term efficacy of preventing AF is similar for CA and MIPI. CA results in 
significantly less complications than MIPI. 
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performed for ipsilateral PVs to provide a geometric reference for catheter navigation 
and localization of the antrum. A 3-dimensional electroanatomic map of the left 
atrium (LA) was constructed (CARTO, Biosense-Webster). Isolation of all PVs was 
performed using circumferential periostial applications of radiofrequency energy, 
with a power limit of 40 Watt on the anterior LA and 30 Watt on the posterior LA, 
and verified with a decapolar circular mapping catheter (Lasso, Biosense Webster). 
The ablation was performed with a 3.5mm irrigated tip catheter (Thermocool, 
Biosense Webster). RF energy was applied for 20-60 seconds until the local 
electrogram amplitude was eliminated. The endpoint of the ablation procedure was 
defined as the absence or dissociation of PV potentials documented with a circular 
decapolar mapping catheter within the PVs ≥30 minutes post-ablation. 
Surgical ablation
In supine position under general anesthesia, a double lumen tube was introduced.In 
the right hemithorax, a 5-10 cm incision in the fourth intercostal space in the anterior 
axillary line was placed. A soft tissue retractor was used to introduce the scope 
through the sixth intercostal space (submammary). The pericardium was opened 
anterior to the phrenic nerve. Two stay sutures were placed in the pericardium. Blunt 
dissection of Waterstone’s Groove was performed followed by a blunt dissection and 
opening of the oblique sinus (OS) caudal of the right inferior pulmonary vein (RIPV). 
Then, blunt dissection and opening of the OS cranial of the right superior pulmonary 
vein (RSPV) between RSPV and right pulmonary artery was performed. Hereafter a 
silastic tape can be placed around the RPV’s in order to facilitate proper positioning 
of the device.
An irrigated bipolar clamp device (Cardioblate, Medtronic, USA) was introduced for 
PV isolation. This device has a self-regulating ablation protocol based on an impedance 
feedback system. Transmurality feedback is indicated based on a steady-state plateau 
in tissue impedance. After introduction of the device, antral tissue around the right 
sided PVs was clamped after gentle traction of the tape and RF energy was applied 
to ablate the left atrial wall adjacent to the junction with the right sided PVs. After RF 
energy application the clamp was repositioned approaching the antrum of the vein 
pair from 180°, then additional applications were performed. Isolation was confirmed 
with pacing manoeuvres at the left atrium-PV junction. After 30 minutes pacing 
manoeuvres were repeated to check for electrical reconnection. The left hemithorax 
was opened similar to the right hemithorax, except for the incision of the pericardium, 
that was incised posterior of the phrenic nerve. Additional left atrial appendage (LAA) 
ablation or removal or exclusion with stapler or preferably with endoloop was 
performed. The LAA exclusion was verified on transesophageal echocardiography. 
Ganglionated plexi ablation and additional ablation lines were not performed. 
more than mild valvular heart disease, should have been excluded by appropriate 
tests. Patients were excluded when they had permanent or persistent AF >3 months, 
ejection fraction <40%, left atrial size >50mm (parasternal long axis), use of amiodarone 
(no use within 6 months prior to study entry), history of cerebrovascular disease, 
pregnancy, life expectancy of less than one year and previous left atrial ablation.
Enrollment
After written informed consent had been obtained, consecutive patients were 
implanted a continuous looprecorder (Reveal® XT, Medtronic, USA). This implantable 
loop recorder (ILR) is a single lead electrocardiographic (ECG) subcutaneous 
monitoring device able to monitor atrial tachyarrhythmia burden. Patients were followed 
for a minimum of one week after ILR implantation and a maximum of 6 months in 
order to establish the required AF burden. 
If a patient had demonstrated a minimum of 10% AF burden after one week ILR 
monitoring and had complaints associated with AF, this patient was randomized to 
one of the treatment arms. Because many patients were highly symptomatic also with 
a burden <10%, or did not reach 10% burden because of early electrical cardioversion, 
we observed that many patients could not be randomized. A protocol amendment 
was initiated therefore, after approval in October 2012, allowing an AF burden of 2% 
in one week as a threshold for randomization. Moreover patients were followed for a 
maximum of 2 months instead of 6 months to establish the required AF burden. The 
majority (75 of 80) of patients were included in the study before the amendment was 
effectuated. Patients were randomized electronically at a 1:1 ratio to catheter ablation 
or surgical ablation. 
Ablation techniques
Catheter ablation
The ablation procedure was performed under general anesthesia. Vitamin K 
antagonists were discontinued for 3-5 days prior to ablation and bridged with low- 
molecular-weight heparin. Transesophageal echocardiography was performed directly 
pre-ablation procedure to assess interatrial septum and to exclude left atrial thrombus 
or other significant structural heart disease. Venous access was obtained through the 
femoral vein. A 6F deflectable quadripolar catheter (Bard, Lowell, Massachusetts, 
USA) was positioned into the coronary sinus. Transseptal access to the left atrium 
was achieved guided by fluoroscopy and pressure with a Brockenbrough needle, 
transseptal sheath (SL1, St Jude) and a guidewire. An initial bolus of 10.000 units of 
heparin was given and additional administration to achieve an activated clotting time 
between 300 and 350 seconds. All sheaths were continuously flushed with saline 
containing 2500 IU heparin per 500 mL saline. Pulmonary vein angiography was 
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categorical variables. We performed Cox survival analysis with log rank test for efficacy 
of both treatment strategies. Time to first documented recurrence was analysed by de 
log-rank statistic and plotted using Kaplan-Meier survival curve. We assessed the 
proportion of patients with AF burden <0.1%, <0.5%, <1.0% during follow-up with a 
chi-squared test for differences. We additionally tested for differences in absolute AF 
burden reduction. Because the age was significantly higher in the CA group, logistic 
regression was used to determine if age influenced the outcome of the variables that 
were significantly different between both groups. Age did not have a significant inter- 
action with the main endpoints and therefore no correction was performed in the 
analysis. 
Results
Eighty patients were enrolled in the study and underwent ILR implantation. Twenty 
eight patients did not reach randomization criteria. Twenty seven patients did not 
reach the required AF burden and one patient was excluded because of a LA size 
larger than 50 mm. A total of 52 patients were randomized, 26 to catheter ablation 
and 26 to surgical ablation. Figure 1 shows the patient distribution. All patients in the 
catheter group received catheter ablation. In the surgical group 23 patients underwent 
MIPI and 2 patients received CA because after randomization these patients refused 
surgical ablation. One patient in the surgical group was excluded because of 
significant coronary artery disease necessitating coronary artery bypass surgery 
combined with PVI. In the CA group one patient was excluded from analyses after 
ablation because on the  pre-procedural TEE a much larger left atrium was seen than 
expected (>50 mm antero-posterior diameter, with LA volume >50 cc/m2). Baseline 
characteristics are demonstrated in Table 1. 
Procedural characteristics
Table 2 demonstrates the procedural characteristics. The total median procedure 
time was not significantly different (P=0.14) between CA (168 min ranging 124-195) 
and MIPI (176 min, 155-221). In the CA group complete electrical isolation was 
achieved in all pulmonary veins (100%). In one patient with AF which could not be 
converted to sinus rhythm using electrical cardioversion after PV isolation, an 
additional roof line and fractionation guided ablation was performed. Afterwards, the 
patient was converted to sinus rhythm. In the MIPI group, PV isolation and LAA 
ligation was successful in all patients. In one patient, the ligament of Marshall was cut 
in addition to PV isolation, again because of recurrent AF after electrical cardioversions. 
This patient could subsequently not be converted to sinus rhythm. Hospitalization 
duration was significantly longer (P<0.001) in MIPI with a median of 9 days (range 
8-10) versus a median of 3 days (2-3) after CA. 
End points
The primary endpoint was defined as freedom from atrial tachyarrhythmias with a 
duration of ≥30 seconds after 6 months of follow-up, without the use of anti-arrhythmic 
drugs. A 3 months blanking period was initiated. Secondary endpoints were AF burden 
<0.5% and reduction of absolute AF burden after 6 months. AF burden postablation 
was calculated per month. The absolute decrease in average AF burden in month 4 to 
month 6 post ablation was determined as compared to the average AF burden up to 3 
months before the procedure. The safety endpoint was the absence of procedure 
related complications. Complications were regarded as major if it resulted in death, 
irreversible damage to structures, stroke, atrio-esophageal fistula, conversion to 
sternotomy or need for re-operation. Pericardial effusion not needing intervention and 
managed conservatively, small groin hematoma not requiring blood transfusion and 
without significant drop in haemoglobin, and procedure related mild infection (such as 
urinary tract infection or respiratory tract infection) were regarded as minor complications.
Post procedural care
Anticoagulation was re-initiated as soon as possible, after control of bleeding, and 
was continued at least 3 months after the procedure. When CHADS score was ≥1, 
patients were kept on anticoagulation. During the blanking period of three months 
the AAD were tapered off. 
Follow-up
During follow up, patients were seen at 3 and 6 months after the ablation procedure 
at the outpatient clinic or at other occasions when patients had symptoms. At each 
visit, a 12-channel ECG and ILR device download was performed to assess any 
recurrences of arrhythmias. 
Statistical analysis
All statistical analyses were performed using the Statistical package for the social 
sciences (SPSS) version 22 (IBM Nederland B.V., Amsterdam, The Netherlands). A two 
sided P-value of <0.05 was considered significant. Because of small sample size we 
performed as-treated patient analysis. Descripitive statistics were used to describe 
patient population and procedure characteristics. Categorical variables were reported 
as frequencies and percentages. Quantitative/continuous variables were described 
using the mean and standard deviation when normally distributed or using the median 
with the interquartile range when not normally distributed. To determine if the data was 
normally distributed the Shapiro-Wilk and Kolmogorov-Smirnov tests were used in 
combination with Q-Q plots and histograms. Data was not normally distributed and 
therefore t-test could not be used. The Mann-Whitney U test was used for the continuous 
variables. The Chi-square test or Fisher’s exact test was used for the comparison of 
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Safety
Procedural related adverse events occurred significantly more often in MIPI than CA 
(34.8% versus 11.1%, P=0.046). This was mainly due to a difference in major 
complications (21.7% in MIPI versus 0% in CA, P=0.016). Table 4 shows procedural 
and non-procedural adverse events. All complications in the CA group were minor 
complications, whereas in the MIPI group there were 5 major complications. In the 
MIPI group one patient required an acute conversion to median sternotomy because 
of bleeding from a laceration of the left upper PV at the LA junction. One patient 
required pericardiocentesis for pericardial effusion with tamponade. Another patient 
in the MIPI group developed post-operative lung herniation through one of the right 
Efficacy
The primary endpoint, freedom from all atrial tachyarrhythmias without AAD after 
6 months, occurred more often after CA than after MIPI (59 versus 39%) but this 
difference was not significant (P=0.16). Kaplan-Meyer plot with log rank test showed 
a difference with P=0.142 (Figure 2). The decrease in AF burden, six months after 
ablation, was 15.5% (95% CI 9.7%-43.1%) in MIPI compared to 26.1% (95% CI 
11.2%-59.6%) in CA (P=0.38). A similar proportion of patients had AF burden <0.5% 
(63% in CA versus 65% in MIPI, P=0.87). AF burden <1.0% was more often present 
in CA (63%) then MIPI (65%), without reaching statistical significance( P=0.87). Table 3 
demonstrates the AF burden during the 6 months follow up. 
Figure 1   Patient distribution.
Study design and patient distribution. AF: atrial fibrillation; CA: catheter ablation; CABG: coronary artery 
bypass grafting; LA: left atrium; MIPI: minimal invasive thoracoscopic pulmonary vein isolation
Not randomized (n=28)
- Low AF burden (n=27)
- LA size too large (n=1)  
Enrolled
(n=80)
Reveal implant (n=80)
 
Randomized
(n=52) 
Allocated to MIPI (n=26)
- recieved allocated intervention (n=23)
- Did not recive allocated intervention      (n=3)
     - crossover to CA-group (n=2)
    -   received CABG instead of MIPI (n=1) 
 
 
 
 
Allocated to CA (n=26)
- recieved allocated intervention (n=26) 
 
Lost to follow up (n=1)
- non cardiac related death 
Excluded by specialist (n=1)
- LA size larger than expected  
Analyzed (n=25) Analyzed (n=25)
Table 1   Baseline characteristics.
Catheter ablation
(N=27)
MIPI
(N=23)
P value
Age 59 (54-66) 55 (48-61) 0.017
Male 20 (74.1%) 19 (82.6%) 0.486
AF duration (years) 3.9 (1.5-8.0) 3.6 (1.6-8.7) 0.977
LVEF (%) 55 (50-60) 55 (50-60) 0.942
LA size, PLAX(mm) 40 (38-44) 39 (37-42) 0.604
Failed AAD prior to 
randomization
  Flecainide
  Propafenone
  Sotalol
  Amiodarone
  Beta-blocker
  Verapamil/diltiazem
  Digoxine
18 (66.7%)
0
14 (51.9%)
3 (11.1%)
14 (51.8%)
6 (22.2%)
4(14.8%)
16 (69.6%)
2 (8.7%)
14 (60.9%)
2 (8.7%)
16(69.5%)
1 (4,3%)
2 (8.7%)
CHA2DS2VASC-score
  0
  1
  2
  3  
9 (36%)
8 (32%)
5 (20%)
3 (12%)
9 (36%)
11 (44%)
4 (16%)
1 (4%)
0.338
AF burden pre-ablation (%) 29.2 (13.0-79.2) 26.3 (15.0-74.7) 0.861
Diabetes mellitus 2 (7.4%) 2 (8.7%) 1.000
Hypertension 11 (40.7%) 11 (47.8%) 0.615
AAD: anti arrhythmic drugs; AF: atrial fibrillation; CHA2DS2VASC-score
CHF, 1. HTN, 1. Age > 75, 2. Diabetes, 1. Stroke/TIA/systemic embolism, 2. Vacular disease (CAD, MI, PAD, 
aortic plaque),: LA: left atrium; LVEF: left ventricular ejection fraction; PLAX: parasternal long axis
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sided surgical incisions for which reconstruction with a patch of marlex mesh was 
performed. One MIPI procedure was complicated by left phrenic nerve paralysis and 
another patient developed a unilateral recurrent laryngeal nerve paralysis related to 
endotracheal intubation. One patient in the CA developed a ventilator associated 
pneumonia, treated with antibiotics. One patient in the CA group developed a 
urosepsis due to an indwelling urinary catheter. Pericarditis without significant 
effusion was successfully treated with ibuprofen in both groups.
Table 2   Procedural characteristics.
Catheter ablation 
(n=27)
Surgical ablation 
(n=23)
P-value
Total procedure time (min) 168 (124-195) 176 (155-221) 0.143
Fluoroscopy time (min) 23 (17-31) -
Total ablation time (min) 31 (24-41)
RF energy (sec) 200 (177-278)
Additional ablation 
     roofline
     Marshall’s ligament     
1
0
0
1
Left atrial appendage ligation .. 23/23 (100%)
Hospitalization (days) 3 (2-3) 9 (8-10) <0.001
RF: radio frequency
Table 3   Atrial fibrillation burden during follow up.
Catheter ablation
(N=27)
Surgical ablation
 (N=23)
p value
Absolute AF burden (%)
0 months
3 months
6 months
29.2 (13.0-79.2)
0.09 (0.0-10.3)
0.09 (0.0-0.1)
26.3 (15.0-74.7)
0.4 (0.09-13.5)
0.1 (0.0-3.7)
0.861
0.118
0.164
Difference AF burden(%)
3 months
6 months 24.1 (6.8-63.6)
26.1 (11.2-59.6)
17.9 (9.5-43.2)
15.5 (9.7-43.1)
0.830
0.375
AF burden <0.1%
3 months
6 months
16/27 (59%)
16/27 (59%)
8/23 (35%)
9/23 (39%)
0.084
0.156
AF burden <0.5%
3 months
6 months
18/27 (66.7%)
17/27 (63%)
12/23 (52.2%)
15/23 (65%)
0.297
0.869
AF burden<1.0%
3 months
6 months
18/27 (67%)
17/27 (63%)
14/23 (61%)
15/23 (65%)
0.670
0.869
Values for as treated population. 
Values are given in frequencies/total number of patients and percentages.
Figure 2   Kaplan–Meier curves displaying time to first atrial tachyarrhythmia with 
3-month blanking period. (log-rank: p = 0.142).
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percutaneous first-line treatment of AF, although with differences in class and level of 
evidence (class 1, A class 2a, A for CA in paroxysmal and persistent AF, and class 2b, 
B for surgical ablation).2,3 Review studies of minimally invasive surgery for lone AF 
show a 12 months AAD-free, success rate of 65-92%.9,10 However the individual 
studies, are generally small sized, single centre and describe a variety of surgical 
techniques and follow up methods. For this reason a reliable meta-analysis cannot 
be carried out. Moreover, in most studies, patients after unsuccessful CA are included, 
which is an importantly different group of patients than patients without previous 
ablation. 
Head-to-head randomized comparison of surgical and catheter ablation was 
performed before, although always in populations comprising a large proportion of 
patients with unsuccessful previous CA.11, 12 The FAST trial was a prospective, 
randomized trial in 124 patients who had failed a previous CA procedure or had 
hypertension and an enlarged LA.11 Patients were randomized in a 1:1 ratio to either 
CA or MIPI. Importantly, 2/3 of patients had unsuccessful CA before randomization. 
The 12 months success rate, defined as freedom from atrial tachyarrhythmias >30 
seconds in duration, measured by 7 day holter monitoring, was significantly higher 
for the surgical group than the CA group (65.6% versus 36.5%, p= 0.0022). The 
authors explained the relatively poor efficacy in the catheter group by the fact that 
patients were in an advanced stage of AF and might have required additional 
substrate ablation. Moreover, performing epicardial ablation lines after previous 
endocardial ablation, increases the probability of creating transmural lesions without 
gaps in lines, and thus isolation of the PVs and elimination of triggers. In vivo as well 
as in vitro studies demonstrate a large heterogenity in thickness and composition of 
the atrial epicardium and myocardium. Aging and associated disease promote 
development of elastic fibres, collagen, fat content and smooth muscle cell 
hyperplasia. This process has a hindering effect on RF electrical current in the tissue 
and limits the creation of a transmural lesion.13 Traditionally, surgical epicardial 
approach is performed in patients with one or more endocardial ablation attempts. In 
these patients it is more likely to create electrical PV disconnection with additional 
epicardial ablation than in patients without a previous endocardial ablation.
Importantly, follow-up method in the FAST trial did not consist of continuous 
monitoring, and shorter episodes of AF can be easily missed in this way. When 
assessing AF burden <0.5% in our study, which is only 0.8 hours per week, success 
rates would be 63-65% for MIPI and CA. Although efficacy was superior for surgical 
ablation in the FAST trial, the major early complication rate was significantly higher for 
the surgical group (23.0% versus 3.2%), which is in accordance with our present 
study. The same phenomenon of higher efficacy rates in patients with previous 
Discussion
This is the first randomized controlled trial that randomized patients without structural 
heart disease with symptomatic AF to surgical or percutaneous ablation as a first 
invasive procedure to prevent recurrences of AF. After short-term follow-up with ILR, 
no significant differences could be observed in efficacy, although there was a trend 
towards higher success after CA. Both strategies reduced AF burden significantly 
and similarly. Procedure related complications occurred significantly more often in 
MIPI than in CA, mainly because of a difference in major complications. 
Endocardial, as well as epicardial PVI ablation approaches have demonstrated to be 
successful. Whereas CA is most popular as a first line therapy in paroxysmal and 
early persistent AF, surgical epicardial ablation is mostly restricted to patients with 
(multiple) unsuccessful CA procedures or evidence of advanced substrate.7,8 Both 
European and American guidelines however recommend both surgical and 
Table 4   Procedural and non procedural related adverse events.
Catheter ablation
(n=27)
Surgical ablation
(n=23)
P value
Pericarditis 1 2
Pleuropericarditis with bloth cloth 0 1
Pericardial effusion 0 1
Conversion to sternotomy 0 1
TIA/stroke 0 0
Pneumothorax 0 0
Phrenic nerve paralysis 0 1
Upper respiratory tract infection 1 0
Pacemaker implant 0 0
Death 0 0
other 1
(urosepsis)
2
(lung herniation 
requiring surgical 
correction, laryngeal 
nerve palsy)
Total
   Minor
   major
3 (11.1%)
   3
   0
8 (34.8%)
   3
   5
0.046
1.00
0.016
TIA: Transient ischemic attack
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trial was conducted in a single center. Pooling of randomized data from different 
centers and new larger multi-center randomized data are mandatory. The present 
follow-up duration of 6 months is relatively short, but was pre-defined as the primary 
endpoint. Furthermore, most recurrences occur between 3 and 6 months of follow-up. 
In conclusion, in patients without structural heart disease and with symptomatic 
paroxysmal or persistent AF, first line invasive treatment by minimal invasive surgical 
PVisolation seems equally effective as CA on the short term. CA however, has much 
lower complication rates.  
unsuccessful CA was described by Pokushalov et al. They randomized 64 patient 
with paroxysmal and persistent AF after a failed initial pulmonary vein ablation to 
repeat CA (n=32) or MIPI (n= 32).12 The follow-up method consisted of continuous 
monitoring with an ILR. The surgical procedure consisted of PV isolation, lines to 
create a box lesion and ablation of ganglionic plexi. At 12 months follow-up 81% of 
surgical patients were free of atrial arrhythmias without AAD versus 47% in the CA 
group (p=0.004). Again, in this study, major complication rate was much higher in 
surgical procedures than after CA (22 versus 3.2%, P=0.02). Surgical and catheter 
AF ablation are highly complex procedures. The most recent worldwide survey of CA 
reported a 4.5% complication rate.14 It has to be recognized that the data were from 
voluntary surveys and likely underestimate the true complication rates. In our present 
study, most complications were general surgery related complications, like bleeding 
and damage to organs or the nervous system. The high complication rate of ablation 
surgery is observed in many studies involving highly experienced surgeons, possible 
highlighting the need for cardiac electrophysiological surgery as a subspecialty in 
order to reduce complication rates. 
Our study has some unique aspects. We randomized patients to MIPI or CA only in 
patients undergoing a first invasive treatment for AF. Further, we used continuous 
rhythm monitoring to assess arrhythmia outcome. It has been shown that monitoring 
of symptoms in AF patients is unreliable in that respect. Only 52% of symptoms 
correlate with documented AF and nearly half of AF episodes are asymptomatic.15 
The HRS task force recommends 24-hour holter monitoring as an acceptable 
monitoring strategy for patients enrolled in a clinical trial. Hanke et al demonstrated 
that intermittent monitoring dramatically overestimates the success rate of ablation 
procedures. Fourtyfive patients were monitored after AF surgery with ILR as well as 
quarterly 24-hour holter monitoring. The sensitivity of detecting AF with holter 
monitoring was only 0.60.16 Another study in 647 AF patients with a mean AF burden 
of 0.12% showed that even with intensive intermittent monitoring at least 30 days of 
holter monitoring would be required to reach a sensitivity of 82% in detection of AF.17 
For scientific as well as for AF patient management decisions continuous monitoring 
after ablation procedures is strongly recommended. Apart from the AF burden, the 
objective evaluation of the characteristics of various atrial arrhythmias after ablation 
will guide the best strategy and best time of re-intervention.
The main limitation of our study is the small sample size. A larger than expected 
proportion of patient did not meet the requirement of AF burden >10%. Highly 
symptomatic episodes of AF required electrical cardioversion before patients could 
reach the 10% within one week looprecorder monitoring criterion. Later, nearly at the 
end of the study, we changed this inclusion criterium to 2% AF burden. Secondly, this 
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Introduction
Surgical treatment of atrial fibrillation (AF) using the Cox maze technique is highly 
successful but is a complex procedure requiring cardiopulmonary bypass and cardio- 
plegic arrest, and is associated with significant morbidity.1 
Since the first report by Wolf et al.,2 minimally invasive thoracoscopic radiofrequency 
ablation has been an accepted technique for surgical AF treatment. Principle of this 
epicardial ablation method is to isolate the pulmonary veins (PVs) in order to prevent 
the initiation of AF. One-year success rates of this ablation technique range from 
51 to 85%.3 Reports regarding the mechanism, electrophysiological findings 
and treatment of recurrent atrial arrhythmias are very limited. In the present study, 
we assessed the clinical and electrophysiological characteristics of recurrent 
symptomatic atrial arrhythmias after minimally invasive surgical PV isolation (MIPI) 
and left atrial appendage ligation and the long-term outcome of catheter ablation for 
these arrhythmias. 
Methods
From May 2006 to February 2012, 41 patients underwent MIPI at the Isala Hospital. 
The indication for MIPI in all patients was symptomatic paroxysmal or persistent 
lone-AF, refractory to at least one class 1 or class 3 antiarrhythmic medication. All 
patients preferred a surgical approach as an alternative to catheter ablation. Patients 
with previous left atrial ablation procedures were excluded from this study. In 23 
patients, electrophysiological study was performed because of recurrent symptomatic 
atrial arrhythmias. All patients consented to their data being registered and used for 
publication as did the Board of Hospital Administrators.
Statistical analysis
Continuous data were reported as mean ± standard deviation in case of normal 
distribution or median ± interquartile range when variables were not normally 
distributed, and unpaired t -tests were used for group comparisons. Nominal data 
were expressed as percentages and numbers. A probability value of <0.05 identified 
a statistically significant result. Kaplan–Meier analysis was used to assess freedom 
from reintervention after surgery. 
Surgical procedure
PVs were isolated using an irrigated bipolar RF ablation clamp (Cardioblate, 
Medtronic, USA). All lesions were made with this bipolar RF ablation device, which 
Abstract
Objectives
Minimally invasive thoracoscopic epicardial pulmonary vein isolation (MIPI) has an 
important role in the surgical treatment of atrial fibrillation (AF). However, the 
management of recurrent atrial arrhythmias after MIPI and long-term success rate of 
catheter ablation have not  been well studied.
Methods 
Electrophysiological study was performed in 23 patients, 378 ± 282 days after MIPI 
surgery, because of recurrent symptomatic atrial arrhythmias.
Results 
A total of 20 patients presented with paroxysmal and persistent AF, 2 patients had a 
combination of AF and atrial tachycardia  (AT) and 1 patient had a combination of AF 
and atrial flutter. All patients showed pulmonary vein (PV) reconnection. ATs were 
micro- re-entry PV-related ATs and atrial flutter was cavotricuspid isthmus dependent. 
Eighteen of 23 patients (78.3%) were free of atrial arrhyth- mias after one catheter 
ablation procedure at a mean follow-up of 50 ± 16 months. Three patients underwent 
a second ablation procedure for recurrent AF and macro-re-entry left atrial flutter. 
Eventually 20 of 23 patients (87%) remained free of atrial arrhythmias after a mean of 
1.1 ± 0.3 ablation procedures.
Conclusions 
Catheter ablation of recurrent atrial arrhythmias following MIPI for paroxysmal and 
persistent AF is a feasible and effective treatment with a good long-term success 
rate. Reconnection of PVs accounts for most recurrences.
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Electrophysiological study and ablation after surgical pulmonary 
vein isolation
Patients with symptomatic atrial arrhythmias after surgery were referred to our cardiac 
electrophysiology division, and underwent electrophysiological study.
Transoesophageal echocardiography was performed before each procedure. Oral 
anticoagulants were substituted to low molecular weight heparin 4 days prior to the 
procedure. Patients were transferred to the cardiac catheterization laboratory in a 
fasting state, and conscious sedation was administered. All catheters were introduced 
through the femoral vein. Using fluoroscopic guidance, a quadripolar electrode 
catheter (EPX, Bard, USA) was positioned in the coronary sinus. In all patients, a 
double trans-septal puncture was performed using fluoroscopic guidance. Two 
8.5-Fr SL1 sheaths (St Jude Medical, Inc.) were advanced to the LA by a modified 
Brockenbrough technique. After trans-septal catheterization, intravenous heparin 
was administered to maintain an activated clotting time of 300–350 s. Additionally, 
continuous infusion with heparinized saline was connected to the trans-septal 
sheaths (flow rate of 1 ml/min) to avoid thrombus formation or air embolism. Atriove-
nography of the LA and PVs was performed in all patients to define the ostium of the 
PVs. For circular mapping of PV ostia, a decapolar adjustable circular mapping 
catheter (Lasso, Biosense-Webster, USA) was placed trans-septally at the ostium of 
the target PVs. Bipolar and unipolar electrograms were filtered at band-pass settings 
of 30–500 and 0.05–200 Hz, respectively, and were recorded digitally (LabSystem 
pro, Bard, USA). Pacing was performed from the coronary sinus or LAA with a 
stimulator (Bard, USA) at twice the diastolic threshold with a pulse width of 2 ms. RF 
energy was applied with a Stockert (Cordis Webster) generator delivering a 
500–550-kHz sine wave output.
After double trans-septal puncture, a decapolar circular mapping catheter (Lasso, 
Biosense-Webster, USA) and mapping catheter (Navistar, Biosense-Webster) was 
introduced into the LA. A three-dimensional (3D) shell representing the LA was 
constructed by use of an electroanatomical mapping system (Carto, Biosense-Web-
ster, USA). First, all the PVs were mapped to assess gaps in the ablation lines at the 
LA-PV junction. In patients with gaps at the LA-PV junction, a circular mapping 
catheter was positioned within the PV ostia during RF delivery. PV isolation was 
performed by applying RF energy at ostial sites at which the earliest bipolar PV 
potentials and/or the earliest unipolar electrograms with the most rapid intrinsic 
deflection were recorded. Irrigated RF energy was delivered with a target temperature 
of 43°C, a maximal power limit of 40 W and an infusion rate of 8–15 ml/min during RF 
energy application. RF ablation sites were tagged on the reconstructed 3D map of 
the LA. RF energy was applied for ≥20 s until the maximal local electrogram amplitude 
has a self-regulating ablation protocol based on an impedance feedback system. 
Transmurality feedback is indicated based on a steady-state plateau in tissue 
impedance. This minimally invasive PV isolation procedure was performed on a 
beating heart.
In supine position under general anaesthesia, double lumen tube was introduced. 
Defibrillator pads were placed on the thoracic wall. In the right hemithorax, a 10 cm 
incision in the fourth intercostal space in the anterior axillary line was placed. A soft 
tissue retractor was used to introduce the scope through the sixth intercostal space 
(submammary). The pericardium was opened anterior to the phrenic nerve. Two stay 
sutures were placed in the pericardium. Blunt dissection of Waterstone’s Groove was 
performed followed by a blunt dissection and opening of the oblique sinus (OS) 
caudal of the right inferior pulmonary vein (RIPV). Then, blunt dissection and opening 
of the OS cranial of the right superior pulmonary vein (RSPV) between RSPV and right 
pulmonary artery was performed. After introduction of the bipolar ablation device, 
antral tissue around the right-sided PVs was clamped after gentle traction of the tape 
and RF energy was applied to ablate the left atrial wall adjacent to the junction with 
the right-sided PVs. After RF energy application, the clamp was repositioned 
approaching the vein pair from 180°, then a second RF application was performed. 
Isolation was confirmed with pacing manoeuvres at the left atrium (LA)-PV junction. 
After 30 min, pacing manoeuvres were repeated to check for electrical reconnection. 
The left hemithorax was opened similar to the right hemithorax, except for the incision 
of the pericardium, that was incised posterior to the phrenic nerve. Additional left 
atrial appendage (LAA) ablation or removal or exclusion with stapler or preferably 
with endoloop was performed. Ganglionated plexi ablation and additional ablation 
lines were not performed. Complications of surgical ablation were temporary phrenic 
nerve palsy in 2 patients, 1 patient with pleuropericarditis, 1 patient with tamponade 
requiring pericardial drainage and 1 patient with TIA 5 days after surgery.
Postoperative care and cardiac rhythm monitoring
All patients were treated with oral anticoagulant for at least 3 months, and continued 
based on the patient’s stroke risk scheme CHA2DS2-VASc (congestive heart failure, 
hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, 
vascular disease, age 65–74 years, sex category). Antiarrhythmic drugs were tapered 
off 3 months after surgery in the presence of stable sinus rhythm. After discharge, 
patients were seen at the outpatient clinic 1 week, 3, 6 and 12 months after surgery. 
The rhythm follow-up was either 24-h Holter monitoring at 3, 6 and 12 months or 
continuous rhythm monitoring with implantable loop recorder (Reveal XT; Medtronic, 
Inc.).
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Results
Of 41 patients who underwent MIPI, 23 patients (56.1%) aged 58 ± 10 years (range: 
37–75) had electrophysiological (EP) study and ablation because of recurrent atrial 
arrhythmias. Five other patients had recurrent atrial arrhythmias after surgery but did 
not undergo EP study either because they were asymptomatic, responded well to 
antiarrhythmic drugs or for personal reasons refused EP study. Patients who underwent 
EP study had AF with a duration of 6.0 ± 4.5 years prior to MIPI. AF episodes lasted 
for 4 h to >24 h and 16 patients (69.6%) had paroxysmal AF and 7 patients (30.4%) 
had persistent AF. Clinical characteristics are provided in Table 1. All patients under- 
went AF surgery as described. The actual surgical bipolar radiofrequency ablation 
time was 180 ± 66 s. Procedure-related complications of catheter ablation were 
 cerebrovascular accident (with minimal function loss of right hand) in 1 patient, groin 
haematoma in 1 patient, another patient with a femoral arterio-venous fistula requiring 
thrombin injection and 1 patient with a cardiac perforation with open pericardium 
managed conservatively. 
decreased by ≥70% or double potentials or disappearance of PV potentials was 
noted. Depending on the location of the gaps in the surgical RF ablation lines, 
endocardial irrigated RF ablation was performed in the posterior wall >1 cm and in 
the anterior wall >5 mm from the angiographically defined PV ostia. At the narrow 
border between the anterior aspect of the left PVs and the LA appendage, ablation 
was performed within ~5 mm of the ostium of the PVs. The circular mapping technique 
in conjunction with the 3D electroanatomical map substantially facilitated identification 
of gaps (Fig. 1 ). The end point of the ablation procedure was defined as absence or 
dissociation of PV potentials documented with the circular mapping catheter within 
the PVs ≥30 min postablation. In patients with AT/AFL, activation mapping and/or 
entrainment mapping was performed to identify the arrhythmogenic substrate. In 
case of re-entrant atrial flutter, entrainment mapping was used to identify the critical 
isthmus of the flutter circuit, and RF energy was applied until block across the isthmus 
was achieved. 
Figure 1   Carto bipolar electroanatomical voltage map of the LA from the posterior 
view of a representative patient with reconnection in all four pulmonary 
veins after MIPI procedure. The left and right panels show the situation 
before ablation and after ostial endocardial pulmonary vein ablation, 
respectively. Note extensive scarring with voltages <0.05 mV after 
electrical isolation.
Table 1   Clinical preoperative patient characteristics (mean).
No of patients 23
Age (years) 58 ± 10
Gender male/female 17/6
BMI (kg/m2) 29.2 ± 3.7
CHADS-VASC (range) 1.4 (0-5)
Type of AF
   Paroxysmal
   persistent
16
7
Duration of AF (years) 6.0 ± 4.5
Hypertension 8 (34%)
Diabetes mellitus 3 (13%)
Preoperative flutter ablation 3 (13%)
No of antiarrhythmic drugs for AF 3.4 ± 0.9
Structural/congenital heart disease 1 (situs inversus)
History of stroke/TIA 2
Left atrial dimension (mm) 43 ± 3.3
Demographics and clinical characteristics of all patients who underwent electrophysiological study for 
recurrent atrial arrhythmias after minimal invasive surgical ablation for atrial fibrillation.
AF = atrial fibrillation; BMI = body mass index; TIA = transient ischemic attack
a Statistically significant compared with preoperative AF burden P , <0.05.
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Eighteen of 23 patients (78.3%) were free of atrial arrhythmias after percutaneous 
catheter ablation with a follow-up duration of 48.1 ± 16.0 months (range: 15.6–78.6). 
Five patients had symptomatic recurrence of atrial arrhythmias after catheter ablation. 
Three of these patients, all presenting with recurrent paroxysmal AF, underwent a 
second electrophysiological procedure 8–23 months after the first catheter ablation 
procedure. Two patients showed reconnection at the same site as during the previous 
procedure. Again reisolation was performed. After a follow-up of 42 and 52 months, 
both patients remained free of arrhythmias. The third patient subsequently required a 
third ablation procedure for symptomatic paroxysmal atrial flutter and AF, which he 
Electrophysiological study and catheter ablation after surgery
Electrophysiological study was performed 378 ± 282 days after surgery (Fig. 2 ). All 
patients had symptomatic postoperative atrial arrhythmias resistant to antiarrhythmic 
drug therapy. The arrhythmias in 20 patients were recurrent paroxysmal AF, 2 patients 
presented with the combination of paroxysmal AF and PV-related (micro-re-entry) 
atrial tachycardia (AT) and 1 patient had a combination of paroxysmal AF and 
cavotricuspid isthmus-dependent atrial flutter (Fig. 3 ). In all 23 patients, there was PV 
reconnection. Two patients had reconnection of a single PV (8.7%). Six patients 
(26.1%) had reconnection in two PVs, 5 of these patients showed reconnection in a 
PV pair (3 left-sided PV pair and 2 right-sided PV pair). Six patients (26.1%) had 
reconnection of 3 PVs and 9 patients (39.1%) presented with reconnection of all PVs. 
The reconnected PVs showed conduction delay between the LA and PV. 
The most common site for reconnection on the left was the ridge between left-sided 
PVs and LAA and the intervenous ridge between the left-sided PVs, whereas on the 
right side most gaps were found at the inferior side of the right lower PV. The right 
upper PV did not show a specific pattern of reconnection site. The residual LA-PV 
conduction gaps were eliminated with additional RF deliveries. Electrical 
disconnection of all targeted PVs was achieved in all patients. In the patient who 
presented with AF and atrial flutter, entrainment mapping confirmed cavotricuspid 
isthmus-dependent atrial flutter and an ablation of the cavotricuspid isthmus was 
performed in addition to PV reisolation.
Figure 2   Kaplan–Meier curve demonstrating freedom from reintervention  
following MIPI.
Figure 3   Treatment and outcome of recurrent atrial arrhythmias after MIPI.  
AF: atrial fibrillation; AFL: atrial flutter; AT: atrial tachycardia; CTI: cavotricuspid isthmus ablation; FU: 
follow-up; MIPI: minimally invasive pulmonary vein isolation and left atrial appendage ligation; P: patients; 
PAF: paroxysmal atrial fibrillation; PV: pulmonary vein; PVI: pulmonary vein isolation; SR: sinus rhythm
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Previous studies
Kron et al. found recurrent atrial arrhythmias in 20 of 50 patients (40%) after minimally 
invasive thoracoscopic AF surgery. PV reconnection was the predominant finding by 
EP study. The authors speculate on reasons for reconnection. Particularly, 
reconnection on the left-sided PVs has a preference site at the intervenous ridge and 
the PV-LAA ridge. This might be related to atrial folds and ridges that increase 
myocardial thickness, which affect both endocardial and epicardial techniques.6 , 7 
These results are in line with the findings of the current study. However, Zeng et al. 
investigated sites of reconduction after minimally invasive PV isolation, and found that 
recurrent atrial arrhythmias are related to gaps at the roof and the bottom of the PV. 
The main reason for reconduction at this site would be that the electrodes of the 
ablation clamp could only sufficiently achieve transmural lesion when myocardial 
tissue is ‘squeezed’ inside the clamp and ablating perpendicular to the target tissue. 
At the roof and bottom of the PV rings, this effect is not reached.8 In the current study, 
at least two RF applications with two different clamp positions were performed on 
both sides. After the first RF application, the clamp was repositioned approaching the 
vein pairs from a different angle to overcome this effect. 
Liu et al.9 studied 8 patients with recurrence of atrial arrhythmias after minimally 
invasive thoracoscopic PV isolation. They found, like Zeng et al. , that PV gaps are 
distributed exclusively in the roof or the bottom of the PV antrum. However, the 
mechanism maintaining the clinical or induced atrial arrhythmia in the majority of their 
patients was not the reconnected PV but macro-re-entry or non-PV focal activity. In 2 
patients, complex fractionated atrial electrogram (CFAE) ablation converted AF into 
AT, perimitral re-entry was found in 4 patients and 3 patients had focal left atrial ATs. 
The authors emphasize the potential proarrhythmic effect of the left atrial appendix 
excision lesion. This lesion in the lateral LA creates an isthmus between LAA and 
mitral annulus and an isthmus between LAA and anterior wall of the left PV, facilitating 
development of perimitral macro re-entrant ATs. Patients who develop perimitral atrial 
flutter often have more severe and drug-refractory symptoms than they had from AF 
and this arrhythmia is relatively difficult to treat with catheter ablation, often requiring 
ablation within the coronary sinus.10 The findings in our study are clearly different 
from those of Liu et al. Although all the patients included in our study had LAA ligation, 
only 1 patient developed macroreentrant LAA-related left atrial flutter. In fact, 20 
patients (87%) who presented with recurrent atrial arrhythmias had PV reconnec-
tion-related arrhythmias. Whether the surgical technique of LAA ligation, lesion size 
or patient characteristics predict the development of postoperative macroreentrant 
left atrial arrhythmias remains to be investigated. 
developed soon after reablation. The LIPV appeared to be reconnected, and was 
reisolated. Entrainment and propagation mapping revealed a macro-re-entry left 
atrial flutter around the occlusive LAA. RF ablation at the ridge between LAA and 
LSPV terminated the arrhythmia. Unfortunately, the patient developed recurrent AF 
and flutter, and was eventually treated with AV nodal ablation and pacing. There were 
2 patients with recurrent arrhythmias, respiratory paroxysmal AF and combination of 
paroxysmal AF and atrial flutter after one catheter ablation procedure who refused 
another invasive procedure. These patients were treated with AV nodal ablation and 
pacing, respiratory antiarrhythmic drugs and pacemaker therapy. Thus eventually, 20 
of 23 patients (87.0%) were free of atrial arrhythmias after one MIPI and a mean of 1.1 
± 0.3 percutaneous ablation procedures.
Discussion
The results of the present study demonstrate that symptomatic atrial arrhythmias 
after minimally invasive epicardial PV isolation are predominantly due to reconnection 
of epicardial ablation lines. To the best of our knowledge, this is the first report that 
describes the long-term success rate of percutaneous catheter reablation in this 
population. At a mean follow-up of 48.1 ± 16.0 months, 78.3% of patients were free 
of arrhythmias after catheter ablation and 87.0% of patients after a second ablation 
procedure after MIPI. The adverse event rate was 10%, which is slightly higher when 
compared with prior reports.4 
Since the first report of epicardial ablation by Wolf et al. , this procedure gained 
popularity. The studies published in the last decade describing results of minimally 
invasive surgery for lone AF are small sized, and observational in nature. The 1-year 
success rate, defined as freedom from AF off antiarrhythmic drugs, ranges from 51 
to 86%.3 , 5 Furthermore, there is a wide variety in patient selection, follow-up method, 
lesion pattern, surgical technique and energy source among different reports and 
this might be responsible for differences in outcome. The current study shows a 
relatively high rate of postoperative recurrent atrial arrhythmias. However, data from 
the subgroup patients with continuous monitoring, implanted with a loop recorder, 
demonstrate that the mean AF burden significantly reduced after surgery from 42.7 ± 
40.0% preoperatively to 7.6 ± 15.1% at 3 months post-surgery ( P = 0.003). Although such 
a significant reduction in AF burden does not fulfil the definition of procedural 
success, it might still be judged as a successful procedure from a patient’s 
perspective. EP study revealed that recurrent arrhythmias were predominantly related 
to PV reconnection. This suggests that initial lesions were often not transmural. 
Possibly, additional RF applications or more extensive testing for isolation could have 
resulted in better outcome. 
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patients.15 , 16 Further research is warranted to determine the best approach for 
(long-standing) persistent AF patients and identifying the patient characteristics 
benefitting most from additional ablation procedures. 
Role of epicardial fat
Epicardial fat is a form of visceral adipose tissue and the volume of epicardial fat has 
been correlated to visceral adiposity. Enhanced local inflammation due to increased 
adipocytokines and proinflammatory cytokines by adipocyte secretion may generate 
myocardial remodelling, and contribute to the development of AF.17 Furthermore, 
epicardial fat hampers epicardial ablation techniques. An in vivo study in sheep has 
shown that epicardial fat has a detrimental effect on lesion formation. Fat absorbs 
part of the RF energy, and creates a barrier to the transmission of energy to the 
myocardium during epicardial ablation.18 The current study presents a population 
of patients presenting with recurrent atrial arrhythmias after epicardial ablation. The 
population is remarkably obese with a body mass index of >25 in 83% of patients. 
Epicardial fat may have contributed to the lack of transmural epicardial lesion 
formations in the patients. Whereas the amount of epicardial fat and thickness of the 
epicardium undoubtedly limits lesion depth, one should realize that the histological 
composition, particularly fibrosis is another factor influencing lesion formation. 
Hybrid techniques
Recently the hybrid technique has been introduced, which combines transvenous 
endocardial and thoracoscopic epicardial ablation procedure either as a concomitant 
or staged procedure.19–21 Generally, surgical epicardial PV isolation is followed by 
additional endocardial substrate ablation. A major advantage is the verification of 
epicardial PV isolation by endocardial entrance- and exit block and endocardial gap 
closure if conduction is still present. La Meir et al. 19 found that in 5 of 35 patients 
(14%), who underwent a hybrid ablation approach, endocardial PV conduction was 
still present after epicardial confirmation of bidirectional block. In another study, 23% 
of patients required additional endocardial ablation to complete PV isolation.20 
A recent study by Eckstein et al. gives important insight into atrial transmural 
conduction of fibrillation waves. Simultaneous endo-epicardial mapping in goats 
revealed that the degree of endo-epicardial dissociation of electric activations 
resulting in transmural conduction of fibrillation waves is correlated with increasing 
AF substrate.22 Whereas focal ectopic discharge in patients with little substrate can 
be targeted by either epicardial or endocardial ablation, the endo-epicardial 
dissociation concept supports a dual treatment with hybrid approach for patients 
with advanced remodelling. 
Pulmonary vein isolation only versus substrate ablation
The concept described by Haïssaguerre et al.11 that initiation of paroxysmal AF is due 
to PV-related triggers, and can be successfully eliminated by PV isolation is well 
accepted. However, in non-paroxysmal AF, PV triggers are less dominant, and the 
arrhythmogenic substrate involves a larger portion of the LA. Although the type of AF, 
paroxysmal versus persistent, is a definition by duration and not by pathophysio-
logical substrate, it is appreciated that in the majority of persistent AF patients a 
mechanically and electrically remodelled atrial substrate is responsible for AF 
perpetuation. Previous data suggested that in these cases, additional substrate 
ablation with linear left atrial lesions or ablating areas with CFAEs was necessary to 
achieve more satisfying arrhythmia-free outcome.12 , 13 
However, recently the randomized STAR AF 2 trial was presented. This trial was 
designed to explore the optimal method and outcomes of ablation in persistent AF. A 
total of 589 persistent AF patients received either PV isolation alone, PV isolation plus 
CFAE ablation or PV isolation plus additional LA lines. At 18 months, freedom with or 
without antiarrhythmic drugs was not significantly different between the three 
strategies.14 It is uncertain if these results of endocardial catheter ablation studies 
apply for surgical epicardial ablation. There are no randomized data in minimally 
invasive surgical studies regarding the approach in persistent AF patients. During 
minimally invasive epicardial ablation, a wider antral area is ablated when compared 
with endocardial catheter ablation. Thus, a larger left atrial volume and relatively more 
substrate is treated. Wolf et al. described minimally invasive thoracoscopic PV 
isolation in his series of 27 patients. Nine out of the 27 patients had persistent and 
permanent AF and success was achieved in all these non-paroxysmal AF patients.2 
Our findings are in line with Wolf et al. All 7 patients with persistent AF who had 
recurrent atrial arrhythmias appeared to have PV reconnection, suggesting 
non-transmural lesion rather than lack of substrate treatment. The results can be 
partially explained by the fact that the current study did not include long-standing 
persistent and permanent AF patients and patients did not have greatly enlarged left 
atria, which is known to represent advanced substrate. 
A review paper by La Meir et al. demonstrated that minimally invasive epicardial 
AF surgery yields a 12-month success rate of 67–80%, off antiarrhythmic drugs, 
in persistent AF patients. Studies performing additional lines were relatively more 
successful than studies describing PV box lesion only.3 One has to realize that 
creating additional lines is challenging. Incomplete ablations can cause non- 
transmural gaps that are potentially proarrhythmic. Furthermore, extensive ablation 
can have a deleterious effect on left atrial mechanical function, and is associated 
with postoperative bradyarrhythmia requiring permanent pacemaker in 6–10% of 
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Follow-up method
The majority of studies describing epicardial surgical PV isolation estimate the 
efficiency of ablation by 24- or 48-h Holter monitoring at different intervals.3 The 
current consensus regarding rhythm monitoring post-AF ablation recommends at 
least two 24-h Holter monitoring examinations annually.4 Previous studies in minimally 
invasive AF surgical patients have demonstrated that more intensive monitoring 
significantly increases detection of recurrent arrhythmias and that up to 19% of 
patients have asymptomatic recurrent AF episodes.23 , 24  Charitos et al. investigated 
the sensitivity of intermittent rhythm monitoring after intervention in 647 AF patients 
with implantable continuous monitoring devices. The study demonstrated that the 
random follow-up with four 24 h Holter monitoring tests would have a sensitivity of 
only 54% in detecting recurrent AF, and a single 30-day Holter a sensitivity of 63%.25 
It is clear that intermittent monitoring overestimates procedural success. Furthermore, 
as the nature of these postoperative arrhythmias is intermittent and symptoms are 
often lacking, the preferred follow-up method is continuous monitoring, particularly 
for anticoagulant decision-making. 
Limitations
The current study has limitations due to its observational, non-randomized design 
and the limited number of patients enrolled. Furthermore, the population consists of 
patients with paroxysmal and persistent AF with limited substrate. The electrophysio-
logical properties and long-term success rate of patients with long-standing persistent 
and advanced atrial remodelling were beyond the scope of this study.
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Introduction
In general, atrial fibrillation (AF) is associated with a doubling of cardiovascular 
mortality, an increased risk of systemic emboli and stroke (4- to 5-fold increase in 
non-rheumatic patients and 18-fold increase in patients with rheumatic valve disease), 
and a deterioration in cardiac function due to a combination of loss of atrial transport, 
irregular or rapid ventricular rates, and progressive cardiomyopathy. The increased 
mortality associated with AF is independent to the underlying cardiovascular 
condition.
Martinek et al. 1 demonstrated in a series of 14 patients with a pacemaker device and 
treated with pulmonary vein radiofrequency ablation (RFA) for their drug-refractory 
and highly symptomatic AF, that continuous monitoring enables the detection of 
significantly more AF episodes than routine follow-up of patients, i.e. based on 
perception of symptoms or on 24–48 h Holter monitoring. The outcome of RFA in 
patients with AF is likely easily overestimated, especially in patients with paroxysmal 
AF.1–10  Recurrences of atrial arrhythmias might increase the risk for stroke, therefore, 
adjustment of anticoagulant drug regiment should be based on appropriate 
monitoring. In this respect, the definition of an ‘atrial arrhythmic episode’ can be 
questioned as some guidelines refer to a minimum time period of 30 s, increasing the 
likelihood of erroneous diagnosis of sinus rhythm.1–3 In this study, we evaluated the 
additional value of a new external cardiac rhythm monitoring device, i.e. the AF-Alarm 
device in patients with paroxysmal AF who underwent surgical RFA.
Methods
From January 2006 to January 2008, 33 patients were included in the minimal 
invasive surgical pulmonary vein isolation registry. We evaluated the medium-term 
results of a novel ablation technique to eliminate AF by means of an irrigated bipolar 
RF ablation device. All patients consented to their data being registered and used for 
publication as did the Board of Hospital Administrators. All patients underwent a 
minimal invasive pulmonary vein isolation and left atrial appendage ligation (MIPI) 
procedure. Patients were followed in the outpatient clinic or follow-up data were 
obtained from attending or referring physicians.
Surgical procedure
In a supine position under general anesthesia, a double lumen tube was introduced. 
Defibrillator pads were placed on the thoracic wall. In the right hemithorax, a 10-cm 
incision in the fourth intercostal space in the anterior axillary line was placed. The 
Abstract
Studies have shown that continuous rhythm monitoring enables the detection of 
significantly more atrial fibrillation (AF) episodes than routine follow-up of patients, i.e. 
based on perception of symptoms or on 24–48 h Holter monitoring. The positive 
outcome of radiofrequency ablation (RFA) may be easily overestimated, especially in 
patients with paroxysmal AF. Thirty-three consecutive patients, aged 59.4±8.9 years 
(range 38–75 years) participated in this study. All patients had documented AF 
episodes with an AF duration of 9.4±7.1 years (range 1.5–25 years). A new monitoring 
device, the AF-Alarm was used to more accurately assess the outcome after surgical 
isolation of pulmonary veins. The AF-Alarm was applied for a duration of 128±42.5 h 
(range 49–191 h) during a period of 8–15 days. The success rate was 87% based on 
serial electrocardiograms (ECGs) and 24–48 h Holter monitoring during regular 
outpatient visits. Combination of ECG, Holter and AF-Alarm data yielded a significantly 
lower success rate, i.e. at the latest follow-up 69% of the patients were free from AF 
after surgical ablation (P<0.05). Furthermore, the AF-Alarm device demonstrated a 
dissociation between symptoms and atrial arrhythmic events and confirmed the 
occurrence of asymptomatic AF episodes. The most important limitation of the 
AF-Alarm device was noise detection with oversensing and inappropriate detection 
of non-existing AF episodes in 9% of patients. Long-term follow-up of the patients 
seems to be essential as success rates of the initial ablation procedure might vary 
over time. External recorders like the AF-Alarm may be used as an additional tool to 
document symptomatic and asymptomatic episodes of atrial arrhythmias in the 
outpatient setting.
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AF-Alarm device
The AF-Alarm is a battery powered electronic arrhythmia detection device with ECG 
recording capabilities. The AF-Alarm provides the patient with an audible and visual 
signal upon detection of AF and provides storage of ECG strips and RR intervals at 
AF onset and termination.
The AF-Alarm device (Fig. 1 ) provides extra buttons that can be used to program the 
device but also to mark symptomatic episodes. Automatic detection as well as 
manual triggers result in the storage of the digitized ECG. For automatically detected 
episodes, the ECG during the 2-min ‘onset’ time window is stored, as well as the 
2-min time window within which ‘sinus rhythm’ is detected; for manually triggered 
episodes the time window from 2 min before until 2 min after the trigger is stored in 
the device memory.
Statistical analysis
Categorical variables are expressed as frequencies and percentages. Continuous 
data are presented as mean±S.D. Comparison of continuous variables was 
performed with the Student t-test. Comparison of proportions was performed with χ2 
pericardium was opened anterior to the phrenic nerve. Two stay sutures were placed 
in the pericardium. Blunt dissection of Waterston’s Groove was performed followed 
by a blunt dissection and opening of the oblique sinus (OS) caudal of the right inferior 
pulmonary vein (RIPV). Then, blunt dissection and opening of the OS cranial of the 
right superior pulmonary vein (RSPV) between RSPV and the right pulmonary artery 
was performed. The Navigator was used to pass a tape around the RSPV and RIPV 
in one or separately, or the Navigator was used to apply the bipolar ablation device 
directly.
Introduction and application of the bipolar device around the pulmonary veins after 
gentle traction of the tape and ablating the left atrial wall adjacent to the junction with 
the pulmonary veins. RF energy was applied twice per pulmonary vein pair. Isolation 
was confirmed with pacing maneuvers at the LA-PV junction. The left hemithorax was 
opened similar to the right hemithorax, except for the incision of the pericardium, that 
was incised posterior of the phrenic nerve. Additional left atrial appendage ablation 
or removal or exclusion with stapler or preferably with endoloop was performed.
Cardiac rhythm monitoring
Early postoperative care, including anticoagulant management, was similar as for 
routine cardiac surgery. Cardiac rhythm was continuously monitored after surgery 
until stable rhythm returned. Temporary epicardial wires attached to the right ventricle 
as well as to the right atrium were used to pace the patient, to monitor the rhythm, or 
to overdrive the atrium. Postoperative atrial arrhythmias were treated with sotalol 
80–160 mg or amiodarone 200 mg and combined with direct-current cardioversion if 
necessary. After discharge, patients were seen in the outpatient clinic within four 
weeks, at three months, at six months and at 12 months after operation, or earlier 
when necessary. Antiarrhythmic drugs were tapered gradually after cardiac rhythm 
was considered stable. The presence of atrial contraction as documented by 
transthoracic and transesophageal Doppler echocardiography was performed at 
three and six months after surgery and related to the presence of electrical activity in 
the surface electrocardiogram (ECG). In all patients at variable time points, but 
minimally three months after the surgical procedure, the external loop recorder was 
applied for a duration of 128±42.5 h (range 49–191 h) during a period of 8–15 days. 
The ECG was recorded in this time period by means of the AF-Alarm including a 
patient cable and using three skin-electrodes. The patient was requested to manually 
activate the marking of symptomatic episodes. The documented episodes (either 
resulting from automatic detection or from manual triggers) were analyzed for 
appropriate detection and for AF-burden assessment. The next section describes the 
AF-Alarm device in detail. Figure 1   AF-Alarm device (A) and an example of ECG signals registered with this 
device (B).
A 
B 
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Cardiac rhythm after surgical PV isolation and LAA ligation
The mean follow-up duration was 15±5.3 months (range 3–30 months). Fig. 2 shows 
cardiac rhythm at the latest follow-up based on ECG, combination of ECG and Holter 
and combination of ECG, Holter and AF-Alarm recordings. During follow-up, 
sustained sinus rhythm, including atrial rhythm (AR) or an atrial-based paced rhythm 
(ABPR) was present in 87% of patients based on ECG only, 84% based on ECG plus 
Holter and the success decreased to 69% after combining the ECG, Holter and 
AF-Alarm data (P<0.05). Antiarrhythmic drugs were used in 64% of survivors who 
were free of AF. Oral anticoagulation was taken by 97% of patients. In the postoperative 
period when the AF-Alarm registrations were made, 19 patients were free from anti- 
arrhythmic medication and three were not treated with anti-coagulant medication. 
The AF-Alarm device confirmed successful ablation in 69% of patients as indicted by 
0% AF burden (time spent in AF). One patient demonstrated the presence of 
persistent AF, as revealed by an AF-burden of 99%. In three patients (9%) automatic 
analysis or Fisher’s exact test. All P-values are two-sided and P<0.05 was considered 
statistically significant. A two-tailed P<0.05 indicated statistical significance. Statistical 
analysis was performed using SPSS (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
Thirty-three patients, aged 59.4±8.9 years (range 38–75 years) participated in the RF 
MIPI registry. All patients had documented AF episodes with an AF duration of 9.4±7.1 
years (range 1.5–25 years). Each AF episode lasted 4–24 h. Thirteen patients (39%) 
had paroxysmal AF and 20 patients (61%) had persistent AF. Clinical characteristics 
of the patients are summarized in Table 1.
Table 1   Baseline patient characteristics
Number (±SD) Range
No of Patients 33
Gender (m/f) 20/13
Age (years) 59.4 ± 8.9 38-75
Hypertension 11 (33%)
History of TIA/stroke 2 (6%)
Family history of AF 6 (18%)
Left atrial size PSLAX (mm) 41.2 mm + 6.5 31-47
Dextrocardia 2 (6%)
LVEF (%) 54±4.3 25-61
Duration of AF (years) 9.4 ± 7.1 1.5-25
No of ineffective AADs 2.9±1.7 2-6
Type of AF
Paroxysmal
Persistent
Permanent
13
20
0
S.D., standard deviation; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; TIA, transient ishemic 
attack; PSLAX, left parasternal long axis view; AADs, antiarrhythmic drugs.
Figure 2   Bar graph demonstrating cardiac rhythm at the latest follow-up based  
on ECG, combination of ECG and Holter and combination of ECG,  
Holter and AF-Alarm recordings. During follow-up sustained sinus 
rhythm, including atrial rhythm (AR) or an atrial-based paced rhythm 
(ABPR) was present in 87% of patients based on ECG only, 84% based 
on ECG plus Holter and the success decreased to 69% after combining 
the ECG, Holter and AF-Alarm data (P<0.05). See text for details.
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Discussion
Conversion to and maintenance of sinus rhythm is often chosen as the primary 
end-point in studies looking at the success rate of AF ablation, however, many 
controversies exist in the determination of the success rate of the ablation procedure. 
The success rates also vary with the treatment of persistent or paroxysmal AF, the 
applied ablation procedures and evidence for potential underlying substrates.
As nicely indicated by previous studies,6–10 the success rate varies if one looks at 
freedom from AF recurrences with or without associated symptoms. Vasamreddy et 
al. 6 demonstrated that studies requiring an intensive monitoring of the recurrences of 
episodes lack from a sufficiently high patient compliance since they lack the 
consistency to accurately register every occurrence of symptomatic episodes, even 
when using a special wireless monitoring system that was applied in every patient on 
several occasions for five consecutives days.
The use of long-term ECG-observational devices to document presence or recurrence 
of arrhythmic episodes have been frequently proposed but rarely implemented. 
Several devices are commercially available to allow out-of-hospital monitoring of the 
analogue ECG-signal for up to 96 continuous hours. Subsequent analysis to identify 
arrhythmic episodes as short as 30 s requires adequate attention and resources. 
Continuous recording might help to better detect asymptomatic episodes as 
compared to discontinued recordings – e.g. triggered by occurrences of symptoms 
or at fixed time points during the day – which methodology often suffers from low 
patient compliance adhering to the protocol. Implantable devices assure 100% 
patient compliance, yet available devices are rather expensive. External devices, 
such as the AF-Alarm, allow for easy application and fast diagnosis of relevant ECG 
information while offering a good cost/effectiveness balance and assuring high 
patient compliance.
The outcome of this observational study confirms that continuous observations is a 
good tool to document the absence/presence of asymptomatic episodes which will 
trigger subsequent medication adjustments. In this particular study, one patient was 
even diagnosed to have a non-sustained ventricular tachycardia during the extended 
period of ECG registration.
Limitations and shortcomings
It has been suggested to take a blanking or stabilization period into account of some 
three months post-ablation prior to assessing the recurrence of arrhythmias. In this 
stabilization period, the rate of recurrences might gradually decay and is not 
recordings were documented by the AF-Alarm which appeared inappropriately 
detected either as a result of noise registration (muscle potentials and/or poor 
connection/contact of ECG-electrodes with skin, Fig. 3 ) or to frequent premature 
atrial contractions jeopardizing and misleading the detection algorithm (Fig. 4 ). In 
five patients, manually triggered ECG registrations during presence of symptoms 
correlated with sinus rhythm; in a sixth patient the symptoms correlated with the 
presence of a non-sustained ventricular tachycardia.
Figure 3   False positive detections: noise registration (loose electrodes,  
muscle potentials).
Figure 4   False positive detections: occurrence of premature atrial contractions.
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representative for the final clinical outcome, yet documentation of recurrences might 
help to better understand the remodeling process that is ongoing. Unfortunately 
today, too limited observations allow for such an adequate understanding.
If patients would have been monitored in the current study for longer time periods, 
there is a likelihood that more patients would have demonstrated recurrences. Longer 
registration periods merely depend on the tolerance of the patient to wear the sticky 
electrodes longer. This study was applied in only 33 patients, representing only a 
small sample of the current population presenting itself in the outpatient clinic. 
Therefore, observed ablation success rates are only indicative.
Conclusion
This study demonstrates that the longer the observational period the lower the 
success rate post-surgical ablation for AF. Furthermore, the current observed results 
demonstrate that the use of an external cardiac rhythm monitoring device like 
AF-Alarm is feasible to support the diagnosis of atrial arrhythmic recurrences in a 
better way than current standard practice. AF-burden is a continuous measure and a 
better parameter to assess success of the ablation therapy. Assessment of the 
AF-burden at regular time intervals allows optimal titration of the anti-arrhythmic and 
anti-coagulant therapies. In the future, implantable loop recorders may offer an 
objective mean to document occurrences of atrial episodes while the patient is out of 
the hospital and no longer under direct control of the treating physician. Thus, 
demonstration of long-term absence of recurrences seems to be the most solid 
end-point to determine success of the initial ablation procedure.
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General discussion and summary
 
This thesis highlights novel insights regarding several aspects of the pathophysiology 
and invasive treatment of a spectrum of complex atrial arrhythmias, particularly 
atrial fibrillation (AF) in different settings and discusses the value of different treatment 
modalities and follow up methods of invasive AF ablation procedures. AF is an  electro- 
cardiographic diagnosis with a wide spectrum of underlying diseases. The variety 
of underlying triggers, substrates and modulating factors result in wide variation 
in  interindividual clinical presentation and unpredictable response to therapies. 
Particularly in last decade an enormous progress has been made in identifying 
mechanisms of complex atrial arrhythmias, identification of triggers, its localization 
and amount of substrate, attempting to tailor ablation techniques and monitoring 
of ablation result. Although great progress has been made in the treatment of this 
arrhythmia, the incomplete understanding of the underlying pathophysiological 
mechanisms has been one of the reasons for the lack of fully tailoring therapy to 
the individual patient’s underlying heart disease and limited long term success of 
the currently available drug and ablation therapies. 
Mechanism of atrial fibrillation 
Paroxysmal AF usually begins with ectopic electrical activity in the pulmonary veins 
(PVs). Rapidly firing atrial activity in the mus cular sleeves at the PV ostia or in side the 
PVs have been described as potential underlying mechanism for AF.1 These muscle 
sleeves have distinct electrophysiological (EP) properties, e.g. shorter action potential 
duration, shorter effective refractory period and enhanced autonomic sensitivity. In 
experimental studies, high frequency electrical stimulation of autonomic neurons in 
the vicinity of the PVs resulted in early afterdepolarizations and ectopic firing in the 
PVs. Atropine prevented action potential shortening and triggered firing of myocytes 
in the PVs. Furthermore, atenolol allowed action potential shortening and prevented 
triggered firing in the PVs. 2, 3
The interaction between the two limbs of the autonomic nervous system, ectopic 
triggers and the development of structural and electrical atrial changes, known as 
remodeling, leads to progression of AF. The major stressors promoting atrial 
remodeling are high rate of atrial cell depolarizations and excessive volume and 
pressure load. The remodeling process includes myocyte growth, hypertrophy, 
necrosis and apoptosis, alterations in the compo sition of extracellular matrix, 
recalibration of en ergy production and expenditure, changes in the expression of 
cellular ionic channels and atrial hor mones. These changes result in a cascade of 
reactions leading to structural, functional, electrical, metabolic, and neurohormonal 
consequences.4 Mechanisms underlying the progression of paroxysmal AF with 
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interest in modifiable modulating factors such as hypertension, obstructive sleep 
apnea, obesity, valvular heart disease, congestive heart failure, ischemia, endocrine 
abnormalities and inflammation.11,12 It is known that modification of important risk 
factors and treatment of underlying diseases is very important and significantly 
enhances outcome of surgical and catheter ablation for AF.
AF and acute coronary syndrome
AF is a common complication of acute myocardial infarction (MI) with an overall 
incidence of 5–22%. Not surprisingly, the development of new onset AF is more likely 
in patients of older age, extensive myocardial damage, higher Killip class, and signs 
of cardiogenic shock.13,14  
The prognostic impact of AF that occurs in the setting of acute MI is controversial. 
Some studies describe an independent adverse effect on mortality and others failed 
to detect this association.15 New AF may lead to adverse outcomes in patients with 
MI through adverse haemodynamic effects such as loss of atrial contraction, high 
ventricular rates, loss of atrioventricular synchrony and an irregular ventricular 
intervals leading to a decrease in cardiac output.16
A recent systematic review and meta-analysis, including 43 studies and 278 854 
patients, showed that AF carries an excess risk of in-hospital, short-term (30 days to 
1 year), and long-term (>1 year) mortality among patients with acute MI, with at least 
a 40% increase, regardless of the type of AF (pre-existing or new-onset). Increased 
risk included both sudden and non-sudden cardiac death. This worse prognosis 
persisted, in patients with new-onset AF, even after adjustment for confounding 
factors such as age, diabetes mellitus, hypertension, prior MI, heart failure, and 
coronary revascularization.17
In Chapter 2 we describe the association of timing of AF with regard to mortality in 
primary percutaneous coronary intervention (PCI) patients presenting with a ST 
elevation MI. In this substudy of a multicenter randomized trial, electrocardiographic 
data before primary PCI  from a total of 1623 ST elevation MI patients were available 
and 53 (3.3%) of these patients had documented AF. In addition, of the 1728 patients 
with electrocardiographic data available after primary PCI, 52 patients (3.0%) had AF. 
Factors associated with AF were older age, Killip class >1, TIMI 0 flow prior to PCI, 
unsuccesfull reperfusion and occlusion of the right coronary artery. Multivariate 
analyses revealed that mortality was significantly higher in patients with AF after PCI 
and not in patients with AF prior to PCI.
short duration of arrhythmic episodes to more frequent episodes with longer duration 
of AF and eventually persistent and longstanding persistent AF is not fully delineated 
yet. 5,6 It is likely that structural atrial remodeling leading to atrial pathology enables 
the development of cardiovascular events, which might explain the relatively high 
stroke rate among the patients with AF progression. In addition, Glotzer et al showed 
that patients with a higher AF burden, which is the case in patients demonstrating AF 
progression, are more prone to have a stroke. 7
Chapter 3 describes the results of high density intra-operative mapping of long - 
standing persistent AF. This study explored the effects of acute stretch on intra atrial 
conduction properties (cycle length, conduction velocity and pattern, amount of 
conduction block) in patients with longstanding persistent AF undergoing open heart 
surgery. In nine patients who were scheduled for cardiac surgery and concomitant 
radiofrequency (RF) modified maze surgery were studied intraoperatively with 
bi-atrial high density mapping using epicardial multielectrode arrays. Atrial pressure 
and size were altered by modifying extracorporal circulation settings. Atrial dedilatation 
resulted in a significant decrease of the mean cycle length (7% and 9% for the left 
atrium and right arium, respectively) and amount of conduction block and subsequent 
dilatation increased the mean cycle length and percentage of  conduction block 
significantly. This is the first study in humans with longstanding persistent AF that 
demonstrates the amount of intra-atrial conduction block decreases with acute 
dedilatation.  Several animal studies show a similar effect of stretch on prolongation 
of the atrial effective refractory period. 8,9
In contrast, Solti et al reported that atrial dilatation resulted in a decrease of atrial 
effective refractory period along with an increase of atrial conduction times in a dog 
study. In this latter study, atrial stretch was induced with balloon inflation. 10 The 
vulnerability of the atrium to arrhythmias significantly increased on balloon dilatation 
(either spontaneous arrhythmias or induced by extrastimulus or burst pacing). 
Although the mechanism for these differences is not clear, our patients had long- 
standing persistent AF whereas in the latter study, AF and atrial flutter was artificially 
induced in healthy dogs. Therefore, it is not possible to compare our clinical study 
with the canine data. Several factors, including different atrial tissue characteristics or 
unequal atrial stretch may play a role in the discrepancy between these experimental 
results and our patient data. A resembling conclusion among the studies is the 
enhanced susceptibility to AF during an acute rise in atrial pressure. 
An unanswered question remains to which extent electrical reverse remodeling can 
be achieved with long term reduction in atrial size and pressure, especially in patients 
with longstanding persistent AF. From a therapeutic point of view, there is increasing 
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Chapter 5 compares the outcome of PVAC catheter ablation to conventional point by 
point ablation to isolate the PVs. In this prospective, non-randomized observational 
study the efficacy of first generation PVAC ablation in 89 patients was compared to 
conventional circumferential RF point by point ablation in 96  patients with paroxysmal AF. 
At 12 months follow up 82% of PVAC patients and 80% of conventional PVI patients were 
free of AF off AAD (P=0.989). Furthermore the mean procedure time was significantly 
shorter for PVAC ablation (133.25±37.99 min versus 171.73±2.87, P<0.001). No major 
adverse events occurred in either group.
Other studies describe a similar 12 months outcome of PVAC ablation in paroxysmal 
AF.24,25 The long term outcome of PVAC ablation shows similar result compared to 
conventional PVI.26,27 As mentioned in Chapter 1 of this thesis major concerns about 
the safety of the PVAC catheter arose in 2011 when an increased incidence of silent 
cerebral embolisms was reported with the phased RF technique in comparison with 
irrigated tip RF ablation.28,29 For this reason several improvements in the design of 
the original PVAC catheter were made which resulted in the development of the PVAC 
Gold catheter (Medtronic Inc, Minneapolis, MN, USA). This newer generation catheter 
contains 9 instead of 10 electrodes to eliminate the potential bipolar short circuit 
between overlapping electrodes 1 and 10 which was assumed to be the major reason 
for micro embolisms. In addition, platinum electrodes were replaced by gold which 
has a better thermal conductivity, thereby providing faster cooling and more precise 
temperature control, preventing of tissue overheating. Furthermore  a 20-degree 
forward tilt was added to the distal segment of the catheter for a more uniform elec-
trode-tissue contact with the PV antrum.30,31
Initial experiences with the PVAC Gold catheter were promising with similar one year 
success rate compared to the first generation PVAC but shorter RF application time 
and less fluoroscopy.32,33
In 2016 the PRECISION GOLD trial reported the results of cerebral magnetic 
resonance imaging in 51 patients within 48 hours pre- and 24 hours post-ablation. 
The results were a low incidence of asymptomatic cerebral embolism (2.1%) when 
using the PVAC gold catheter in combination with uninterrupted oral anticoagulant 
therapy and heparinization with ACT levels ≥ 350 seconds.34 However the rate of micro- 
embolic signals with PVAC gold is still significantly higher as compared to conventional 
irrigated tip catheter ablation as demonstrated by a recent randomized study.35
AF complicating acute MI is multi-factorial in its pathogenesis. A variety of factors 
have been proposed to initiate AF in the setting of acute MI such as haemodynamic 
disturbance, atrial ischaemia, excess catecholamine release,  electrolyte imbalance, 
heart failure, ventricular remodelling, acute hypoxia, pericarditis and inflammation – 
either on their own or in varying combinations.18
Although incidence and prevalence of AF is reduced to some extent by improved 
reperfusion strategies, occurrence of AF in the setting of acute MI and its prognostic 
significance is still dependent on the associated co-morbidities as well as the 
magnitude and consequences of MI.
Single shot ablation for AF, The PVAC catheter
Catheter ablation for AF has emerged as an alternative to antiarrhythmic drug (AAD) 
therapy in patients who remain symptomatic despite AAD or even as a first line 
treatment in selected patients.19,20 Although a wide variety of ablation techniques 
have been used to treat AF, it is generally agreed that the electrical disconnection of 
all PVs is still the cornerstone of the treatment. Novel methods aiming at simpler and 
faster pulmonary vein isolation (PVI) by use of the so-called “single shot” devices 
have therefore been developed in recent years. The introduction, Chapter 1, gives a 
detailed overview of the current techniques available. In chapter 4 and 5 the results of 
the circular multi-electrode PV ablation catheter (PVAC; Medtronic Inc, Minneapolis, 
MN, USA) are described.
In Chapter 4 we present the 12 months follow-up data including efficacy and safety 
outcome of the first generation PVAC. The study included 102 consecutive patients 
(90 paroxysmal AF and 12 persistent AF) with AF for a mean duration of 9.3+7.5 years 
(range 1.5–25) of time since first diagnosis of AF. The mean fluoroscopy time required 
for PVAC ablation was 17+12 min (median 16, range 12–33) and the mean total 
procedure time was 139.30+37.72 min (median 135, range 115–172). In eight patients 
with persistent AF, additional ablations were performed to defragment septal and 
posterior part of the left atrium and in 5 patients additional ablation with a conventional 
catheter was required. After a mean follow-up duration of 12.2+3.9 months 62 of 102 
(60.8%) patients were in sustained sinus rhythm without anti-arrhythmic drugs. There 
were no procedural complications in this study.
The efficacy outcome in our study with the first generation PVAC devices is slightly 
lower when compared to other reports. This might be related to the fact that this was 
an unselected group of patients (“real life data”) including paroxysmal and persistent 
AF patients with a relatively extensive substrate for AF. Furthermore the learning curve 
might have played a role is this early PVAC study.21,22,23,24
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important structures in the paraseptal region such as the, His bundle and arrhyth-
mogenic tissue in the aortic sinus. 
Chapter 6 presents a case series, our experience in mapping and ablation of ATs 
originating from the aortic sinus and the NCC and extensive literature review of focal 
AT arising from this area.  EP study was performed in 7 patients (4 males; age 40 ± 
9 years, range 2851 years) with drug-refractory AT. A parahisian origin was confirmed 
in all patients after initial right atrial mapping. The second step was left atrial mapping 
and subsequently mapping of the aortic sinus including the NCC either if left and 
right atrial mapping failed to identify a successful ablation site or RF applications 
were not successful in terminating the tachycardia. Mapping of the NCC demonstrated 
earliest atrial activation during AT 38 ± 14 ms (ranging 1756 ms) before the onset of 
the P-wave. Earliest atrial activation in the NCC was earlier than earliest activation in 
the right atrium and left atrium in all patients. The tachycardia was successfully 
terminated by RF application in 10 ± 6 s (216 s), without complications. All patients 
were free of symptoms during a follow-up of 19 ± 9 months. 
NCC related AT is difficult to recognize on the surface ECG. The specific morphology 
among different reports is not consistent. The most typical morphology is 
predominantly negative P-waves in the inferior leads, positive or isoelectric in leads I 
and AVL, and biphasic in right precordial leads V1 and V2 (mostly negative–positive). 
NCC AT typically shows a positive P-wave in leads I and AVL and a local A/V ratio of 
>1 (as opposed to a negative–positive P-wave deflection in left coronary cusp AT 
with a local A/V ratio ≤1).39,40
A couple of algorithms have been reported  to determine the site of origin of focal 
AT.41,42 However the diagnostic accuracy is very limited for foci located close to the 
interatrial septum and NCC.  Because of the central position of this area in the heart 
slight cardiac rotation and variation in body habitus and atrial tissue mass distribution 
can dramatically influence the P wave morphology polarity. Ablation of focal AT 
requires 3D mapping systems. The current 3D mapping systems combined with 
dedicated multi-electrode diagnostic catheters, enable operators to map during AT 
and automatically create high-density 3-dimensional electroanatomic maps. The 
techniques provide detailed insight into AT mechanisms and facilitates rapid mapping 
and ablation of these ATs. However, the currently available multipolar mapping 
catheters are not suitable for mapping in the sinus of Valsalva, which still requires 
conventional mapping with conventional ablation catheters. Although no randomized 
studies are available, based on our experience and published reports, novel 
technologies such as image integration and intracardiac echocardiography contribute 
to safety and efficacy of mapping and ablation in this area.
In view of the increasing number of AF patients requiring invasive therapy and the 
results of the STAR-AF trial, which emphasizes the relevance of PVI even in patients 
with persistent AF, the significance of technologies aiming at PVI exclusively will 
probably increase further.36
The most widespread “single shot” device for PVI at this moment is the cryoballoon. 
Both, the cryoballoon and the PVAC are effective in reducing procedure time and 
require less operator experience compared to point by point ablation. The main 
shortcoming of the PVAC system is that mapping possibilities are limited. For 
example, during RF delivery EGMs recorded with the PVAC cannot be displayed and 
therefore disappearance of PV potentials cannot be followed in real time. On the 
other hand, ablation procedure with the PVAC Gold catheter seems to require less 
fluoroscopy time and procedure time compared to cryoballoon ablation.32,33
In conclusion, the increasing demand of ablation therapy for AF patients requires 
faster, safer and more cost-effective techniques. There are concerns regarding 
increasing incidence of asymptomatic cerebral embolization with the PVAC Gold. 
These safety issues should be settled before widespread use of this device. The 
results of ongoing prospective, randomized trials should be awaited. If proven safe, 
phased multi-electrode radiofrequency ablation is a potentially promising technology 
providing a time efficient method of pulmonary vein isolation in paroxysmal AF 
patients. 
Focal atrial tachycardia
Focal atrial tachycardia (AT) was previously considered an arrhythmia due to enhanced 
automaticity. Nowadays, it is known that triggered activity and micro re-entrant etiologies 
are even more common in the arrhythmogenesis of the so-called “focal” ATs. 
By definition focal AT is an atrial arrhythmia originating from an area (focus smaller 
than 2 cm) with an excitation wave spreading centrifugally to the rest of the atria.37,38
Focal AT may occur in conditions leading to enhanced atrial stretch such as 
hypertension or cardiomyopathy or in response to toxic agents or hypoxemia. A 
specific incessant form of focal AT is seen in post AF ablation patients. Particularly 
linear ablation and ablation of complex fractionated activity may lead to these very 
symptomatic and drug-refractory “focal” ATs. 
In the absence of structural heart disease or previous ablation, focal AT has a good 
prognosis and is amenable to ablation therapy. Of note, mapping and ablation of ATs 
can be very challenging, particularly ATs arising from the interatrial septal area, 
including non coronary aortic cusp (NCC) due to its anatomical relationship with 
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It should be mentioned that they included small sized studies (ranging from 14 to 114 
patients) and rhythm follow up varied with only intermittend ECG or Holter monitoring.
Studies comparing stand alone surgical AF ablation with catheter ablation are very 
limited. A recent meta-analysis of comparative studies investigating minimally 
invasive thoracoscopic AF surgery versus catheter ablation for AF suggests a superior 
efficacy of surgery (freedom from recurrent atrial arrhythmias 78% vs 53%).50 Major 
complications however were significantly higher in surgical treated patients (28% vs 
8%). Although surgical PV ablation may be more likely to result in transmural lesions 
the differences in efficacy in these studies may also be driven by patient selection. 
Most patients included in these studies had failed prior invasive AF ablation 
procedures. Furthermore follow up in the included studies was performed with 
intermittent monitoring.
Chapter 7 of this thesis describes the results of a randomized controlled trial 
comparing surgical AF ablation with catheter ablation, with the use of continuous 
rhythm monitoring (ILR). A total of 50 patients (57 years, 39 male), with “lone” 
symptomatic paroxysmal or persistent AF, were randomized to either minimally 
invasive thoracoscopic PVI with LAA ligation or point by point radiofrequency PVI. 
The ILR was implanted prior to treatment to record a pre-ablation AF burden. At 6 
months the decrease in AF burden was 15.5% (95% CI 9.7%-43.1%) in the surgical 
group compared to 26.1% (95% CI 11.2%-59.6%) in the catheter ablation group 
(P=0.375). Freedom from AF, defined as an AF burden of <0.5%, at 6 months was 
63% in the surgical group versus 65% in the catheter group (P=0.87). Complications 
occurred significantly more often in the surgical patients 34.8% versus 11.1% in the 
catheter group (P=0.046). In conclusion, the short term outcome, in terms of 
preventing AF, is similar for catheter ablation and surgical ablation but surgery is 
associated with significantly more complications.
Although the sample size of the trial is small, the strength of this study is the fact that 
these patients did not have a previous ablation procedure. Therefore this population 
can be regarded as a “real life” unselected, lone AF cohort. We realize that superiority 
of surgical technique, as previous reports suggest, might be related to the patient 
selection; patients with several unsuccessful endocardial ablations are more likely to 
benefit from an epicardial approach.49
Furthermore, in light of frequent episodes of silent AF after ablation, continuous 
monitoring with ILR follow up is the only method that can provide reliable results when 
a trial endpoint is defined as “freedom of AF”.51 A major advantage of a preoperative 
implanted ILR is that symptomatic AF can be definitively confirmed and pre-operative 
Atrial fibrillation - Surgical approach
The maze procedure was introduced in 1987 by Dr Cox for the surgical treatment of 
AF. This procedure with a set of multiple specific biatrial lesions was designed to 
interrupt atrial macro re-entrant circuits, thereby creating a “maze” and reducing the 
ability of the atrium to fibrillate. Although freedom of AF and even freedom from late 
stroke were high, the procedure was technically challenging requiring sternotomy, 
cardiopulmonary bypass and extensive suture lines.43,44
In 2002 the Cox-maze IV procedure was introduced which replaced the bilateral 
incisions of the traditional cut-and-sew procedure with epicardial linear lines of 
ablation created with bipolar RF devices (or less often cryothermy or microwave 
energy). During the procedure the left atrial appendage (LAA) is generally excised. 
Although the Cox-maze IV can be performed through a small right-sided intercostal 
thoracotomy, it still requires cardiopulmonary bypass.45,46
Since 2005 AF surgery made a major step with the introduction of minimally invasive 
thoracoscopic technique providing access to the entire atrial epicardium of a beating 
heart. A variety of ablation strategies exist involving isolating the PVs either as a box 
or separately with or without ablation of the ganglionated plexi and with or without 
additional ablation lines.47
The bidirectional bipolar RF ablation devices are often used for surgical treatment of 
AF and consist of a clamp with two jaws, which are applied on opposite sides of the 
atrial tissue. The energy passes through the tissue between the two jaws. When 
conductance falls, transmurality is inferred. Because RF energy is delivered between 
two closely approximated electrodes embedded in the jaw of a clamp device, the 
energy is focused and results in discrete lesions. The energy is confined to between 
the jaws of the clamp, reducing the possibility of collateral cardiac or extracardiac 
damage. The limitation of these devices is that they can only ablate tissue that can be 
clamped within the jaws of the device. This shortcomming has limited the potential 
lesion sets, particularly in the beating heart. Moreover, in the clinical situation, multiple 
ablations are often required to achieve entrance and exit block. These devices have 
been incapable of fully ablating the right and left atrial isthmus and have required 
adjunctive ablation with cryothermy, or unipolar or unidirectional bipolar RF ablation 
to perform a complete Cox-maze III lesion set.48
La Meir et al describe in their meta analysis a succes rate of stand alone thoracoscopic 
AF surgery, defined as freedom from any AF episode longer than 30 seconds off 
AAD at 12 months, of 65-92% for paroxysmal AF patients and 67% to 80 % in 
persistent AF patients.49
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Particularly patients with advanced substrate and persistent AF who were treated 
with PV isolation only were likely to develop perimitral macrore-entry circuits. The 
authors conclude that a simplified maze procedure albeit curative for AF may 
nevertheless, predispose to macroreentry tachycardias. On the one hand these 
patients may be undertreated, on the other hand it is well known that mitral isthmus 
ablation can be cumbersome in thoracoscopic epicardial procedures. A staged 
endocardial or hybrid approach may be a good alternative.
Rhythm Follow up after AF ablation
Although catheter ablation and surgical ablation for AF is an effective treatment and 
there is currently an explosive number of AF ablation trials, there is no consensus of 
the definition of success or follow-up strategies. Symptoms are the main motivation 
for undergoing catheter or stand alone surgical ablation in patients with AF, however 
it is well known that reliance on perception of AF by patients after AF ablation results 
in an underestimation of recurrence of the arrhythmia. Even in patients with highly 
symptomatic AF, as many as half of all episodes can occur without any associated 
symptoms.56
Verma et al demonstrated with ILR monitoring that the ratio of asymptomatic to 
symptomatic episodes increases  from 1.1 before to 3.7 after ablation. Possible 
mechanisms for this effect are the shorter durations of arrhythmic episodes after 
ablation, slower rates, or autonomic modulation.51
Symptoms alone underestimated post ablation AF burden, with 12% of patients 
having asymptomatic recurrences only. Other studies report rates of post ablation 
asymptomatic AF episodes as high as 44%.57
In Chapter 9 we describe the evaluation of an external cardiac rhythm monitoring 
device the AF-Alarm in patients who underwent surgical AF ablation. Thirty-three 
patients, aged 59.4± 8.9 years (range 38–75 yrs) with paroxysmal or persistent AF 
with a duration of 9.4±7.1 years since AF diagnosis, underwent minimal invasive 
thoracoscopic PVI and LAA ligation. The AF-Alarm was applied for a duration of 
128± 42.5 h (range 49–191 h) during a period of 8–15 days. Apart from the AF alarm 
serial ECGs and 24-48 hour Holter monitoring was performed. Patients were 
requested to manually activate when they experienced   symptomatic episodes. The 
AF Alarm provides an audible and visual signal upon detection of AF and provides 
storage of ECG strips and RR intervals at AF onset and termination. Automatic 
detection as well as manual triggers resulted in the storage of the digitized ECGs. 
After a mean follow-up duration of 15±5.3 months, the combination of ECG, Holter 
and AF-Alarm data yielded a success rate of 69%, defined as sustained sinus rhythm. 
AF burden provides necessary data to make a reliable comparison with the post- 
operative situation.
Recurrent atrial arrhythmias after AF surgery
With the improvement of techniques for minimal invasive AF surgery, this treatment is 
becoming more effective and safe and therefore available for use on a larger scale. 
Nevertheless early and late ablation failures is still a major clinical concern. 
Chapter 8 examined the electrophysiological characteristics of recurrent atrial 
arrhythmias after surgical AF ablation and the long term outcome of catheter ablation 
of these arrhythmias. The study included 23 patients who underwent an EP study, 
378 ± 282 days after AF surgery, because of recurrent symptomatic atrial arrhythmias. 
Surgical ablation consisted of minimally invasive thoracoscopic PVI with an irrigated 
bipolar RF ablation clamp (Cardioblate, Medtronic, USA) and ligation of the LAA. 
Intra operatively the PVs were tested for entrance block and retested for reconnection 
after 30 minutes. The recurrent arrhythmias consisted of paroxysmal and persistent 
AF in 20 patients, 2 patients had a combination of AF and AT and 1 patient had a 
combination of AF and atrial flutter. All patients showed PV reconnection. ATs 
appeared to be micro-reentry, PV-related ATs and atrial flutter was cavotricuspid 
isthmus dependent. Eighteen of 23 patients (78.3%) were free of atrial arrhythmias 
after one catheter ablation procedure at a mean follow-up of 50 ± 16 months. Three 
patients underwent a second ablation procedure for recurrent AF and macro-reentry 
left atrial flutter. Eventually 20 of 23 patients (87%) remained free of atrial arrhythmias 
after a mean of 1.1 ± 0.3 ablation procedures. This study demonstrates that 
recurrences of atrial arrhythmias after surgical ablation are predominantly due to 
reconnection of surgical ablation lines and that touch up ablation, in a staged manner, 
with catheter ablation is very effective.
Despite achieving exit and entrance block post ablation with bipolar epicardial RF, PV 
reconnection seems to be the most common finding in patients with recurrent AF. 
Previous reports demonstrate a similar finding.52,53,54 PV reconnection likely develops 
during the healing process. Prolonged atrial-to-PV conduction times is seen often 
during EP studies, consistent with damaged myocardial tissue that is still able to 
conduct. 
On the other hand we have to acknowledge that the study population consisted of 
patients with limited AF substrate and therefore macro reentrant tachycardias outside 
the PVs is less likely. Trumello et al emphasize the need for appropriate lesion set in 
the initial surgical procedure.55 The study analysed 36 patients with recurrent atrial 
arrhythmias after surgical ablation with various energy sources and lesion sets. 
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Conclusion 
The results of this thesis provide novel insights into the pathophysiological 
mechanisms and invasive treatment and follow up  patients with complex atrial 
arrhythmias and AF in particular. AF represents a spectrum of arrhythmias with a 
wide variation in underlying diseases. Knowledge about the underlying mechanisms 
in each individual patient with AF is essential for determining the most appropriate 
treatment options. The outcome of catheter ablation for the large group of patients 
with paroxysmal AF and limited amount of substrate using the so called “single-shot” 
percutaneous ablation techniques is very promising whereas patients with advanced 
substate require a tailored  approach in which surgeons and electrophysiologists 
collaborate. Moreover, integrated AF care models result in improved freedom from 
AF and patient survival.
The combination of only ECG and Holter resulted in success rate of 84% (p<0.05). 
Five patients (15%) had several manual activated episodes which appeared to be 
sinus rhythm. Oversensing of the AF alarm occurred in 9% of patients. In conclusion, 
external rhythm monitoring with the AF Alarm after AF surgery is feasible and results 
in better detection of recurrent arrhythmias than standard practice.
In the absence of continuous monitoring post ablation, great caution should be 
exercised when AF is judged “suppressed” or “cured.” As mentioned before, the 
freedom from symptoms related to AF has been used as a surrogate endpoint of 
freedom from AF episodes and ablation success. It is clear that also external event 
recorder monitoring is not capable of detecting 100% of arrhythmias and the main 
drawback of these systems is that they are only tolerated by highly motivated patients 
over a short period of time. Post procedure arrhythmia monitoring is also relevant 
because of the significant number of patients experiencing palpitations in the 
absence of an arrhythmia. Israel et al describe in their study population that included 
40% of pacemaker patients,  reporting symptoms suggestive of AF that were not 
confirmed by ECG, neither by pacemaker interrogation.58
The ILR is a subcutaneous device that allow for continuous monitoring of arrhythmias 
for up to 3 years, which overcome the limitations described above. Originally in the 
AF algorithms, AF detection is performed using incoherence of R-R intervals over a 2 
minute period as the PP intervals couldn’t be sensed reliably . As assessed in the 
XPECT study, the Reveal XT ICMs have an overall accuracy for AF detection of 
98.5%.59
However false positive AF detection was a concern. The majority of inappropriate AF 
detections in ILRs are caused by runs of atrial ectopy with irregular coupling intervals, 
sick sinus, and sinus arrhythmia.  The latest generation of a loop recorder (Reveal 
LINQ, Medtronic) utilizes an advanced algorithm  involving identification of a P wave 
between 2 RR complexes to reduce inappropriate detections. Recent studies 
demonstrated a significant reduction in the false positive detection rate compared to 
the previous device generations and showed an even higher overall accuracy for AF 
detection of 99.4%, with sensitivity, specificity, positive predictive value, and negative 
predictive value for identification of AF of 98.4%, 99.5%, 97.2%, and 99.7%, respectively.60
The use of ILRs opens exciting new possibilities for monitoring the ablation result, for 
scientific reasons, as well as for selection of patients for an ablation procedure. 
However, future research is needed to assess the value of ILR in AF treatment before 
official recommendations can be given,
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Algemene discussie en samenvatting
In dit proefschrift worden diverse aspecten belicht van de pathofysiologie en invasieve 
behandelingen van verschillende atriale aritmieën, voornamelijk atriumfibrilleren (AF), 
in verschillende omstandigheden. Daarnaast worden verschillende behandelings-
modaliteiten beschreven evenals de waarde van follow-up methodes na een invasieve 
AF ablatie procedure. AF is een electrocardiografische diagnose met een breed 
spectrum aan onderliggende aandoeningen. De variëteit aan onderliggende triggers, 
substraat en modulerende factoren resulteert in enorme verschillen in interindividuele 
klinische presentatie en een onvoorspelbare respons op behandeling. De laatste tien 
jaar zijn grote stappen gemaakt in het ontdekken van mechanismen van complexe 
boezemritmestoornissen, het identificeren van triggers, de oorsprong van deze 
triggers en de hoeveelheid substraat. Ook is tegenwoordig meer aandacht voor het 
monitoren van het ablatieresultaat. Ondanks deze vooruitgang is de nog immer 
incomplete kennis van de pathofysiologie één van de redenen waarom tegenwoordig 
nog geen toegespitste behandeling bestaat, gericht op de onderliggende oorzaak 
van de boezemritmestoornis en is het lange termijn succes van ablatieve en 
medicamenteuze therapieën beperkt. 
Mechanismen van atriumfibrilleren
Paroxysmaal AF begint met ectopische, elektrische activiteit in de pulmonaal venen 
(PVs). Het onderliggende mechanisme van AF berust op snel vurende atriale activiteit 
vanuit de zogeheten muscular sleeves rond de PV ostia of in de PVs.1 De muscular 
sleeves hebben markante electrofysiologische (EP) eigenschappen. Zo is de duur en 
effectieve refractaire periode van de actiepotentiaal korter in vergelijking met het 
overige atriale weefsel en is er sprake van een versterkte autonome sensitiviteit. In 
experimentele studies konden vroege na-depolarisaties en ectopische elektrische 
activiteit worden geprovoceerd door middel van hoogfrequente elektrische stimulatie 
van de autonome neuronen in de nabijheid van de pulmonaal venen. Atropine 
verhindert actiepotentiaal verkorting en stimuleert spontane triggers van PV 
myocyten. Atenolol geeft daarentegen wel actiepotentiaal verkorting en remt de 
spontaan vurende triggers in de PVs. 2,3
Progressie van AF wordt veroorzaakt door de interactie tussen de beide takken van 
het autonome zenuwstelsel, ectopische triggers en de ontwikkeling van structurele 
en elektrische atriale veranderingen, ook wel atriale remodeling genoemd. De 
belangrijkste factoren die atriale remodeling bevorderen zijn de hoge frequentie van 
atriale depolarisaties en overmatige volume en drukbelasting. Het proces van 
remodeling bestaat uit myocytontwikkeling, hypertrofie, necrose en apoptose, 
verandering van de samenstelling van de extracellulaire matrix, recalibratie van ener-
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experimentele studies en patiëntendata. Een overeenkomstige conclusie is de 
verhoogde gevoeligheid voor AF tijdens acute toename van atriale druk.
Het blijft onduidelijk in welke mate herstel van atriale elektrische remodeling, het 
zogenaamde reverse remodeling, kan worden bereikt met afname van atriale druk en 
omvang, in het bijzonder bij patiënten met langdurig persisterend AF. Vanuit 
therapeutisch oogpunt groeit de interesse in modificeerbare modulerende factoren 
zoals hypertensie, obstructieve slaapapnoe, obesitas, hartklep-aandoeningen, 
hartfalen, ischemie, endocriene afwijkingen en inflammatie.11,12 Het is alom bekend 
dat modificatie van deze risicofactoren en behandeling van onderliggende ziektes 
een significant verschil kunnen maken in uitkomst van chirurgische- en catheterabla-
tie van AF. 
AF en acuut coronair syndroom
AF is een veel voorkomende complicatie van een acuut myocard infarct (MI) met een 
incidentie van 5-22%. New onset AF komt zoals verwacht meer voor bij hogere leeftijd, 
uitgebreide myocardiale schade, hogere Killip-klasse en cardiogene shock.13,14
De prognostische impact van AF ten tijde van een acuut myocard infarct is 
controversieel. Er zijn studies die een onafhankelijk negatief voorspellend effect op 
mortaliteit beschrijven terwijl andere studies deze associatie niet kunnen bevestigen.15 
New onset AF heeft een negatieve invloed op de klinische uitkomst van MI-patiënten 
vanwege onder meer de negatieve hemodynamische effecten zoals verlies van 
atriale contractiliteit, hoge ventriculaire volgfrequentie, verlies van atrioventriculaire 
synchroniciteit en irregulaire ventriculaire intervallen die leiden tot een afname van de 
cardiac output.16
Recente meta-analyses en systematic review, in totaal 43 studies en 278 854 
patiënten, laten zien dat de mortaliteit, zowel korte termijn (30 dagen tot 1 jaar) als 
lange termijn (> 1 jaar), van een acuut MI met ten minste 40% is verhoogd wanneer 
er sprake is van AF, ongeacht het type AF (pre existent of new onset). Het verhoogde 
risico geldt zowel voor plotse dood als niet plotse, cardiale sterfte. Zelfs na correctie 
voor confounders zoals leeftijd, diabetes mellitus, hypertensie, eerder MI, hartfalen 
en coronaire revascularisatie, is er sprake van een slechtere prognose bij patiënten 
met new onset AF.17
In Hoofstuk 2 wordt de associatie beschreven tussen mortaliteit en het moment dat 
AF optreedt bij patiënten met een ST elevatie MI die een primaire percutane coronaire 
interventie (PCI) ondergaan. In deze substudie van een multicenter, gerandomiseer-
de trial waren de elektrocardiografische gegevens voorhanden van 1623 ST-elevatie 
gieproductie en verbruik, verandering van de expressie van cellulaire ionkanalen en 
atriale hormonen. Deze processen leiden op hun beurt weer tot een cascade van 
reacties die resulteren in structurele, functionele, elektrische, metabole en neuro- 
hormonale veranderingen.4 Het is niet volledig bekend welke mechanismen 
 verantwoordelijk zijn voor de progressie van paroxysmaal AF met korte aritmische 
episoden naar persisterend en uiteindelijk langdurig persisterend atriumfibrilleren.5,6 
Het is aannemelijk dat structurele atriale remodeling die leidt tot atriale pathologie 
medeverantwoordelijk is voor het ontstaan van cardiovasculaire events. Dit verklaart 
de relatie tussen het risico op cerebrovasculaire aandoeningen (CVA) en AF 
progressie. Zo hebben Glotzer e.a. aangetoond dat patiënten met een relatief hogere 
AF burden, zoals wordt gezien bij AF progressie, meer risico hebben op een CVA.7
Hoofdstuk 3 beschrijft de resultaten van peroperatief atriale high-density mapping 
bij patiënten met persisterend AF. De studie onderzoekt het effect van acute 
verandering van atriale druk, ofwel stretch op de intra-atriale geleidingseigenschap-
pen (cycluslengte, geleidingssnelheid en patroon, mate van conductie blok) bij 
patiënten met langdurig, persisterend AF die een openhartoperatie ondergaan. 
In totaal werden 9 patiënten, die gepland waren voor een openhartoperatie met 
concomitante radiofrequente (RF) gemodificeerde maze-chirurgie, peroperatief 
onderzocht met bi-atriale high density mapping met behulp van epicardiale 
multielectrode arrays. Verandering van atriale druk en omvang werd gestuurd door 
de instelling van extracorporele circulatie te wijzigen. Afname van de atriale omvang 
(dedilatatie) resulteerde in een significante afname van de gemiddelde cycluslengte 
(7% en 9% van linker- respectievelijk rechter atrium) en afname van conductieblok. 
Het effect van dilatatie was een significante toename van gemiddelde cycluslengte 
en percentage conductieblok. Dit is de eerste studie bij mensen met langdurig, 
persisterend AF die aantoont dat de mate van intra-atriale conductieblok afneemt bij 
acute dedilatatie. Verschillende experimentele dierstudies laten een vergelijkbaar effect 
zien van stretch op de atriale effectieve refractaire periode.8,9 Solti et al. daarentegen 
beschrijven in een onderzoek bij honden dat atriale dilatatie een afname van atriale 
effectieve refractaire periode veroorzaakt en juist een toename van de atriale gelei-
dingstijden. Deze studie heeft gebruik gemaakt van balloninflatie om atriale stretch te 
genereren.10 De gevoeligheid van het atrium voor aritmieën werd significant groter na 
ballondilatatie (zowel spontane aritmieën als geïnduceerde aritmieën bij extrastimulus 
testen of burst pacing). Alhoewel er geen verklarend mechanisme is voor deze 
verschillende bevindingen moet worden opgemerkt dat onze patiënten bekend 
waren met langdurig persisterend AF terwijl de laatst beschreven studie kunstmatig 
AF en atriale flutters hebben geïnduceerd bij gezonde honden. Diverse factoren, 
waaronder verschil in weefselkarakteristieken van de atriale wand en ongelijkmatige 
verdeling van atriale stretch kunnen een rol spelen bij de discrepantie tussen de 
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defragmentatie van septum en linker atrium posteriorwand te verkrijgen en bij 5 
patiënten werd additionele ablatie met een conventionele RF ablatie-catheter verricht. 
Na een gemiddelde follow-up duur van 12.2 ± 3.9 maanden waren 62 van de 102 
(60.8%) patiënten blijvend in sinusritme, zonder AAD. Er waren geen procedurele 
complicaties in deze studie.
De effectiviteit van de eerste generatie PVAC catheter in onze studie is enigszins 
lager in vergelijking met andere studies. Dit zou gerelateerd kunnen zijn aan het feit 
dat de studiepopulatie een ongeselecteerde groep patiënten betrof ('real life data') 
waaronder paroxysmaal en persisterend AF patiënten met relatief uitgebreid substraat 
voor AF.  Daarnaast kan de leercurve een rol gespeeld hebben aangezien dit een van 
de eerste PVAC-studies betreft.21,22,23,24
Hoofdstuk 5 vergelijkt de uitkomst van pulmonaal vene isolatie door middel van 
PVAC-ablatie met conventionele point-by-point ablatie. In deze prospectieve, niet-ge-
randomiseerde observationele studie werd de effectiviteit van de eerste generatie 
PVAC ablatie bij 89 patiënten vergeleken met 96 patiënten met paroxysmaal AF die 
een conventionele ablatieprocedure ondergingen. Na een follow-up duur van 12 
maanden was 82% van de PVAC-patiënten en 80% van de conventioneel behandelde 
patiënten vrij van AF zonder anti-aritmica (p=0.989). De gemiddelde proceduretijd 
was significant korter voor de PVAC-ablatie procedures (133.25 ± 37.99 min versus 
171.73 ± 2.87, p<0.001). Er waren geen belangrijke ongewenste effecten in één van 
de groepen. 
Andere studies beschrijven een vergelijkbaar 12-maanden-uitkomst van PVAC 
ablatie bij paroxysmaal AF.24,25 De langetermijnuitkomst van PVAC ablatie laat een 
soortgelijk resultaat zien als conventionele PVI.26,27 Zoals in hoofdstuk 1 van dit 
proefschrift staat beschreven ontstond in 2011 reden tot zorg toen een verhoogde 
incidentie van asymptomatische cerebrale microembolieën werd gerapporteerd bij 
gebruik van phased RF in vergelijking met geïrrigeerde tip catheter RF ablatie.28,29 
Dit is de reden dat diverse verbeteringen werden aangebracht in het design van de 
originele PVAC catheter die hebben geresulteerd in de PVAC gold catheter (PVAC; 
Medtronic Inc, Minneapolis, MN, USA). Deze nieuwe generatie catheter bevat 9 in 
plaats van 10 electroden om de mogelijkheid van een elektrische kortsluiting tussen 
overlappende electroden 1 en 10 te verhinderen die de vermoedelijke hoofdoorzaak 
was van de micro-embolieën. Tevens werden de platinum electroden vervangen 
door gouden electroden waarvan de thermische geleidingseigenschappen beter zijn 
dan die van platinum. Hierdoor kan snellere koeling worden verkregen, betere tempe-
ratuurregulatie en kan weefsel oververhitting worden voorkomen. Daarnaast werd 
een 20 graden-voorwaardse kanteling aangebracht aan het distale segment van de 
MI-patiënten voorafgaand aan primaire PCI. In deze groep hadden 53 (3.3%) 
patiënten AF. Voorts waren de elektrocardiografische gegevens aanwezig van 1728 
patiënten na primaire PCI. In deze groep hadden 52 (3.0%) patiënten AF. De volgende 
factoren waren geassocieerd met AF: hogere leeftijd, Killip klasse>1, TIMI 0 flow 
voorafgaand aan PCI, onsuccesvolle reperfusie en occlusie van de rechter coronair 
arterie. Multivariate analyse toonde aan dat de mortaliteit significant hoger was bij 
patiënten met AF ná PCI en niet bij patiënten met AF voorafgaand aan PCI.
De pathogenese van AF als complicatie van het acute MI is multifactorieel. 
Verschillende factoren worden verantwoordelijk geacht voor de initiatie van AF in de 
setting van een MI waaronder hemodynamische instabiliteit, atriale ischemie, 
overvloedige catecholamine uitstoot, elektrolyt stoornis, hartfalen, ventriculaire 
remodeling, acute hypoxie, pericarditis en inflammatie. Zowel een combinatie van 
factoren als afzonderlijk kunnen AF initiëren.18
Ondanks de afname van incidentie en prevalentie van AF door verbeterde reperfusie 
technieken wordt het ontstaan van AF in de setting van een acuut MI en de 
prognostische impact nog steeds bepaald door zowel de co morbiditeit als de 
omvang en het beloop van het MI. 
Single shot ablatie voor AF, de PVAC catheter
Catheterablatie voor AF is uitgegroeid tot een goed alternatief voor antiaritmische 
medicatie (AAD) voor patiënten die symptomatisch blijven ondanks AAD en zelfs als 
eerstelijns therapie voor bepaalde AF-patiënten.19,20 Hoewel er tegenwoordig een 
veelheid bestaat aan ablatietechnieken om AF te behandelen blijft de hoeksteen van 
de behandeling de elektrische disconnectie van alle PVs. De laatste jaren zijn nieuwe 
ablatiemethoden ontwikkeld, waaronder de zogenaamde “single shot devices”, met 
als doel pulmonaal vene isolatie (PVI) eenvoudiger en sneller te laten verlopen. In 
hoofdstuk 1, de introductie, wordt een gedetailleerd overzicht gegeven van de 
technieken die tegenwoordig beschikbaar zijn. In hoofdstuk 4 en 5 worden de 
resultaten beschreven van de circulaire multi-electrode PV-ablatie catheter (PVAC; 
Medtronic Inc, Minneapolis, MN, USA).
In Hoofdstuk 4 presenteren we de 12 maanden follow-up, waaronder effectiviteit en 
veiligheids uitkomsten, van de eerste generatie PVAC catheter.  Er werden 102 
patiënten geïncludeerd (90 paroxysmaal AF en 12 persisterend AF) met een historie 
van AF gedurende gemiddeld 9.3±7.5 jaar (range 1.5-25).  De gemiddelde 
fluoroscopie tijd voor de PVAC procedure bedroeg 17±12 min (mediaan 16, range 
12-33) en de gemiddelde totale proceduretijd was 139±38 (mediaan 135, 115-172). 
Bij 8 patiënten met persisterend AF werd additionele ablatie verricht, om 
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Focale atriale tachycardie
Vroeger dacht men dat het mechanisme van focale atriale tachycardie (AT) uitsluitend 
berustte op versterkte automatie. Later werd duidelijk dat met name de mechanismen 
triggered activity en micro re-entry verantwoordelijk zijn voor de aritmogenese van 
focale AT. Focale AT wordt gedefinieerd als een atriale aritmie, afkomstig uit één 
gebied (focus kleiner dan 2 cm2) met een activatiegolf die zich centrifugaal verspreidt 
over de rest van de atria.37,38 
Focale AT kan worden uitgelokt door situaties waarbij er sprake is versterkte atriale 
stretch zoals hypertensie of cardiomyopathie, als reactie op toxische stoffen of 
bijvoorbeeld hypoxemie. Een specifieke onophoudelijke vorm van focale AT wordt 
gezien bij post AF ablatiepatiënten. Met name lineaire ablatie en ablatie van complex 
gefragmenteerde atriale activiteit zijn geassocieerd met deze vorm van sterk 
symptomatische focale AT die vaak medicatie resistent is. 
Wanneer er geen sprake is van structureel hartlijden of eerdere ablatiebehandeling 
heeft focale AT een goede prognose en is toegankelijk voor ablatietherapie. Elektroa-
natomisch mappen en ableren van ATs kan echter erg complex zijn. Zo zijn ATs uit de 
interatriale septum regio, waaronder de non coronary cusp van de aorta (NCC) vaak 
een uitdaging om te ableren vanwege de anatomische relatie met belangrijke 
structuren in de paraseptale regio waaronder de bundel van his.
In Hoofstuk 6 wordt de ervaring beschreven van het mappen en ableren van AT met 
een oorsprong in de sinus aorta en NCC en een uitgebreid literatuuroverzicht gegeven 
van focale AT uit dit gebied. Elektrofysiologisch onderzoek werd verricht bij 7 
patiënten (4 mannen; leeftijd 40 ± 9 jaar, range 28-51 jaar) met medicamenteus 
resistente AT. Een oorsprong nabij de bundel van his, parahisian, werd bevestigd bij 
alle patiënten na initieel mappen van het rechter atrium. De tweede stap was het 
mappen van het linker atrium en vervolgens de sinus aorta en NCC wanneer linker- 
en rechter atrium mapping niet de succesvolle ablatie localisatie kon identificeren of 
wanneer RF-applicaties niet resulteerden in het termineren van de ritmestoornis. 
Mappen van de NCC liet zien dat de vroegste atriale activatie tijdens tachycardie 38 
± 14 msec (range 17-56 msec) voor de onset van de P-top werd gevonden. De 
vroegste activatie in de NCC was vroeger dan de vroegste activatie in het rechter en 
linker atrium bij alle patiënten. De tachycardie werd succesvol beëindigd middels RF 
binnen 10 ± 6 sec (range 2-16 sec) zonder complicaties. Alle patiënten waren vrij van 
symptomen gedurende een follow up van 16 ± 9 maanden. 
NCC gerelateerde AT is moeilijk te herkennen op het oppervlakte ECG. De beschrijving 
van de p top morfologie is niet consistent in de verschillende artikelen. De meest 
catheter om optimaal, uniforme electrode-weefsel contact te verkrijgen met het PV 
antrum.30,31
De eerste ervaringen met de PVAC gold zijn veelbelovend waarbij een vergelijkbaar 
12 maanden succes wordt beschreven in vergelijking met de eerste generatie PVAC 
catheter maar kortere RF-applicatietijd en kortere fluoroscopietijd.32,33
In 2016 kwam de PRECISION GOLD trial met resultaten van cerebrale magnetische 
resonantie (MRI) onderzoek bij 51 patiënten die 48 uur voorafgaand en 24 uur na de 
ablatie ingreep werd verricht. Het resultaat was een lage incidentie van asymptoma-
tische cerebrale embolieën (2.1%) bij ablatie met de PVAC gold catheter in combinatie 
met ononderbroken orale anticoagulantia en heparinisatie met activating clotting 
time (ACT) ≥ 350 seconden.34 Echter, recent gerandomiseerd onderzoek heeft 
aangetoond dat de incidentie van microembolieën nog steeds hoger is bij PVAC 
Gold dan bij conventionele geïrrigeerde tip catheterablatie.35
Met het oog op het stijgende aantal AF-patiënten die voor invasieve therapie in 
aanmerking komen en het resultaat van de STAR AF trial, die het belang aangeeft van 
isolatie van PVs zelfs bij patiënten met persisterend AF, zal de vraag naar technieken 
die zich primair richten op PV isolatie steeds verder stijgen.36
Het “single shot” device dat momenteel het meest wordt gebruikt is de cryoballon. 
Zowel de cryo ablatie als de PVAC-ablatie hebben hun dienst bewezen waar het gaat 
om reductie van proceduretijd. Ze vereisen minder ervaring van de operateur in 
vergelijking met point-by-point ablatie. De belangrijkste tekortkoming van het 
PVAC-systeem is de beperkte mappingsmogelijkheden. Zo kan bijvoorbeeld tijdens 
RF-applicatie geen EGM-registratie worden weergegeven, waardoor het verdwijnen 
van PV-potentialen niet real time kan worden weergegeven. Anderzijds zijn er 
aanwijzingen dat ablatieprocedures met de PVAC Gold catheter lagere fluoroscopie- 
en proceduretijden hebben, vergeleken met cryo ablatie.32,33
Concluderend kan men zeggen dat de immer groeiende vraag naar AF ablatiethera-
pie vereist dat de technieken sneller, veiliger en meer kosteneffectief worden. Er zijn 
zorgen omtrent de verhoogde incidentie van asymptomatische cerebrale micro-em-
bolieën van de PVAC Gold catheter waarvoor gepaste oplossingen dienen te komen 
alvorens op grote schaal gebruik gemaakt gaat worden van dit device. De resultaten 
van lopende, prospectieve, gerandomiseerde trials moeten worden afgewacht. Mits 
het een veilige techniek blijkt is phased multielectrode RF-ablatie een potentieel 
veelbelovende technologie, die voor paroxysmaal AF-patiënten een tijd-efficiënte 
methode van PVI betekent.
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In 2005 werd een belangrijke stap gezet op het gebied van AF chirurgie met de 
introductie van de minimaal invasieve thoracoscopische techniek waarbij toegang 
wordt verkregen tot het gehele atriale epicard bij een kloppend hart. Er bestaat een 
variëteit aan ablatiestrategieën waaronder isolatie van alle PVs als één blok, de zgn 
'box lesion' danwel separaat. Daarnaast kan ablatie worden verricht van ganglion 
plexi met of zonder additionele ablatie lijnen.47
Het veel gebruikte bi-directionele bipolaire RF-ablatie device voor chirurgische AF 
ablatie bestaat uit een tang, die RF energie afgeeft en wordt aangebracht op twee 
tegenoverliggende delen van atriaal weefsel. De energie verloopt door het weefsel 
tussen de twee poten van de tang. Transmuraliteit is bereikt, wanneer een daling van 
de geleiding zichtbaar is. Doordat de RF-energie wordt afgegeven tussen twee dicht 
bij elkaar gelegen electroden, die zijn ingebed in de bek van de tang, is de energie 
geconcentreerd en resulteert in discrete laesies. Juist doordat deze energie 
gebundeld is tussen de bek van de tang, is het risico op bijkomende cardiale of 
extracardiale schade beperkt. Het nadeel van deze devices is dat uitsluitend atriaal 
weefsel kan worden ge-ableerd dat door de tang geklemd kan worden. Hierdoor is 
het aantal potentiële laesies beperkt, met name bij een procedure zonder hartlong-
machine. Er zijn vaak multipele applicaties nodig om entrance en exit block te 
verkrijgen. De klemdevices blijken niet capabel te zijn in het compleet ableren van 
rechter- en linker atrium isthmus, waardoor het noodzakelijk is om additionele ablatie 
met cryothermie of unipolaire of unidirectionele bipolaire RF-device te verrichten, om 
een complete Cox-maze III laesie set te verkrijgen.48
La Meir et al. beschrijven in een meta-analyse een succeskans van standalone 
 thoracoscopische AF chirurgie van 65-92% voor paroxysmaal AF en 67% tot 80% 
voor persisterend AF. Succes in dit kader is gedefinieerd als afwezigheid van AF 
episodes langer dan 30 seconden, zonder AAD na 12 maanden.49 Er moet worden 
opgemerkt dat de geïncludeerde studies niet omvangrijk waren (variërend van 14 tot 
114 patiënten)en ritme follow-up bestond slechts uit intermitterend ECG of holter-
monitoring. 
Studies die standalone AF chirurgie vergelijken met catheterablatie zijn schaars. Een 
recente meta-analyse welke minimaal invasieve chirurgische AF chirurgie versus 
catheter ablatie voor AF beschrijft, suggereert dat chirurgie superieur is qua 
effectiviteit (vrij van recidief atriale aritmieën 78% vs 53%).50 Daarentegen treden 
majeure complicaties significant vaker op bij chirurgisch behandelde patiënten (28% 
vs 8%). Hoewel de chirurgische PV-ablatie waarschijnlijk resulteert in meer transmu-
raliteit van de laesies, kan het verschil in effectiviteit in deze studies ook vooral 
gedreven zijn door patiëntenselectie. De meeste patiënten die in deze studies waren 
typische morfologie is een voornamelijk negatieve p top in de inferior afleidingen, 
bifasisch in de rechts precordiale afleidingen V1 en V2 (met name negatief-positief). 
NCC AT heeft typisch een positieve p top in afleidingen I en AVL met een locale A/V 
ratio van >1 (in tegenstelling tot de linker coronary cusp welke een negatief-positieve 
P top deflectie vertoont met een locale A/V ratio ≤ 1).39,40
Diverse algoritmes zijn beschreven die de origine van de focale AT bepalen.41,42 
De diagnostische betrouwbaarheid is echter beperkt voor foci nabij het interatriale 
septum en NCC. De P-top morfologie en polariteit kan sterk beïnvloed worden door 
onder meer de centrale positie van dit gebied in het hart, cardiale rotatie en variatie 
in habitus.  Ablatie van focale AT vereist een 3D mappingsysteem. De huidige 3D 
mapping systemen, gecombineerd met diagnostische multi-elektrode catheters, 
maken het mogelijk gedurende AT automatisch een hoge densiteit 3-dimentionele 
elektro-anatomische map te creëren.  De technieken geven een gedetailleerd inzicht 
in het AT mechanisme en faciliteert het spoedig mappen en ableren van deze ATs. 
Desondanks kunnen de huidige multipolaire mapping catheters niet gebruikt worden 
voor het mappen in de sinus van Valsalva en dienen conventionele mapping en abla-
tiecatheters hiervoor te worden gebruikt. Alhoewel er geen gerandomiseerde studies 
bestaan, kunnen we op basis van onze ervaring en de aanwezige literatuur stellen dat 
nieuwe technieken zoals image intergration en intracardiale echocardiografie 
bijdragen aan veiligheid en effectiviteit van mappen en ableren in deze regio. 
Atriumfibrilleren- chirurgische benadering
De maze-procedure, als chirurgische behandeling van AF, werd in 1987 door Dr Cox 
geïntroduceerd. Deze procedure, waarbij een patroon van multipele bi-atriale laesies 
wordt gemaakt, heeft als doel het onderbreken van atriale macro-re-entry circuits 
waarbij een soort electrisch 'doolhof'(engels: 'maze') wordt gecreëerd waardoor het 
atrium niet meer in staat is te fibrilleren. Alhoewel de ingreep zeer succesvol is in de 
zin van uitblijven van AF en zelfs het voorkomen van herseninfarct op de lange termijn, 
is het technisch gezien een moeilijke ingreep die een thoracotomie vereist, hartlong-
machine en een patroon van uitgebreide atriale incisies en hechtingen.43,44
 In 2002 werd de Cox-maze IV procedure geïntroduceerd, waarbij de traditionele 
bi-atriale incisies, het zogenaamde snijden en hechten (“cut-and-sew”), werd 
vervangen door epicardiale lineaire ablatielijnen. Deze ablatielijnen werden verricht 
met bipolaire RF devices (of minder gebruikelijk cryothermie of microgolf energie). 
Doorgaans wordt tijdens dezelfde ingreep excisie van het linker hartoor (LAA) verricht. 
Alhoewel de Cox-maze IV kan worden verricht via een beperkte rechtszijdige 
intercostale thoracotomie, is nog steeds een hartlongmachine vereist.45,46
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Hoofdstuk 8 bestudeert de elektrofysiologische karakteristieken van recidief atriale 
aritmieën na chirurgische AF ablatie en de langetermijn uitkomst na catheterablatie 
van deze aritmieën. Er werden 23 patiënten geïncludeerd die een EP studie 
ondergingen, 378 ± 282 dagen na AF chirurgie, vanwege recidief symptomatische 
atriale aritmieën. Chirurgische ablatie bestond uit minimaal invasieve thoracoscopische 
PVI met een geïrrigeerde bipolaire RF-ablatie klemdevice (Cardioblade, Medtronic, 
USA) en LAA ligatie. Peroperatief werden de PVs gecontroleerd op entrance block en 
opnieuw getest op reconnectie na 30 minuten. De recidieven van aritmieën bestonden 
uit paroxysmaal en persisterend AF bij 20 patiënten, 2 patiënten hadden een 
combinatie van AF en AT en 1 patiënt had een combinatie van AF en atriale flutter. 
Alle patiënten vertoonden PV reconnectie. ATs bleken te berusten op micro re-entry, 
PV gerelateerde AT en atriale flutter bleek een cavotricuspidale isthmus afhankelijke 
flutter. Achttien van de 23 patiënten (78.3 %) waren vrij van atriale aritmieën na één 
catheterablatie procedure na een gemiddelde follow up periode van 50 ± 16 
maanden. Drie patiënten ondergingen een tweede catheter ablatie behandeling, 
vanwege recidief AF en macro re-entry linker atrium flutter. Uiteindelijk waren 20 van 
de 23 patiënten (87%) vrij van atriale aritmieën na gemiddeld 1.1 ± 0.3 catheterablatie 
procedures. Deze studie toont aan dat recidief atriale aritmieën na chirurgische AF 
ablatie voornamelijk berusten op reconnectie van chirurgische ablatielijnen en dat 
complementeren van deze hiaten met catheter ablatie, op een gefaseerde wijze, zeer 
effectief is. 
Ondanks het bereiken van acuut exit block en entrance block na ablatie met een 
bipolair epicardiaal RF-device blijkt PV reconnectie toch de meest voorkomende 
bevinding bij patiënten met recidief AF. Eerdere studies beschrijven een vergelijkbare 
uitkomst.52,53,54 PV reconnectie ontstaat vermoedelijk tijdens het rijpingsproces. 
Vaak ziet men bij EP studies verlengde atrium-PV geleidingstijden, hetgeen past bij 
beschadigd myocardweefsel dat nog wel in staat is te geleiden. Daartegenover 
moeten we bekennen dat de studiepopulatie bestaat uit patiënten met beperkt AF 
substraat en derhalve het risico op macro re-entry tachycardieen buiten de PVs lager 
is. Tumello et al benadrukken de noodzaak voor een adequate laesie set bij de initiële 
chirurgische procedure.55 De studie analyseerde 36 patiënten met recidief atriale 
aritmieën na chirurgische ablatie met verschillende energiebronnen en laesie sets. 
Voornamelijk de patiënten met uitgebreid substraat en persisterend AF die waren 
behandeld met uitsluitend PV isolatie liepen het risico op het ontwikkelen van 
perimitraal annulus gerelateerde macro re-entry tachycardieën. De auteurs 
concluderen dat het uiterst onwenselijk is wanneer een gesimplificeerde maze 
ingreep, ofschoon deze curatief voor AF kan zijn, patiënten vatbaar maakt voor 
macrore-entry tachycardieën. Enerzijds moet men waken voor onderbehandeling bij 
deze patiëntencategorie, anderzijds is het alom bekend dat mitraal isthmus ablatie 
geïncludeerd hadden een voorgeschiedenis van niet-geslaagde catheterablatie. 
Bovendien bestond de follow-up in de geïncludeerde studies uit intermitterend 
monitoring. 
Hoofdstuk 7 van dit proefschrift beschrijft de resultaten van een gerandomiseerde 
studie die chirurgische AF ablatie vergelijkt met catheterablatie, waarbij gebruikt 
wordt gemaakt van continue hartritme monitoring (ILR). Er werden 50 patiënten 
gerandomiseerd (gemiddeld 57 jaar, 39 mannen) met symptomatisch paroxysmaal 
of persisterend AF naar hetzij minimaal invasieve thoracoscopische PVI met LAA 
ligatie, hetzij punt bij punt radiofrequente PVI (catheterablatie). Een ILR werd 
geïmplanteerd voorafgaand aan de behandeling, om de pre-ablatie AF burden te 
bepalen. Na 6 maanden was de AF burden afgenomen met 15.5% (95% CI 
9.7%-43.1%) in de chirurgische groep en 26.1% (95% CI 11.2%-59.6%) in de cathete-
rablatie groep (p=0.375). Vrijheid van AF, gedefinieerd als AF burden <0.5%, na 6 
maanden was 63% in de chirurgische groep versus 65% in de catheter groep 
(p=0.87). Complicaties traden significant vaker op bij chirurgische patiënten 34.8% 
versus 11.1% in de catheterarm (p=0.046). Concluderend kan gezegd worden dat de 
korte termijn uitkomst van catheterablatie en chirurgische AF ablatie vergelijkbaar is 
wat betreft effectiviteit, maar chirurgie is geassocieerd met significant meer 
complicaties. 
Hoewel de omvang van de studie klein is, is de kracht van de studie onder meer het 
feit dat de patiënten geen eerdere ablatie hebben ondergaan. De populatie kan 
worden gezien als een 'real life' AF cohort. Wij realiseren ons dat de superioriteit van 
de chirurgische techniek, zoals voorgaande artikelen suggereren, gerelateerd kan 
zijn aan patiëntenselectie; patiënten met diverse niet succesvolle endocardiale 
ablatie ingrepen in de voorgeschiedenis zijn wellicht meer gebaat bij een epicardiale 
poging.49
In het kader van de vaak voorkomende episodes van “silent AF” na een AF ablatie 
ingreep is follow-up met ILR de enige methode die een betrouwbaar resultaat kan 
geven wanneer men het studie eindpunt definieert als “vrijheid van AF”.51 Een 
belangrijk voordeel van een preoperatief geïmplanteerde ILR is dat symptomatische 
AF definitief kan worden bevestigd. Pre-operatieve AF burden is noodzakelijk om een 
vergelijking te maken met de postoperatieve situatie. 
Recidief atriale aritmieën na AF chirurgie
Met de verbeterde technieken van minimaal invasieve AF chirurgie is deze behandeling 
effectiever en veiliger geworden en daarmee geschikt voor gebruik op grotere schaal. 
Desalniettemin zijn de vroege en late recidieven van aritmieën een reden tot zorg.
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Zonder gebruik van continue monitoring na ablatie, dient men uiterst voorzichtig te 
zijn met opmerkingen als “AF is verdwenen”, “afwezig” of “genezen”. Zoals eerder 
vermeld, de vrijheid van AF gerelateerde symptomen wordt gebruikt als surrogaat 
eindpunt van vrijheid van AF en als ablatie succes. Vanzelfsprekend is ook een 
externe eventrecorder niet in staat om 100% van de aritmieën te detecteren. De 
voornaamste beperking van het systeem is dat deze devices alleen getolereerd 
worden door zeer gemotiveerde patiënten gedurende een relatief korte periode. 
Naast het detecteren van postoperatieve aritmieën is monitoring ook zeer relevant 
voor het vastleggen van palpitatieklachten welke niet berusten op aritmieën.  Israel et 
al. beschrijven in hun studie met pacemakerpatienten dat 40% van de patiënten 
symptomen van AF rapporteert die niet in overeenstemming zijn met het ECG of 
pacemaker interrogatie gegevens.58
De ILR is een subcutaan device die continue monitoring van aritmieën uitvoert tot 3 
jaar na implantatie. AF-detectie door het device berust op registreren van incoherentie 
van RR-intervallen gedurende 2 minuten periode, omdat pp intervallen niet 
betrouwbaar gesensed kunnen worden. De XPECT studie evalueerde de Reveal XT 
intracardiale monitor, waaruit blijkt dat AF episodes in 98.5% adequaat werden 
beoordeeld.59 Niettemin is de foutpositieve AF detectie een zorgelijk gegeven. Het 
leeuwendeel van de onterechte AF detectie episodes in de ILRs worden veroorzaakt 
door runs van atriale ectopieën met irregulair koppelingsinterval, sick sinus en sinus 
aritmieën. De laatste generatie loop recorder (Reveal Linq, Medtronic) maakt gebruik 
van een geavanceerd algoritme waarin ook de registratie van een p top tussen 2 RR 
complexen wordt meegenomen om het aantal incorrecte AF registraties te reduceren. 
Recente studies bevestigen dat het percentage foutpositieve AF-detectie episodes 
significant lager is vergeleken met oudere versies van het device. De sensitiviteit, 
specificiteit, positie voorspellende waarde en negatief voorspellende waarde voor 
identificeren van AF bedragen respectievelijk 98.4%, 99.5%, 97.2% en 99.7%.60
Het gebruik van ILRs biedt nieuwe mogelijkheden voor het monitoren van AF-ablatie-
resultaat, voor wetenschappelijke doeleinden en niettemin voor het selecteren van 
patiënten voor een ablatie ingreep. Evenwel is verder onderzoek noodzakelijk om de 
exacte waarde van ILR voor AF behandeling te bepalen voordat officiële aanbevelingen 
kunnen worden gegeven. 
Conclusie
De resultaten van dit onderzoek geven een nieuw inzicht in het pathofysiologische 
mechanisme, invasieve behandeling en follow-up methoden van patiënten met 
complexe atriale aritmieën, in het bijzonder van AF. AF representeert een spectrum 
van aritmieën met een grote variatie aan onderliggende ziektes. Kennis over het 
zeer lastig kan zijn bij thoracoscopische epicardiale procedures. Een gefaseerde 
endocardiale of hybride benadering kan een goed alternatief zijn. 
Ritme follow-up na AF ablatie
Ondanks het feit dat zowel catheterablatie als chirurgische ablatie effectieve 
therapieën zijn gebleken voor AF en er momenteel een enorme hoeveelheid aan AF 
studies bestaan, is er geen consensus over de definitie van succes of follow-up 
strategieën. Symptomen zijn nog altijd de belangrijkste reden om catheter- of 
chirurgische ablatie te verrichten. Daarentegen wordt het aantal recidief aritmieën 
sterk onderschat, wanneer men uitsluitend vertrouwt op de perceptie van AF 
aangegeven door patiënten. Zelfs bij patiënten met sterk symptomatisch AF blijkt dat 
minstens de helft van alle AF episodes symptoomloos verloopt.56 Verma et al. 
hebben laten zien middels ILR monitoring dat de ratio asymptomatische/
symptomatische AF episodes toeneemt van 1.1 voorafgaand tot 3.7 ná ablatie. 
Mogelijke verklaring voor dit effect kan zijn de kortere duur van aritmische periodes 
na ablatie, lagere hartfrequentie of autonome modulatie.51 Louter vertrouwen op 
symptomen geeft een onderschatting van de werkelijke AF burden aangezien 12% 
van de patiënten alleen asymptomatische recidieven heeft. Een andere studie 
beschrijft dat zelfs 44% van de post ablatie AF episodes asymptomatisch verloopt.57
In hoofdstuk 9 beschrijven we de evaluatie van een extern hartritme monitoring 
device, het AF alarm, bij patiënten die een chirurgische AF ablatie hebben ondergaan. 
Drieëndertig patiënten, leeftijd 59.4 ± 8.9 jaar (range 38-75 jaar) met paroxysmaal of 
persisterend AF met een gemiddelde duur van 9.4 ± 7.1 jaar sinds de diagnose AF, 
ondergingen minimaal invasieve thoracoscopische PVI en LAA ligatie. Het AF-alarm 
werd aangebracht gedurende 128 ± 42.5 uur (range 49-191 uur) tijdens een periode 
van 8-15 dagen. Behoudens het AF-alarm werd tevens een serie ECGs en 24-48 uur 
holtermonitoring verricht. Patiënten werden verzocht het device manueel te activeren 
wanneer ze een symptomatische episode ervaarden. Het alarm geeft een visueel en 
auditief teken wanneer detectie van AF plaatsvindt en legt ECG strips vast op het 
moment van AF begin en einde. Zowel automatische als manuele triggers resulteren 
in digitale opslag van de ECGs. Na een gemiddelde follow-up duur van 15 ± 5.3 
maanden geeft de combinatie van ECG, holter en AF-alarm aan dat het succesper-
centage van de ingreep 69% bedraagt (gedefinieerd als sustained sinusritme). De 
combinatie van uitsluitend holter en ECG resulteert in een succespercentage van 
84% (p<0.05). Vijf patiënten (15%) hadden diverse manueel geactiveerde episodes, 
waarbij sprake bleek van sinusritme. Oversensing van het AF-alarm trad op bij 9% 
van de patiënten. We kunnen concluderen dat externe ritmemonitoring met het 
AF-alarm na AF-chirurgie goed toepasbaar is en resulteert in adequatere detectie 
van recidief aritmieën vergeleken met standaard follow-up. 
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Dr J.J.J. Smit. Beste Jaap Jan. Ik ben dankbaar dat je mij hebt opgeleid tot elektro-
fysioloog. Ik heb veel van jou geleerd; een elektrofysioloog gaat naar huis wanneer 
de ritmestoornis niet meer induceerbaar is, niet wanneer het donker wordt.
Dr P.P.H.M. Delnoy. Beste Peter Paul. Ik en velen met mij kennen jou als perfecte 
leermeester wanneer het gaat om implanteren van pacemakers en ICDs. Tevens heb 
ik je altijd bewonderd als algemeen cardioloog. Als supervisor geef je de vrijheid en 
ben je er wanneer het nodig is. 
Dr A. Adiyaman. Beste Ahmet. Je bent een wetenschapper pur sang. Dank voor je 
kritische, en waardevolle blik op diverse artikelen. 
Dr H.T. Sie, cardiothoracaal chirurg. Beste Hauw. Als pionier op het gebied van de ritme- 
chirurgie heb je veel betekend. Dank voor de samenwerking. Geniet van je pensioen!
De overige co-auteurs ben ik dankbaar voor hun bijdrage aan de verschillende artikelen.
Beste Vera, het is onvoorstelbaar hoeveel ondersteunend werk jij verzet voor de 
onderzoekers in Zwolle.  Zeg nou eerlijk, ieder ziekenhuis zou toch een Vera Derks 
moeten hebben?
Prof Dr M.J. de Boer. Beste Menko Jan. Je hebt een zeer respectabele carrière. Je geniet 
wereldfaam sinds de eerste Zwolle studies over primaire percutane coronaire interventie 
en hebt als afdelinghoofd cardiologie van het Radboudumc veel voor de afdeling en 
in het bijzonder voor mij persoonlijk betekend. Ik ben je zeer erkentelijk. 
Prof Dr H. Suryapranata. Beste Harry. Net als Menko Jan heb jij aan de wieg gestaan 
van baanbrekend onderzoek op het gebied van de primaire PCI. Een stille kracht maar 
geniale wetenschapper en leider. Mijn huidige positie in de staf van de cardiologie 
in het Radboudumc heb ik voor een groot deel aan jou te danken. Dat realiseer ik 
mij terdege.
De research medewerkers van Diagram Zwolle ben ik veel dank verschuldigd. In het 
bijzonder Petra Koopmans en Evelien Kolkman. De statistische jungle van onderzoek 
is geen pretje en die tocht laat ik graag aan jullie over. 
De afgelopen drieënhalf jaar werk ik met veel plezier in het Radboudumc. De vreugde 
op het werk wordt in de eerste plaats gecreëerd door mijn directe collega’s. Onderdeel 
zijn van het Ritmeteam is een groot genoegen. Reinder Evertz, Sjoerd Westra, Esther 
Meindersma en Martin Hemels. Onze som is meer dan de som der delen.
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Rypko Joost Beukema is op 17 juni 1975 geboren in Groningen. In 1993 behaalde hij 
zijn VWO diploma aan het Hogeland College te Warffum. Vervolgens heeft hij een 
jaar English Literature and Culture gestudeerd in Bournemouth (GB) waarna hij aan 
de studie geneeskunde aan de Rijks Universiteit van Groningen is begonnen. Na het 
behalen van zijn artsdiploma is hij gedurende anderhalf jaar gaan werken als junior- 
en later senior house officer General Medicine in The Princess Royal Hospital, Telford 
(GB). Tijdens het werken op de hartbewaking onder leiding van Dr M. Heber werd 
Rypko gegrepen door het vak cardiologie. Na het engelse avontuur werd hij in 2004 
aangenomen als arts-assistent cardiologie in de Isala klinieken, Zwolle. Voorts 
werd hij in 2006 aangenomen voor de opleiding tot cardioloog in de Isala klinieken 
(Dr J.C.A. Hoorntje, Dr A.W.J. van ’t Hof, Dr A.R. Ramdat Misier). Al vroeg in de 
opleiding is Rypko betrokken bij wetenschappelijk onderzoek in de klinische elektro-
fysiologie onder supervisie van Dr A. Elvan. Na het B-jaar cardiologie in het Deventer 
ziekenhuis (Dr J. van Wijngaarden) werd naast de opleiding tot cardioloog de start 
gemaakt met dit promotieonderzoek. In 2012 rondde hij de opleiding tot cardioloog 
af en werd aansluitend aangenomen voor een fellowship elektrofysiologie in de Isala 
klinieken. Sinds 2014 is hij werkzaam als cardioloog elektrofysioloog in het Radboudumc 
te Nijmegen en is in 2016 toegetreden tot de staf. Rypko is tevens nauw betrokken bij 
het onderwijs als docent voor geneeskunde studenten van de Radboud Universiteit 
Nijmegen.
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